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Abstract 
Impact of Incident Cancer on Coronary Artery Disease-Related Concomitant Medication Adherence, 
Short-Term Health and Economic Outcomes among Elderly Medicare Beneficiaries with Coronary Artery 
Disease 
Ishveen Kaur Chopra 
Coronary artery disease (CAD) is one of the most burdensome chronic conditions in the elderly. The two key goals 
of long-term management of CAD are (i) to reduce symptoms and ischemia and (ii) prevent myocardial infarction 
and death, by lowering lipids and blood pressure. Of all the risk reduction strategies, use and adherence to 
concomitant pharmacotherapy with statins and beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs) or 
angiotensin II receptor blockers (ARBs) have been shown to be highly effective and has become the cornerstone of 
CAD management. However, adherence to concomitant pharmacotherapy can be influenced by many factors 
including the development of other life-threatening conditions such as cancer. To date, no real-world study has 
assessed how incident cancer can affect adherence to concomitant pharmacotherapy and whether concomitant 
pharmacotherapy can minimize the negative effects of some cancer treatments on CAD-related morbidity and 
expenditures among individuals with CAD and incident cancer. To fill the knowledge gap, the three related aims of 
this dissertation were to analyze: 1) the association between incident breast, colorectal, and prostate cancer diagnosis 
and adherence to statins and/or ACEIs/ARBs/beta-blockers among elderly fee-for-service (FFS) Medicare 
beneficiaries with pre-existing CAD; 2) the impact of non-adherence to these medication classes on short-term 
CAD-related hospitalizations in patients with incident cancer diagnosis; and 3) the impact of incident cancer 
diagnosis on short-term CAD-related inpatient and outpatient healthcare expenditures. The study used a 
retrospective observational longitudinal cohort study design was conducted among elderly Medicare FFS 
beneficiaries with pre-existing CAD and those with incident breast cancer (BC), colorectal cancer (CC), or prostate 
cancer (PC), using multiple years (2005-2012). The study data was derived from the cancer registry data from 
Surveillance, Epidemiology and End Results (SEER) program linked with the Medicare claims data, the American 
community survey census-tract files and Area Health Resource Files. Aim 1 and Aim 3 also included 5% non-cancer 
random sample of Medicare beneficiaries, residing in SEER regions, with pre-existing CAD. Each individual was 
observed for 48 months with 24-month baseline (for identification of CAD and baseline characteristics) period, 12-
month pre-index, and 12-month post-index periods. In the first aim, only 28.9% of the elderly with CAD were 
adherent to both statins and ACEIs/ARBs/beta-blockers. In the adjusted analyses, women [AOR = 0.70; 95% CI = 
0.58, 0.81; P < 0.0001] and men [AOR = 0.63; 95% CI = 0.51, 0.75; P < 0.0001] with CC and men with PC [AOR = 
0.92; 95% CI = 0.85, 0.99; P = 0.022] were significantly less likely to be adherent to both medication classes 
compared to women and men with NC, respectively. No significant differences in adherence to medications were 
observed among women with BC compared to women with NC. Even among those using single medication class, 
women [AOR = 0.64; 95% CI = 0.50, 0.79; P < 0.0001] and men with CC [AOR = 0.59; 95% CI = 0.42, 0.76; P < 
0.0001] were significantly less likely to be adherent to that medication class compared to women and men with NC. 
In the second aim, adherence to both statins and ACEIs/ARBs/beta-blockers was estimated at 31.2% during the 120-
day period immediately after cancer diagnosis; 13.7% were not adherent to both medication classes during the same 
period; 27.4% had CAD-related hospitalizations immediately after cancer diagnosis and this percentage declined to 
10.6% during the last four months of the post-cancer period. In the adjusted analyses, those not adherent to both 
statins and ACEIs/ARBs/beta-blockers were more likely to have CAD-related hospitalization compared to those 
who were adherent to both medication classes [AOR = 1.82; 95% CI = 1.72, 1.92; P < 0.0001]. In the third aim, 
overall, CAD-related mean healthcare expenditures at pre-index period accounted for about 32.6% - 39.5% of total 
expenditures among women and 41.5% - 46.8% among men. In the adjusted GLMM, all cancer groups had 
significantly higher CAD-related healthcare expenditures compared to the non-cancer groups. Women with CC 
153% higher expenditures compared to women with no cancer [β = 0.93, P < 0.0001].  Men with CC had 166% 
higher expenditures compared to men with NC [β = 0.98, P < 0.0001]. Further, men and women with CC had 57% 
and 55% higher expenditures compared to men with PC and women with BC, respectively. In summary, the study 
findings, collectively, suggest that cancer diagnosis negatively impacts adherence to CAD pharmacotherapy. 
Reduction in adherence was associated with increase in CAD-related hospitalizations and subsequent increase in 
CAD-related expenditures. This warrants the integration of cardiovascular care in the elderly diagnosed with cancer. 
Future studies need to explore whether the emerging collaborative care models, such as medical homes, can reduce 
inpatient use, and consequently, CAD-related expenditures. 
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1 CHAPTER 1 
Introduction 
 
1.1 Coronary Artery Disease 
1.1.1 Epidemiology of Coronary Artery Disease 
Coronary artery disease (CAD), also referred to as coronary heart disease or ischemic heart disease, is caused 
by atherosclerosis, is a disease in which there is narrowing or blockage of the coronary arteries, blood vessels that 
carry blood and oxygen to the heart [1]. Globally, CAD prevalence rate in 2006-2013 was 13.8% [2]. The 
Framingham study investigators estimated a lifetime risk of developing CAD at 49% in men and 32% in women [3]. 
In the United States (US), nearly 15.5 million adults aged 20 and older are diagnosed with CAD, [4] with 
prevalence rates of 6.2% [4]. In 2015, approximately 635,000 new cases of CAD were diagnosed in adults aged 20 
years and older [4]. Sex and race/ethnicity differences in CAD incidence and prevalence rates were also reported [4-
6]. The average age-standardized CAD incidence rates have been reported to be 9.0 per 1,000 person years for black 
men versus 8.1 for white men and 5.0 for black women versus 3.4 for white women [5]. Hispanics (6.1%) have 
higher age-adjusted prevalence of CAD as compared to whites (5.8%) [6]. Women have lower prevalence of CAD 
(5.0%) as compared to men (7.6%) [4]. However, it is not known as to whether this lower prevalence is due to 
differences in presentation of CAD leading to under-detection of CAD in women [7, 8]. 
 
1.2 Burden of CAD 
1.2.1 Mortality 
Although the survival rate of CAD has been steadily improving [9], it still remains the leading cause of 
mortality worldwide; with 7.4 million deaths in 2012, 13.2% of total global mortality [10]. It is projected that by 
2020, worldwide, 11.1 million deaths will be due to CAD [11]. In the US, CAD is responsible for more than two-
thirds of all heart-related mortality, with more than 380,000 deaths annually [12]. CAD claims more lives than all 
forms of cancer combined [4]. Mortality from CAD disproportionately affects the elderly, men, and racial minorities 
[4, 13, 14]. For example, 80% of CAD-related mortality is reported among elderly population (65 years and older) 
[4]. 
 
1.2.2 Morbidity – Complications of CAD 
Worldwide, CAD is the leading cause of morbidity, with 32.4 million myocardial infarctions (MI) every year 
[15, 16]. In the US, approximately 1.5 million individuals experience MI each year, and amongst them, majority are 
either hospitalized for unstable angina or for treatment of stable chest pain syndromes. Every year, nearly 735,000 
adults in the US have a heart attack, among which 525,000 are a first heart attack and 210,000 are recurrent heart 
attacks [12]. Observational studies on patients recovering from an acute MI reported that 1 in 5 patients had 
recurring angina within one year, even after intensive treatment [17]. 
 
 2 
 
1.2.3 Morbidity – Disability due to CAD 
Globally, the overall burden of CAD (measured in terms of disability-adjusted life years (DALYs) is projected 
to increase to 82 million DALYs in 2020 from about 47 million in 1990 [18]. CAD is the leading cause of DALYs 
in the US for both males and females (11.2% of the total) [19]. In the global burden of disease report, US was 
ranked 12 among 15 countries for age-standardized rates of DALYs for CAD relative to comparator countries 
(where 1 indicated best performance and 15 worst performance) [20]. 
 
1.2.4 Morbidity – Health-Related Quality of Life (HRQoL) 
Another aspect of morbidity is the humanistic outcomes, specifically HRQoL. Individuals with CAD may 
experience poor HRQoL due to the symptom burden, complications resulting from CAD, such as MI, limited 
physical functioning capacity, and psychological stress [21]. It is reported that patients with MI have lower HRQoL 
compared to those with heart failure. Another study indicated that 25-30% of individuals with cardiovascular event 
experience a constant feeling of uneasiness concerning their health, resulting in lower HRQoL [22].  Such lower 
HRQoL can lead to higher risk of mortality. A study by Bosworth et al (1999) observed 2,800 patients with CAD 
over period of 3.5 years. This study indicated that lower HRQoL was related to an approximately threefold greater 
all-cause risk of mortality and a 3.6-fold greater risk of mortality due to CAD [23]. 
 
1.2.5 Healthcare Utilization 
The high burden of CAD can lead to intensive healthcare utilization. In the US, in 2010, there were 11 million 
ambulatory care visits, 10.5 million physician office visits, 587,000 emergency department visits, and 764,000 
outpatient department visits with a primary diagnosis of CAD [4]. Further, Merrill et al (2008) indicated that 74.8% 
of emergency department visits for CAD resulted in hospital admission [24]. Among the elderly Medicare 
beneficiaries (> 65 years), of the average of 2.1 million hospitalizations per year, 42.0% of the visits occurred 
among those with CAD followed by heart failure (28.9%), cardiac dysrhythmia (17.8%), and other diseases of the 
heart (11.3%) [25]. 
 
1.2.6 Direct and Indirect Healthcare Costs 
The direct healthcare costs of caring for individuals with CAD are substantial; direct medical care costs of CAD 
in the US is projected at $106.4 billion in 2030, a 198% change from 2010 [26]. Nearly, 50% of direct healthcare 
costs can be attributed to the hospitalizations [27]. Hospital or inpatient expenditures may be higher because of 
invasive procedures needed to manage CAD. According to the Healthcare Cost and Utilization Project (HCUP) 
statistics (2012), the mean hospital charges for a vascular/cardiac surgery or procedure was $78,897, cardiac 
revascularization was $149,480, and percutaneous interventions was $70,027 [4]. 
The costs due to lost productivity, have been estimated to be $81 billion [4, 27]. The indirect costs measured as 
lost productivity from morbidity and premature mortality can also be very high [4, 27, 28]. According to 
Heidenreich et al (2011), the indirect costs attributed to CAD is expected to increase to $112.3 billion in 2030 from 
$73.2 billion in 2010 [26]. 
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In summary, CAD affects millions of adults in the US and contributes to substantial burden in terms of mortality, 
morbidity, poor humanistic outcomes, healthcare utilization, and costs of care. 
 
1.3 Management of CAD 
Long-term management of all forms of CAD follows the guidelines established for stable CAD [27]. According 
to clinical practitioners the management of CAD has two main goals: (i) to reduce symptoms and ischemia; (ii) to 
prevent MI and death [29]. There are many components to CAD management and they include physical activity, 
smoking cessation, blood pressure (BP) control, lipid control, diabetes, prescription of antiplatelet agents, beta-
blockers, renin-angiotensin-aldosterone system blockers, nitrates, calcium antagonists, and ranolazine, and influenza 
vaccine [27]. 
Among all the risk reduction strategies, lowering BP and low-density lipoprotein cholesterol (LDL-C) levels are 
central to achieving the main goals of CAD management. A report from National Health and Nutrition Examination 
Survey (NHANES) indicated that nearly 44% decline in CAD mortality over time was attributable to changes in risk 
factors. Among all the risk factors, lower total cholesterol (24%) and lower systolic BP (20%) accounted for most of 
the decline in mortality compared to lower smoking prevalence (12%) and decrease in physical inactivity (5%) [4]. 
Reducing of LDL-C is associated with a reduced risk of recurring cardiovascular events in individuals with a 
diagnosis of CAD [30-34]. Clinical trials and prospective studies have shown that reducing blood pressure in 
patients with CAD can improve survival and prevent recurrent MI or stroke [35, 36]. Based on robust evidence, the 
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure suggest lowering BP to 140/90 mmHg or less for patients with CAD [35]. Similarly, the Third Report of 
the National Cholesterol Education program recommends lowering LDL-C to less than 100 mg/dL in patients with 
CAD [37]. 
 
1.3.1 The Importance of Statin Therapy 
For attaining guideline recommended LDL-C, pharmacotherapy that lowers lipid levels has become the 
standard of care for individuals with CAD. Although many types of lipid-lowering drugs (statins, bile acid 
sequestrants, fibrates, niacin, and ezetimibe) are available [37], statins are commonly prescribed for many reasons. 
The efficacy of statins in the primary and secondary prevention of cardiovascular events has been demonstrated by 
clinical trials [30-33]. For example, in the Cholesterol and Recurrent Events trial, pravastatin has been shown to 
reduce the risk of mortality, major coronary events, and the need for major invasive procedures compared to placebo 
[33]. 
In addition, statin therapy can be highly effective among older patients with CAD. Studies that have examined 
the effectiveness of statin therapy in reducing cardiovascular events and mortality in older patients suggest that older 
adults have greater reduction in coronary events as compared to younger subjects [38-40]. For example, among 
users of simvastatin, major coronary event rates were reduced by 32% in those ≥ 65 years of age versus 19% in 
those <65 years of age [39]. The differential was even more striking in terms of mortality, which decreased by 45% 
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in those ≥65 years of age compared to11% in patients <65 years of age [39]. Similar benefits among the elderly have 
been observed among Pravastatin users [38]. Statin therapy in the elderly has been projected to be cost-effective, 
where the incremental cost for quality-adjusted life year (QALY) in the elderly was reported to be $18,800 much 
lower than the target of $50,000 per QALY [41]. 
 
1.3.2 Antihypertensive Therapy 
To attain guideline-recommended BP goals, antihypertensive pharmacological therapy is often prescribed for 
individuals with CAD. There are several antihypertensive drug classes such as beta-blockers, angiotensin-converting 
enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), calcium channel blockers, diuretics, and others 
[35], each with their own mechanism of lowering BP. In addition, the efficacy and effectiveness of beta-blockers 
[42, 43] and ACEIs/ARBs [44-48] in reducing cardiovascular events among individuals with CAD have been 
proven. 
 
1.3.2.1 The Importance of Beta-blockers, ACEIs, and ARBs 
However, there is no convincing evidence on the superiority of the cardio-protective effect of one single 
antihypertensive drug class over the others. The choice of antihypertensive drug class is usually guided by the 
compelling indication [49, 50]. Beta-blockers are usually the first-line antihypertensive medication for individuals 
with CAD and are recommended for CAD patients [51]. Beta-blockers have also shown to be cost-effective in 
elderly patients [52]. As it has been established that ACEIs reduce the risk of death, MI, diabetes, and renal 
problems, ACEIs are recommended for individuals with CAD, specifically for those with diabetes to lower the risk 
of heart attack or heart failure. ARBs are prescribed to patients who cannot tolerate ACEIs [36]. ACEIs have 
demonstrated cost-effective in the elderly Australian population; the incremental cost for QALY was reported to be 
29,535 Australian dollars, which is much lower than the target of $50,000 per QALY [53]. 
 
Because of the broad benefits of these agents, the American College of Cardiology Foundation and the American 
Heart Association recommend that statins and antihypertensive medications be initiated and maintained for the 
secondary prevention of CAD [27]. 
 
In summary, pharmacotherapy with statins and ACEIs/ARBs/beta-blockers is the mainstay of the effective CAD 
management. 
 
1.4 CAD Management and the Role of Incident Cancer 
It has been well documented that those with CAD have other co-existing conditions or at risk for developing 
new chronic conditions [54] and these conditions may compromise survival. Adults with CAD are more likely to 
develop other chronic conditions such as cancer, stroke, and congestive heart failure. Using the Duke Databank for 
Cardiovascular Diseases, Sachdev et al (2004) reported that co-existing chronic conditions were very common and 
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were associated with poor survival among individuals with CAD who had undergone medical treatment for CAD 
and followed for an average of 13.6 years [55]. 
Of these, the subsequent presence of incident cancer among individuals with CAD is especially important for 
many reasons: (i) CAD and cancer have shared risk factors and unique pathophysiology; (ii) adults with CAD are 
more likely to develop cancer; (iii) there can be negative effects of some cancer treatments on cardiovascular health; 
(iv) as both CAD and cancer are life-threatening conditions, the co-management of these conditions is especially 
challenging; and (v) both conditions are very costly to treat and manage and such heavy financial burden has 
implications for payers, healthcare providers and patients. 
 
1.4.1 Shared Risk Factors 
There is evidence that cardiovascular diseases including CAD and cancer share many biological (example: 
inflammation, oxidative stress, hyperglycemia, hypertension, hypertriglyceridemia) and behavioral risk factors such 
as obesity, tobacco use, and poor diet. Although the pathways between CAD and cancer are multifaceted and 
complex, these shared risk factors may lead to the development of cancer in individuals with CAD and vice versa 
[56]. For example, inflammation has been shown to mediate all stages (from initiation to progression, and 
thrombosis) of atherosclerosis, a precursor to CAD. Similarly, the role of inflammation in promoting carcinogenesis 
and tumor progression is well established, where inflammation promotes malignant transformation of cells, 
carcinogenesis, and its progression [56]. 
 
1.4.2 CAD as a Risk Factor for Cancer 
Some studies have provided evidence of CAD as a risk factor for development of cancer. The findings from the 
REDUCE study demonstrated that CAD was associated with a 35% increased risk of developing prostate cancer 
[57]. An elevated risk of prostate cancer (adjusted odds ratio, 2.00; 95% confidence interval, 1.18-3.39) has been 
reported among adults with CAD [58]. Diagnosis of CAD has also been associated with increased risk of colorectal 
cancer; Chan et al (2007) reported significantly (P<0.001) higher prevalence of colorectal cancer in those with CAD 
(34.0%) compared to their counterparts (18.8%) [59]. 
 
1.4.3 Negative Effects of Some Cancer Treatments on Cardiovascular Health 
While the goal of CAD management is to reduce coronary events, cancer treatments such as radiotherapy, 
chemotherapy, and hormone therapy can accelerate or worsen pre-existing cardiac disease [60-62]. Breast cancer 
treatments include chemotherapy (e.g., anthracyclines), surgery, radiation therapy, hormone therapy (e.g., 
tamoxifen), and targeted therapies (e.g., trastuzumab). Radiation therapy is of particular concern because of 
proximity to the heart, which can increase the risk of CAD or worsen pre-existing CAD resulting in major coronary 
events (e.g., heart attack) and even death. Anthracyclines and trastuzumab typically result in clinical heart failure or 
heart attack [63-65]. Androgen deprivation therapy (ADT) is the key therapeutic approach for metastatic prostate 
cancer and is also used in patients with a manifestation of disseminated disease with rising or elevated serum 
prostate-specific antigen. However, use of ADT increases the risk of CAD, the risk being further higher in those 
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with pre-existing CAD [66]. Colorectal cancer treatment comprises of surgery, chemotherapy (e.g., capacetabine, 5-
fluorouracil, bevacizumab, etc.), and radiation therapy. The cardiotoxicity is mainly attributed to chemotherapeutic 
agents used for treating advanced and/or metastatic colorectal cancer. For example, patients receiving 5-fluorouracil 
have 45% risk of angina and 22% risk of MI. Capecitabine is metabolized to 5-fluorouracil, thereby results in 
cardiotoxicity [67]. 
 
1.4.4 Dominant Condition as the Driver of Treatments: CAD or Cancer? 
Management of CAD in cancer patients is very challenging. Despite advancements in treatments, both CAD 
and cancer continue to be the leading causes of death [68]. Therefore, in medical decision making, in which life-
threatening conditions are prioritized, cancer can be considered as dominant condition that “eclipses” the 
management of CAD [69], specifically among the elderly. 
CAD-related care after cancer diagnosis may be prioritized because those with CAD may be at a higher risk for 
mortality compared to those without cancer. For example, it has been reported that women with breast cancer were 
at higher risk of mortality due to cardiovascular diseases as compared to women without breast cancer [70]. 
Furthermore, to reduce the negative effects of cancer treatment on cardiovascular health, providers may pay 
increased attention to CAD management, specifically the prescription of statins and ACEIs/ARBs/beta-blockers. A 
meta-analysis of randomized clinical trials and observational studies in general population indicated that statins, 
beta-blockers, and ACEIs/ARBs can reduce cancer treatment-related cardiotoxicity. Cardiac events were 
significantly reduced with beta-blockers (RR = 0.31 [95% CI 0.16–0.63], P = 0.001), statins (RR = 0.31 [95% CI 
0.13–0.77], P = 0.01) and ACEIs/ARBs (RR = 0.11 [95% CI 0.04–0.29], P < 0.0001) [71]. In addition, it is 
recommended that patients with unstable angina or acute MI should be evaluated and stabilized before they undergo 
cancer-related surgery [72] suggesting that CAD management will be prioritized before cancer treatment. 
On the other hand, cancer treatment may be prioritized because of “life-threatening” nature of the disease. 
Indeed, a patient with pre-existing CAD and incident cancer can be considered as a prototype example of a complex 
patient, as defined by Agency for Healthcare Research and Quality “two or more chronic conditions in which each 
condition might influence the care of the other condition, either through a limitation on life expectancy imposed by 
one of the conditions or because these two conditions generally entail therapies which are likely to have interactions 
with each other, or thirdly wherein one of these conditions might be requiring therapies that are contraindicated by 
the presence of the other conditions” [73]. 
 
1.4.5 Healthcare Expenditures: CAD and Cancer 
Both CAD and cancer are very costly to treat and manage and such heavy financial burden has implications for 
payers, healthcare providers and patients. It has already been established that heart disease is a very expensive 
medical condition [74]. Individuals with cancer also have higher expenditures as compared to those without cancer 
[74]. In terms of average per-capita healthcare expenditures, heart disease and cancer were the first and second most 
expensive conditions in the US [75]. Among all heart diseases, CAD is the most expensive condition [26]. CAD-
related expenditures are projected to increase from $135.7 billion in 2010 to $161.4 billion in 2020 [26]. Direct costs 
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of cancer are also projected to increase from $124 billion in 2010 to $158 billion in 2020 [76]. Diagnosis of incident 
cancer in individuals with pre-existing CAD can further result in increased costs resulting from cancer treatment-
related cardiotoxicity. 
 
In summary, incident cancer may play a crucial role in the management and CAD-related outcomes and costs, 
therefore, studies are needed to elucidate the relationship between incident cancer and pharmacotherapy for CAD 
management, CAD-related outcomes and healthcare expenditures. 
 
1.5 Significance of the Study 
To date, few studies have examined the management of CAD in elderly patients with pre-existing CAD and 
incident cancer. Such studies are warranted because of: (i) the relatively high burden of CAD as compared to other 
heart diseases; (ii) substantial disease burden of CAD among the elderly; (iii) high prevalence of CAD and cancer 
among the elderly; (iv) benefits of CAD-related pharmacotherapy for both CAD and cancer survival; and (v) cost 
implications of CAD and cancer. 
 
1.5.1 Burden of CAD in Comparison to Other Heart Diseases 
Among all the cardiac conditions, CAD is the most common form of heart disease in the US adults (≥18 years). 
In 2015, prevalence of CAD was 8.3% compared to other cardiac conditions, i.e., heart failure (3.0%) and stroke 
(3.4%) [26]. Based on National Center for Health Statistics (2008), CAD accounted for 49.9% of all cardiovascular 
deaths compared to stroke (16.5%), other cardiovascular disease (15.6%), hypertensive diseases (7.5%), heart failure 
(7.0%), and diseases of arteries (3.4%) [77]. Further, CAD accounted for $46.8 billion in direct costs compared to 
heart failure ($32.4 billion) and stroke ($38.0 billion) [26]. 
 
1.5.2 Burden of CAD in the Elderly Population 
The prevalence of CAD is highest among individuals 65 years and older; 19.8% of this population having CAD 
versus younger 8.4% among those under age 65 years [6]. Among 60 to 79 years’ age group, approximately 25% of 
men and 16% of women have CAD, and the prevalence further rises in those 80 years and older, i.e., 37% and 23% 
among men and women, respectively [27]. In addition, about 80% of CAD-related mortality is reported in among 
elderly population (65 years and older) [4]. 
The rates of mortality and morbidity further increase with increase in age. CAD accounts for one-third to one-
half of all deaths in the elderly Americans and about one in every four elderly CAD-related functional disabilities. In 
those above 65 years of age, about 8% die annually following MI and at least one half experience fatality related to 
other coronary events within 10 years. This mortality rate is double than that of individuals younger than 65 years of 
age [78]. In approximately 50% of patients, angina is the initial manifestation of CAD and the incidence of angina 
rises with increase in age [4]. Two population-based studies on elderly population (65 years and older) reported 
similar annual rates of MI in patients with symptoms of angina, i.e., 3% and 3.5% per year [79, 80]. 
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Given the higher prevalence of CAD in the elderly population, nearly three-quarters of total expenditures for 
CAD can be attributed to the individuals aged 65 years and older [81]. Moreover, with the increase in the older adult 
population in the US, it has been projected that, relative to year 2010 ($35.7 billion), expenditures for the treatment 
of CAD will increase 66% by the year 2030 ($106.4 billion) [26], and the fastest growth rate in costs will be among 
the elderly population (≥ 65 years) [26]. 
CAD is the second leading cause of disability among older adults, and this attributes to lower self-reported 
HRQoL in this population. Cardiovascular complication resulting from unstable CAD negatively affect physical 
functioning and their ability to perform routine activities of daily living [82]. Although not specific to CAD, an 
association between cardiovascular disease and frailty, resulting in increased risk of disability [83] has been 
reported. Results from the cardiovascular health study indicated that the presence of cardiovascular disease in 
elderly participants was associated with a loss of approximately 5.6 years and 6.5 years of “successful” life (i.e. with 
good health and function) in men and women, respectively [84]. 
 
1.5.3 CAD and Cancer in the Elderly Population 
Age is the most powerful non-modifiable risk factor for both CAD and cancer; the incidence of both cancer and 
cardiovascular disease increases with age [85-87]. Prevalence estimates indicate that 77% of all cancers are 
diagnosed in those aged 55 years or older. Similarly, the risk of CAD increases after the age of 55 years among men 
and 65 years among women [88, 89]. Amongst older individuals diagnosed with cancer, heart disease is the most 
common pre-existing condition; about 20% of elderly individuals with newly diagnosed cancer have some form of 
pre-existing cardiovascular condition [90]. Further, both CAD and cancer are the leading cause of morbidity and 
mortality in elderly population. 
Investigators from the CORONOR study reported that individuals with CAD have similar mortality rates as 
those of the general population [91] and among surgically treated individuals with CAD, the 10-year survival rate 
was estimated at 77% [92]. Therefore, many individuals with CAD can survive to old age. As many types of cancers 
are often considered as the disease of the elderly, an individual may develop cancer after CAD. 
 
1.5.4 Statins, Beta-blockers, ACEIs, and ARBs and CAD-related Outcomes 
While beneficial effects of pharmacotherapy with statins and ACEIs/ARBs/beta-blockers for secondary 
prevention are proven for individuals with CAD, these benefits can be achieved and sustained only when individuals 
adhere to these medications over a period of time. Medication adherence, the “extent to which an individual takes 
medications as prescribed by their healthcare providers” [93], is associated with reduced risk of hospitalizations, 
recurrent coronary events, and cardiovascular mortality [94, 95]. Furthermore, adherence to both statins and 
antihypertensive therapies have been reported to reduce the relative risk of CAD mortality by 80% [96]. In addition, 
optimal adherence to these pharmacotherapies significantly reduces annual costs for secondary prevention of CAD; 
between $294 and $868 per patient, accounting to 10.1% - 17.8% cost reductions between adherent and non-
adherent groups [94]. 
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1.5.5 Cost Implications of CAD and Cancer in the Elderly Population 
An overwhelming percent (96%) of the expenditures among the elderly are due to multiple chronic conditions 
[97, 98]. Cancer and heart disease are two of the most expensive conditions [75]. As 84% of the elderly over 65 
years of age are covered by Medicare [99], this has implications for healthcare financing reforms. As policy makers 
and providers have priorities better health, better value and lower costs, it is important to understand the financial 
burden of CAD and cancer for program, policy planning, and allocation of resources. 
 
To summarize, incident cancer plays a crucial role on CAD-related pharmacotherapy, outcomes, and expenditures. 
 
1.6 Need for the Study 
However, there is paucity of research on the impact of cancer on CAD-related pharmacotherapy, outcomes, and 
expenditures. There is a need for studies that exclusively focus on CAD-related pharmacotherapy, outcomes and 
expenditures among elderly fee-for-service (FFS) Medicare beneficiaries with incident breast, colorectal and 
prostate cancer because: (i) Medicare covers 84% of the elderly population and the primary payer of healthcare for 
the elderly; (ii) elderly share a disproportionate burden of CAD; and (iii) the cancer of breast, prostate, and 
colon/rectum, and lung/bronchus are the most common invasive cancers in the US. 
 
1.6.1 Medicare as the Primary Payer of CAD and/or Cancer 
Nearly 84% of the elderly are covered by Medicare. Payments made by Medicare for CAD are substantial. For 
example, in 2003, the Medicare program paid $12.2 billion for CAD-related hospitalizations, including $12,321 per 
discharge for acute MI and $11,783 per discharge for coronary atherosclerosis [100]. Similarly, Medicare payments 
for treatment of cancer totaled $29 billion in 2006. In addition, $2 billion were spent on drugs to treat the side-
effects of chemotherapy [101]. 
 
1.6.2 Disproportionate Burden of CAD among Elderly Population 
As discussed earlier, elderly population share a disproportionate burden of CAD [4]. Similarly, burden 
associated with cancer is also higher among elderly population [102]. Further, the prevalence of CAD is higher 
among elderly Medicare FFS beneficiaries, with 34% of beneficiaries aged 65 years and older were diagnosed with 
CAD compared to 19% of younger beneficiaries (aged <65 years) [97, 103]. Similarly, prevalence of cancer is 
higher among elderly Medicare beneficiaries [101]. As Medicare is the primary payer for healthcare expenditures 
for elderly Medicare beneficiaries [104], with nearly 42.9 million enrolled (based on 2013 enrollment in Medicare 
Part A and/or B) [99], it is important to focus on this population. 
 
1.6.3 CAD and Common Cancers 
The cancer of breast, prostate, colon/rectum, and lung/bronchus are the most common invasive cancers in the 
US population. Based on the Centers for Disease Control and Prevention statistics (2011), breast, lung, and 
colorectal cancer have the highest incidence rates among all female cancer cases; rates per 100,000 women are 
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122.0, 52.0, and 34.9, respectively. Prostate, lung, and colorectal cancer have the highest incidence rates among all 
male cancer cases; rates per 100,000 men are 128.3, 73.0, and 46.1, respectively [105]. Three cancer sites – breast, 
prostate, and colorectal cancers have been selected because of the availability of commonly used screening 
modalities and the existence of competing therapies. Further, with the currently available screening tests, these three 
cancers have a higher probability of diagnosis at an earlier stage compared to lung cancer, and thus improved 
survival rates. The estimated 5-year relative survival rate is 91% for women with breast cancer, 66% for patients 
with colorectal cancer, and 99% for patients diagnosed with prostate cancer, whereas it is only 18% for lung cancer 
[106]. These cancers are common among older adults (≥65 years). Based on the Surveillance, Epidemiology, and 
End Results (SEER) Program 2008-2012 statistics, incidence of breast cancer (41.8%), colorectal cancer (58.6%), 
and prostate cancer is 41.8%, 48.6%, and 56.7%, respectively [107]. In addition, prevalence of MI and CAD in 
elderly population with breast, colorectal or prostate cancer is about 15.4%, 7.4% or 6.1% and 10.2%, 16.0% or 
16.5%, respectively [108-114]. Thus, CAD and incident cancer are highly prevalent in common cancers such as 
breast, colorectal and prostate cancers. 
 
To summarize, studies on evaluating the relationship between incident cancer and CAD-related pharmacotherapy 
adherence, and expenditures and the broad benefits of CAD-related pharmacotherapy adherence on CAD-related 
outcomes among elderly cancer patients are needed for informing clinical practice, research, program planning, 
and allocation of resources. However, there are critical gaps in knowledge because of paucity of studies in this 
area. The present dissertation is aimed at addressing these aforementioned critical gaps in knowledge by focusing 
on a cohort of elderly Medicare beneficiaries with pre-existing CAD and a diagnosis of incident breast, colorectal 
or prostate cancer. 
 
1.7 Specific Aims 
The specific aims, objectives, and hypothesis of the dissertation are as follows. 
Aim 1: Examine the relationship between incident cancer and adherence to statins and/or ACEIs/ARBs/beta-
blockers among elderly fee-for-service Medicare beneficiaries with pre-existing CAD by comparing those with 
incident (breast, colorectal, and prostate) cancer and without cancer. 
Hypothesis: Adherence to CAD-related concomitant pharmacotherapy will be lower among elderly Medicare 
FFS beneficiaries with CAD and incident cancer as compared to those with CAD and no cancer. 
 
Aim 2: Examine relationship between adherence to both statins and ACEIs/ARBs/beta-blockers and CAD-related 
hospitalizations among elderly fee-for-service Medicare beneficiaries with pre-existing CAD and incident breast, 
colorectal, or prostate cancer, after controlling for cardiotoxic cancer treatments and other risk factors that may 
affect CAD-related hospitalizations. 
Hypothesis: Better adherence to concomitant therapy will be associated with lower risk of CAD-related 
hospitalizations, after controlling for cancer treatment and other risk factors. 
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Aim 3: Estimate the association between incident cancer and short-term CAD-related healthcare expenditures by 
comparing the elderly fee-for-service Medicare beneficiaries with pre-existing CAD and incident cancer to their 
counterparts with CAD and no cancer. 
Hypothesis: The short-term CAD expenditures will be higher among those with CAD and incident cancer as 
compared to those with CAD and no cancer. 
 
1.8 Innovation and Unique Contribution of the Study 
Cardio-oncology or onco-cardiology is an emerging field and most of the existing evidence on management of 
heart diseases in individuals with cancer is based on clinical expert opinion. There is paucity of studies on the 
influence of cancer diagnosis on management of CAD. Our study will contribute to the nascent literature on 
management of CAD in patients with cancer. There are several facets of our study that makes it unique and 
important for understanding the impact of cancer on CAD related medication adherence, outcomes, and healthcare 
expenditures. 
First, the current dissertation fills a critical knowledge gap on the management of chronic conditions among 
cancer survivors has been very limited. It is important to recognize ways in which pre-existing conditions could 
affect the health of cancer patients so that patient-centered care and individualized treatment can be achieved [115]. 
Second, our study can illuminate the complex relationship between CAD management and incident cancer. 
Prior studies have suggested that cardiovascular disease management is compromised in cancer patients. A study 
utilizing Medicare-linked database examined management of cardiovascular disease in older women (≥ 65 years) 
with breast cancer and concluded that these women received inadequate treatment and care for heart problems. Their 
study findings indicate that about 12% of these older women with breast cancer developed heart failure within three 
years of cancer diagnosis and treatment. Further, the findings indicate that only 33% of these patients saw a 
cardiologist within 90 days of developing heart problems [116]. Another study, examined quality of care for chronic 
disease, such as cardiovascular disease, diabetes, and hypertension in cancer survivors, and concluded that the 
cancer survivors received inadequate care for these chronic conditions compared to those without cancer [117]. 
Third, this study is a population-based study utilizing “real-world” data. It has been pointed out by the 
investigators of the CLARIFY study among individuals with stable CAD that real-world studies on CAD are needed 
because “clinical trials or registries which often have stringent exclusion criteria, and do not adequately represent 
populations with stable CAD (in terms of age, comorbidity, and concomitant therapy)” [118]. The current 
dissertation highlights the importance of real-world studies. 
Fourth, this dissertation focuses on elderly population and it is estimated that by 2050, there will be 83.7 
million over the age of 65 [119]. Both CAD and cancer are highly prevalent in aging population. Further, it has been 
previously reported that elderly patients are under-represented in clinical trials, with individuals older than age 65 
years representing only 38% of enrolled patients, specifically those with comorbid conditions [120]. Understanding 
the influence of life events such as cancer diagnosis on management of pre-existing chronic conditions are important 
to the growing elderly population with multiple chronic conditions. Our proposed study is the next best alternative to 
clinical trials for understanding this relationship. 
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Fifth, this dissertation focuses on elderly FFS Medicare beneficiaries. As discussed earlier, Medicare is the 
primary payer of healthcare for elderly in the US [104]. Therefore, Medicare bears the largest share of the clinical, 
humanistic, and economic burden in this population. The findings from this study will have implications for the 
various healthcare delivery and financing reforms such as the establishment of accountable care organizations, 
patient-centered medical home and others undertaken by the Centers for Medicare and Medicaid Services, which is 
responsible for setting policy priorities and healthcare payments. 
Sixth, this dissertation can provide insight into co-management for multiple conditions. CAD and cancer 
share a unique relation. In general, it is difficult to manage multiple health conditions in elderly patients as treatment 
of one medical condition may interfere with treatment of other medical condition [73]. There is paucity of evidence 
on CAD management in patients with cancer. The study findings may be useful in understanding the influence of 
cancer on CAD management. 
 
1.9 Conceptual Framework 
The selection of variables was guided by conceptual frameworks and these differed by specific aims. 
 
1.9.1 Conceptual Framework: Aim 1 
A conceptual framework by Park and Jones was adapted for understanding influence of cancer on adherence to 
cardiovascular medications among elderly population. This model considers patient-related factors, health-system 
factors, provider factors, and external environment. This model has also been used previously by Gellad et al (2009) 
for understanding factors that affect adherence to medications in elderly population [121]. The conceptual 
framework is shown in Error! Reference source not found.. 
 
Figure 1.1 Conceptual framework adapted from Park and Jones for medication adherence. 
Abbreviations – CAD: Coronary artery disease; SEER: Surveillance, Epidemiology, and End Results 
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1.9.2 Conceptual Framework: Aim 2 and Aim 3 
The Andersen behavioral model of health service use and outcomes was adapted for this study as it provides an 
appropriate framework for understanding the relationship between explanatory variables and outcomes. This 
framework also provides basis for selecting other independent variables that may influence CAD outcomes [122, 
123].   
This original model was developed by Andersen and his colleagues in 1968 and has been used to examine 
various types of healthcare utilization in elderly population with chronic conditions. It is a multi-level model that 
includes both individual and contextual determinants of healthcare utilization and categorizes these determinants 
into predisposing, enabling, and need factors, personal health practices/ health behavior, and external environment 
[124, 125]. 
The predisposing factors are the individual’s demographic characteristics which decide their proclivity towards 
healthcare utilization. Factors such as age, sex, and race/ethnicity are “biological imperatives” that influence their 
unique predisposition towards use of healthcare services. The enabling factors include resources available to each 
individual that enable them to obtain services. In the context of this study, these factors include marital status, 
Medicaid coverage (insured, uninsured), education, income, and poverty status. The need-based factors at the 
individual level are those related to the perceived need for health services due to functional and health problems. In 
the context of this study, need-based variables include cancer type, stage of cancer, cancer treatment, comorbid 
chronic physical conditions, and mental health conditions. The personal health practices include tobacco use, alcohol 
abuse, and healthcare-seeking behavior. The external environment includes following variables for this study - 
SEER region, area of residence, health professional shortage area (HPSA), county level number of oncologists and 
cardiologists, and centers for cardiovascular care. The conceptual framework for CAD-related hospitalizations as the 
outcome is shown in Figure 1.2 and for CAD-related healthcare expenditures as the outcome is shown in Figure 1.3 
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Figure 1.2 Conceptual framework adapted from the Andersen Behavioral Model of Health Service Use for 
medication adherence and health outcomes. 
Abbreviations – CAD: Coronary artery disease; PCP: Primary care physician; SEER: Surveillance, Epidemiology, 
and End Results; SES: Socioeconomic status 
 
 
Figure 1.3 Conceptual framework adapted from the Andersen Behavioral Model of Health Service Use for 
medication adherence and economic outcome. 
Abbreviations – CAD: Coronary artery disease; PCP: Primary care physician; SEER: Surveillance, Epidemiology, 
and End Results; SES: Socioeconomic status   
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1.10 Data Sources for the Study 
Data for the study population will be derived from the SEER-Medicare linked files. The comparison group of 
non-cancer patients will be derived from the non-cancer 5% sample files. The files will also be linked to the Area 
Health Resources File (AHRF), census tract files, and county health ranking files. 
 
1.10.1 SEER-Cancer Registry 
SEER program is an epidemiologic surveillance system consisting of population-based tumor registries that 
collects data on all incident cases of cancer that occur in persons residing in 18 SEER areas. These areas include 
Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, Utah, Los 
Angeles and San Jose-Monterey, Rural Georgia, Alaska Native, Greater California, Kentucky, Louisiana, New 
Jersey, and Greater Georgia. SEER data also consists of information about demographic characteristics of the 
patient, diagnosis date, cancer site, stage, and grade, and type of surgical treatment and radiation therapy provided 
within 4 months of diagnosis [126]. The Patient Entitlement and Diagnosis Summary File (PEDSF) contains all of 
this information from the SEER program. 
 
1.10.2 Medicare 
Medicare is the primary health insurance provider of US population above 65 years of age and thus, SEER data 
have been linked to Medicare claims. This database consists of the following files - Medicare Provider Analysis and 
Review (MEDPAR), the Carrier Claims (old name National Claims History (NCH) from physician/supplier), 
Outpatient, Home Health Agencies (HHA), Hospice, Durable Medical Equipment (DME), and Part D Event (PDE) 
files. The MEDPAR file includes hospital claims for all short- and long-term and skilled nursing facility stay. The 
NCH file contains claims from physicians and other non-institutional care providers and has procedure codes 
according to the Health Care Procedure Classification Code (HCPCS) and the Common Procedural Terminology, 
4th Edition (CPT-4), and the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM) procedure codes with service dates. The outpatient file includes claims from institutional outpatient providers, 
including hospitals, rural health clinics, and mental health centers. 
Part A of the Medicare program consists of the following types of services - inpatient hospitalization, Skilled 
Nursing Facility (SNF), home health agency services (HHA) following hospital stay and hospice care. Part B of the 
Medicare program includes physician services, outpatient services, diagnostic test, DME, emergency room visits, 
home health care not following a hospital stay, laboratory services, and other medical services. Part D of the 
Medicare program covers prescription drugs. The Medicare started providing voluntary outpatient medications 
coverage (Part D) since January 2006, and hence Part D data is available only after 2006. 
 
1.10.3 SEER-Medicare 
The Medicare data files have been linked with PEDSF file of cancer cases from SEER using an algorithm based 
on the social security number, last name, first name and date of birth of an individual. Approximately 94% of the 
SEER cancer cases over age 65 years with Medicare enrollment have been linked using this method [126]. Based on 
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the linkage, a common encrypted identification number is given to each enrollee in PEDSF and claims files. Each 
record represents an episode of hospital stay. These records can have up to 10 diagnoses (ICD-9-CM codes) for each 
date of admission and date of discharge. 
 
1.10.4 SEER Non-Cancer Medicare 
SEER non-cancer Medicare database also provides a 5% non-cancer random sample from Medicare program in 
the same catchment areas as those in SEER program that can be used to compare cancer and non-cancer case. The 
Summarized Denominator file (SUMDENOM) provides demographic information. These beneficiaries are 
randomly selected based on the last two digits of their social security number [126]. The individuals who have been 
reported to SEER with an incident cancer are removed from this 5% random sample. The demographic and other 
Medicare enrollment data for non-cancer cases are identical to those of cancer cases and can be linked with the 
cancer files using each beneficiary’s unique Medicare claim number [127]. 
 
1.10.5 American Community Survey (ACS) Census Tract Files 
The ACS 2008 to 2012 census tract and census zip code files were linked to PEDSF files by geographic codes, 
i.e., state and county [128]. These files provided information on the census tract median household income and 
education level. 
 
1.10.6 AHRF File 
The AHRF is a publicly available data file provided by Department of Health and Human Services and contains 
county, state and national files. The AHRF provides more than 6,000 variables for each of the nation's counties. The 
AHRF contains information such as health facilities, health professions, and socioeconomic and environmental 
characteristics. The basic file contains geographic codes and descriptors that can be used to link it to other files and 
to aggregate counties into various geographic groupings [129]. This study will use the AHRF variables to measure 
health care infrastructure and socio-economic status of the counties that can influence medication adherence, CAD-
related outcomes and healthcare expenditures. 
 
1.10.7 County Health Ranking File 
The county health ranking file was linked to PEDSF files by geographic codes, i.e., state and county. These files 
provide a snapshot of a community’s health, such as rates of smoking, obesity, and other health status measures at 
the county-level [130]. These variables can be used as a proxy for external health environment that can influence 
medication adherence, CAD-related outcomes and healthcare expenditures. 
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2 CHAPTER 2 
Incident Cancer and Adherence to Statins and Antihypertensive 
Medications for Coronary Artery Disease among Elderly Medicare 
Beneficiaries 
 
2.1 Abstract 
Objectives: To examine the relationship between incident cancer and adherence to statins and angiotensin-
converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), or beta-blockers among elderly 
individuals with coronary artery disease (CAD). 
Methods: This was a retrospective observational longitudinal study assessing elderly Medicare fee-for-service 
beneficiaries with pre-existing CAD and those with incident breast (BC), colorectal (CC), or prostate (PC) cancer (N 
= 12,096) and those with no cancer (NC) (N = 42,805). Adherence to pharmacotherapy was measured every 120 
days during the one-year pre- and one-year post-index period. Due to the overlap between cancer type and sex, 
cancer diagnosis was grouped into: (1) women with BC; (2) women with CC; (3) women with NC; (4) men with PC; 
(5) men with CC; and (6) men with NC. Medication adherence was categorized into five mutually exclusive groups: 
(1) adherent to both statins and ACEIs/ARBs/beta-blockers; (2) not adherent to both statins and ACEIs/ARBs/beta-
blockers (reference group); (3) adherent to either statins or ACEIs/ARBs/beta-blockers; (4) use of one medication 
class and adherent to that class; and (5) use of one medication class and not adherent to that medication class. The 
adjusted relationship between incident cancer and medication adherence was analyzed using the generalized 
estimating equation. Inverse probability treatment weights were used to account for observed group differences 
between cancer and non-cancer groups. 
Results: Only 28.9% of the elderly with CAD were adherent to both statins and ACEIs/ARBs/beta-blockers. In the 
adjusted analyses, women [AOR = 0.70; 95% CI = 0.58, 0.81; P < 0.0001] and men [AOR = 0.63; 95% CI = 0.51, 
0.75; P < 0.0001] with CC and men with PC [AOR = 0.92; 95% CI = 0.85, 0.99; P = 0.022] were significantly less 
likely to be adherent to both medication classes compared to women and men with NC, respectively. No significant 
differences in adherence to medications were observed among women with BC compared to women with NC. Even 
among those using single medication class, women [AOR = 0.64; 95% CI = 0.50, 0.79; P < 0.0001] and men with 
CC [AOR = 0.59; 95% CI = 0.42, 0.76; P < 0.0001] were significantly less likely to be adherent to that medication 
class compared to women and men with NC. 
Conclusions: Adherence to evidence-based medications for CAD varied by cancer types. Elderly Medicare 
beneficiaries with CC or PC were less likely to be adherent to evidence-based medications for CAD. Future research 
needs to explore the effect of non-adherence to concomitant medications on health outcomes such as survival among 
patients with incident CC and PC. 
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2.2 Introduction 
The two main goals of coronary artery disease (CAD) management are reduction of symptoms and ischemia as 
well as prevention of myocardial infarction and death [29]. The use of angiotensin-converting enzyme inhibitors 
(ACEIs), angiotensin II receptor blockers (ARBs), beta-blockers, and statins has become the standard of treatment 
among individuals with CAD. These medication classes have proven to reduce the risk of major coronary events 
[27], hospitalizations for CAD and recurrent coronary events [94, 95], and cardiovascular mortality by 11–35% 
[131, 132] through improving lipid and blood pressure control [94, 133]. Therefore, CAD management guidelines 
recommend initiating and maintaining these regimens indefinitely in adults with CAD [27, 134]. 
Further, adherence to combined use of statins and ACEIs/ARBs/beta-blockers have been reported to reduce the 
relative risk of CAD mortality by 80% [96]. On the contrary, non-adherence to statins has been shown to increase 
the risk of adverse cardiovascular events (myocardial infarction, heart failure, or stroke) and mortality [94]. 
Nevertheless, non-adherence to statins, beta-blockers, and ACEIs/ARBs is common in the elderly with 
cardiovascular disease [135-138]. A study on elderly Medicare beneficiaries discharged from the hospital after their 
first myocardial infarction reported that only 46.4% were adherent to beta-blockers, ACEIs/ARBs, and statins [138]. 
While many patient, provider, and health-system factors affect medication adherence in the elderly [139-142], 
development of an additional chronic condition may also impact adherence. Since both CAD and cancer are life-
threatening conditions, it may be challenging to effectively manage both simultaneously. Some types of cancer can 
be considered as a dominant condition that “eclipse” the management of CAD [69], whereas other types of cancer 
with a higher expected cure rate, CAD-related care after cancer diagnosis may be particularly important in order to 
reduce the probability of CAD morbidity and mortality due to cancer-related treatments like surgery [72], 
chemotherapy, and radiation [60, 61]. Some medications designed for CAD may even have anti-cancer properties, as 
recent epidemiological studies suggest additional benefits of statins in terms of reduced cancer recurrence and 
cancer-specific mortality among individuals with breast [143], colorectal [144], and prostate cancer [145, 146]. 
However, there is paucity of studies examining adherence to CAD medications in the context of a new cancer 
diagnosis. Calip et al reported a decline in adherence to statins (average medication possession ration (MPR) = 0.78 
vs. 0.68; P<0.001) in the period just after breast cancer diagnosis [147], but the findings from this study may be 
limited because it did not include a non-cancer comparison group. Without a non-cancer comparison group, it is not 
known whether adherence decline is due to cancer or due to the passage of time. Furthermore, the findings may not 
be generalizable to other cardiovascular medications like ACEIs/ARBs/beta-blockers, or elderly patients. Data 
assessing medication adherence among the elderly is particularly limited [148], despite the fact that both cancer 
[102] and CAD [4] disproportionately affect the elderly. In the United States (US), the prevalence of CAD is higher 
among the elderly (19.8%) compared to those under age 65 years (8.4%) [6]. Nearly 80% of CAD-related mortality 
is reported among the elderly population [4]. Similarly, breast, colorectal, and prostate cancer are very common 
among the elderly, with 42.3%, 57.7%, and 56.9% suffering from these cancers, respectively [107]. Examination of 
adherence to statins and ACEIs/ARBs/beta-blockers among the elderly is also important for policy purposes because 
 19 
 
Medicare provides coverage for almost all of the elderly in the US [99] and Medicare payments for CAD [100] and 
cancer care [101] are substantial. 
Therefore, the primary objective of the current study is to examine the relationship between incident cancer and 
adherence to statins and/or ACEIs/ARBs/beta-blockers among elderly Medicare beneficiaries with pre-existing 
CAD by comparing those with incident (breast, colorectal, and prostate) cancer and without cancer. 
 
2.3 Methods 
2.3.1 Conceptual Framework 
The conceptual framework by Park and Jones [121, 149] was adapted to select factors that can influence 
adherence to pharmacotherapy among elderly patients with CAD (Figure 1.1). This framework posits that patient-
related factors (e.g., age, sex, race, census tract education level, poverty status, co-existing chronic physical and 
mental health conditions, tobacco and alcohol use), health-system (e.g., Medicare coverage gap), provider-related 
factors (e.g., visits to primary care and cardiologist), and environmental factors (e.g., Surveillance, Epidemiology 
and End Results [SEER] region, county metro status, community health clinics, county-level health professional 
shortage area [HPSA], and percent of cardiologists and oncologists in the county) affect medication adherence. 
 
2.3.2 Study Design 
The study utilized a retrospective observational longitudinal cohort design with 12-month pre- and 12-month 
post-index period (Figure 2.1). Pre- and post-index periods were defined based on cancer diagnosis dates for the 
cancer cohort. For the non-cancer cohort, pre- and post-index periods were derived using pseudo-diagnosis dates 
randomly selected from the dates of service. A 36-month window, divided into a 24-month baseline (for 
identification of CAD and baseline characteristics) and a 12-month (pre-index) periods were created. The post-index 
period consisted of 12 months after the index date. Adherence to statins and ACEIs/ARBs/beta-blockers and 
selected variables were measured repeatedly every 120 days during the pre- and post-index period, yielding a total 
of six repeated measures for each individual. Thus, t1, t2, and t3 represented the pre-index period and t4, t5, and t6 
represented the post-index period. 
Figure 2.1. Schematic presentation of study design 
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The longitudinal design with repeated measurement of adherence and other variables enabled tracking of the 
variability of adherence within and between individuals. By including a non-cancer comparison group, the study 
avoids the maturation threat to internal validity (i.e. the processes within subjects which act as a function of the 
passage of time). 
 
2.3.3 Data Sources 
Linked data from the following sources was utilized: 1) the SEER registries; 2) Medicare claims linked with the 
SEER registries; 3) 5% non-cancer random sample of Medicare beneficiaries in SEER region; 4) the American 
Community Survey (ACS), and 5) the Area Health Resource Files (AHRF). SEER program is an epidemiologic 
surveillance system consisting of population-based tumor registries that collects data on all incident cases of cancer 
that occur in persons residing in 18 SEER areas. SEER data also consists of information about demographic 
characteristics of the patient, diagnosis date, cancer site, stage, and grade, and type of surgical treatment and 
radiation therapy provided within four months of diagnosis [126]. Individuals without cancer were identified from 
the 5% non-cancer random sample of Medicare beneficiaries living in same catchment areas as those in SEER 
program. These beneficiaries were randomly selected based on the last two digits of their social security number 
[126]. We derived information on the census-tract level poverty status and education from the ACS [128]. The 
individuals who have been reported to SEER with an incident cancer are removed from this 5% random sample. 
County-level healthcare environment factors (community health clinics, HPSA, and percent of cardiologists and 
oncologists in the county) were derived from the AHRF [129]. 
 
2.3.4 Study Population 
The study population comprised individuals with pre-existing CAD and those with incident breast, colorectal, or 
prostate cancer and those without cancer. Individuals with CAD were identified using a validated algorithm 
developed by the Centers for Medicare and Medicaid Services (CMS) [150] to identify individuals with pre-existing 
CAD. The algorithm used the International Classifications of Diseases – 9th edition, Clinical Modification (ICD-9-
CM) codes. Individuals with at least one inpatient, outpatient and carrier claims (clinician encounters only), or home 
health agency service Medicare claims with a primary or secondary diagnosis of CAD during the baseline were 
classified as having pre-existing CAD. 
Cancer and No Cancer Comparison Groups: Individuals with incident cancer, January 2008 through December 
2011, were identified using the International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) codes 
from the SEER registries. Individuals without cancer were identified from the 5% non-cancer Medicare claims from 
the SEER regions. 
Other inclusion criteria were age 68 years or older, alive with continuous FFS Medicare Part A, B enrollment 
during the entire study period, continuous part D enrollment during the pre- and post-index period, no missing 
information on county, and who had two or more prescriptions for either statins or two prescriptions for any or 
combinations of ACEIs, ARBs, or beta-blockers. In the non-cancer cohort, individuals with end-stage renal disease 
were excluded prior to diagnosis date assignments. In the cancer cohort, individuals with missing data for type and 
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stage of cancer and those who were diagnosed with cancer through autopsy or death certificate were excluded. The 
selection criteria are presented in Figure 2.2. 
 
2.3.5 Measures 
2.3.5.1 Dependent Variable: Adherence to Statins, ACEIs/ARB/Beta-blockers 
As this paper focuses on adherence over a long period of time, proportion of days covered (PDC) measure was 
used. PDC has been recommended by the Pharmacy Quality Alliance [151] and used by the CMS in its rating of 
insurance plans [152]. Statins, ACEIs, ARBs, and beta-blockers were identified using the generic names in the Part 
D Prescription Drug Event files. PDC of these medication classes were calculated only among those who filled at 
least two prescriptions for either statins or two prescriptions for ACEIs, ARBs, or beta-blockers. PDC was 
calculated as number of days of medication supplied during each time period (example: t1) divided by the number of 
days in each time period (i.e. 120 days). For those with a drug regimen (i.e. statins and ACEIs/ARBs/beta-blockers), 
PDC considers days within a particular period when an individual is covered for both statins and ACEIs/ARBs/beta-
blockers. PDC ranges from 0 to 1. Individuals with PDC ≥80% were considered as adherent and those with PDC 
<80% as non-adherent [153]. 
We combined the adherence indicator (yes/no) and the type of drug regimens and classified individuals with 
CAD into five mutually exclusive groups: (1) adherent to both statins and ACEIs/ARBs/beta-blockers; (2) not 
adherent to both statins and ACEIs/ARBs/beta blockers; (3) adherent to either statins or ACEIs/ARBs/beta-blockers; 
(4) use of one medication class and adherent to that class; and (5) use of one medication class and not adherent to 
that medication class. This provides more granularity to the understanding of medication adherence based on use 
and adherence. 
 
2.3.5.2 Key Independent Variable: Cancer Type and Sex 
As the study included sex-specific cancers (breast and prostate cancer), the key independent variable was 
categorized into six mutually exclusive groups: women with breast cancer (BCW), women with colorectal cancer 
(CCW), women with no cancer (NCW), men with prostate cancer (PCM), men with colorectal cancer (CCM), and 
men with no cancer (NCM). 
 
 22 
 
Figure 2.2. Schematic presentation of selection criteria for study cohort. 
 
Abbreviations – ACEIs: Angiotensin-converting enzyme inhibitors; ARBs: Angiotensin II receptor blockers; BB: Beta-blockers; CAD: Coronary artery disease; 
HMO: Health Maintenance Organization; Rx: Prescription 
In the non-cancer cohort, individuals with end-stage renal disease were excluded prior to diagnosis date assignments.
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2.3.5.3 Other Independent Variables 
Patient-related factors 
These were time-invariant except when specified otherwise and were measured during baseline. These included 
(i) demographics – age in years measured at index month of incident cancer diagnosis, sex, and race/ethnicity; (ii) 
census-tract socioeconomic status - poverty status and education level; and (iii) CAD severity – a proxy measure 
was used for CAD severity based on the CMS hierarchical condition category (HCC) classification system. Based 
on the CMS risk adjustment model, each of the HCC codes for CAD was assigned specific score based on the risk 
and severity [154], ranging from 0.231 to 0.349. Thus, higher scores represented severe manifestations of CAD. 
Other physical and mental health conditions were selected based on the suggestions of the Multiple Chronic 
Conditions working group [155]. These were categorized into concordant (cardiac arrhythmias, congestive heart 
failure, diabetes, hyperlipidemia, hypertension, and stroke) and discordant (dementia, asthma, chronic obstructive 
pulmonary disease, arthritis, hepatitis, human immunodeficiency virus, and osteoporosis) conditions. Mental health 
conditions included severe mental illness (measured at baseline) and anxiety, depression, tobacco use, and alcohol 
use (measured every 120 days). 
 
Health-system factors 
Medicare Part D coverage gap was measured every 120 days. Part D plans typically start with an annual 
deductible, after which Medicare pays for the prescription drugs up to an initial coverage limit with certain 
coinsurance associated with those payments. The plan stops coverage once an individual reaches the annual 
coverage limit until the cost of prescription drugs reaches to catastrophic limit. The phase between the annual 
coverage limit and catastrophic coverage is called "donut hole" or "Medication coverage gap". During this period, 
enrollees have to bear the entire prescription drug costs. [156]. Based on their status of coverage, patients were 
categorized into three groups – not reached, reached, exceeded donut hole. 
 
Provider-related factors 
This included visit to primary care physician or cardiologist (yes/no), measured every 120 days. 
 
Environmental factors 
This domain included SEER region – Northeast (Connecticut, New Jersey), South (Kentucky, Louisiana, 
Atlanta, rural Georgia, and Greater Georgia), North-central (Detroit, Iowa), and West (San Francisco, Hawaii, New 
Mexico, Seattle, Utah, San Jose, Los Angeles, Greater California), county metro status (metro and non-metro), 
based on urban/rural continuum codes from the AHRF, community health resources – (county-level community 
health clinics, county-level health professional shortage area (HPSA), and percent cardiologists and oncologists in 
the county). These were measured at baseline. 
 
2.3.6 Statistical Analyses 
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Unadjusted subgroup differences in time-invariant characteristics between cancer and non-cancer cohorts were 
tested with chi-square statistics. As medication adherence was measured every 120-days during pre- and post-index 
period, each individual had six observations. These six observations were not independent and applying standard 
regression techniques can lead to misleading results. Therefore, the unadjusted and adjusted relationship between 
cancer and medication adherence were analyzed with a repeated measures design using the generalized linear mixed 
models (GLMM), which can accommodate both linear and non-linear outcome variables. Mixed-effects models are 
very useful in modeling both within and between subject variations. Some non-linear models that can be considered 
for repeated measures include population-averaged (PA) and subject-specific (SS) models [157]. For categorical 
outcomes, the generalized estimating equations (GEE) is often used to model PA effects and random-effects logistic 
regressions can be used to estimate SS effects. Under the GEE approach, the correlation between repeated measures 
within an individual is accounted by a robust estimation, even when the dependency is miss-specified [158]. In this 
study, the PA approach was chosen because the objective is to estimate the average differences in adherence 
between cancer and non-cancer cohorts. 
The adjusted GEE model controlled for time, age, race/ethnicity, census tract education level, poverty status, 
chronic physical and mental health conditions, tobacco use, alcohol use, Medicare coverage gap, visits to primary 
care and/or cardiologist, SEER region, county metro status, community health clinics, county-level HPSA, and 
percent of cardiologists and oncologists in the county. 
 
2.3.6.1 Inverse Probability Treatment Weights (IPTW) 
Our preliminary analyses indicated that there were significant group differences in sex, age, race/ethnicity, 
SEER region, and index year between the cancer and non-cancer cohorts. Therefore, we derived the IPTW and used 
these weights to adjust for these observed differences between cancer and non-cancer cohorts. We derived IPTW 
from the probability of cancer or no cancer based on a logistic regression on cancer and non-cancer with sex, age, 
race/ethnicity, SEER region, and index year as independent variables. The inverse probabilities of cancer or no 
cancer were used as weights in medication adherence analyses. Such weighting allows balancing of sex, age, 
race/ethnicity, SEER region, and index year between the cancer and non-cancer cohorts. Table 2.1 summarizes the 
findings from the logistic regression model used to calculate IPTW. 
 
2.4 Results 
2.4.1 Characteristics of the Study Population Before and After IPTW Adjustment 
The study population comprised 54,901 elderly FFS Medicare beneficiaries with pre-existing CAD (12,096 
with cancer and 42,805 without cancer). Table 2.2 summarizes the characteristics of cancer and non-cancer cohorts 
before and after IPTW adjustment. Prior to adjustment, those with cancer were less likely to be women than men 
(47.2%% vs 62.5%), more likely to be younger than older (example: 80 or older) (66.3% vs 57.2%), and more likely 
to be Whites than African Americans, Hispanics, or other groups (82.1% vs 77.8%). After adjusting with IPTW, 
there were no significant differences in sex, age, race/ethnicity, SEER region, and index year between the cancer and 
non-cancer cohorts. 
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Table 2.1. Logistic Regression Models used to derive IPTW–Cancer and 5% Non-Cancer Sample 
Characteristics OR 95% CI Significance 
Age groups  
68-70 years 1.03 [0.97,1.10]  
71-74 years 1.33 [1.26,1.41] *** 
75-79 years 1.36 [1.29,1.44] *** 
80 years or older  Reference 
Sex    
Female 0.52 [0.50,0.55] *** 
Male Reference 
Race/Ethnicity    
African Americans 0.96 [0.89,1.04]  
Hispanics 0.61 [0.54,0.69] *** 
Others 0.57 [0.52,0.62] *** 
Whites Reference 
SEER Region    
Northeast 1.13 [1.06,1.19] *** 
South 0.98 [0.93,1.04]  
North-central 1.25 [1.17,1.34] *** 
West Reference 
Index year    
2008 1.07 [1.00,1.13] * 
2009 1.04 [0.98,1.10]  
2010 0.98 [0.93,1.04]  
2011 Reference 
 
Asterisks represent significant differences in study population characteristics (time-invariant), non-cancer group 
(reference category) for dependent variable. 
***p < 0.001; **0.001 ≤ p < 0.01; *0.01 ≤ p < 0.05. 
 
Abbreviations 
IPTW: Inverse probability of treatment weighting; OR: Odds ratio 
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Table 2.2. Number, Percent, and Weighted Percent of Patient-level Characteristics by Presence of Cancer 
  Before IPTW After IPTW 
Characteristics Cancer cohort Non-cancer cohort Sig Cancer cohort Non-cancer cohort Sig N % N % Wt. % Wt. % 
Age groups     ***   NS 
68-70 years 1,983 16.4 6,860 16.0  16.0 16.1  
71-74 years 2,887 23.9 8,186 19.1  19.8 20.1  
75-79 years 3,158 26.1 9,423 22.0  22.8 22.9  
80 years and older 4,068 33.6 18,336 42.8  41.5 40.9  
Sex     ***   NS 
Female 5,712 47.2 26,764 62.5  59.4 59.2  
Male 6,384 52.8 16,041 37.5  40.6 40.8  
Race/Ethnicity        NS 
Whites 9,928 82.1 33,308 77.8 *** 78.8 78.8  
African Americans 1,013 8.4 3,538 8.3  8.2 8.3  
Hispanics 319 2.6 1,687 3.9  3.7 3.7  
Others 836 6.8 4,272 10.0  9.3 9.3  
SEER Region     ***   NS 
Northeast 2,749 22.7 9,021 21.1  21.5 21.4  
South 2,977 24.6 10,963 25.6  25.3 25.4  
North-central 1,691 14 5,029 11.7  12.2 12.2  
West 4,679 38.7 17,792 41.6  41 40.9  
Index year     *   NS 
2008 2,966 24.5 10,001 23.4  23.2 23.6  
2009 2,975 24.6 10,480 24.5  24.5 24.5  
2010 2,992 24.7 11,133 26.0  26 25.8  
2011 3,163 26.1 11,191 26.1   26.3 26.1   
Asterisks represent significant differences in time-invariant patient-level characteristics based on chi-square tests   
***p < 0.001; **0.001 ≤ p < 0.01; *0.01 ≤ p < 0.05. Column percentages are reported. 
Abbreviations 
ACEI: Angiotensin-converting enzyme inhibitors; ARB: Angiotensin II receptor blockers; CAD: Coronary artery disease; IPTW: inverse probability treatment 
weighting; Sig: Significance 
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2.4.2 Unadjusted and Adjusted Relationship between Cancer and Adherence to Statins and/or 
ACEIs/ARBs/Beta-blockers 
Table 2.3 summarizes the number and weighted percentage of medication adherence categories among cancer 
and non-cancer cohorts. Overall, only 29.1% were adherent to both statins and ACEIs, ARBs, or beta-blockers and 
14.6% were not adherent to both of these medication classes. Even among those with single medication class, 14.7% 
were not adherent. Table 2.3 also displays the odds ratios and 95% confidence intervals (CI) from the unadjusted 
GEE models on adherence. The significance of the association was derived from the unadjusted GEE models. The 
reference group for the dependent variable was “adherence to both statins and ACEIs/ARBs/beta-blockers”. For ease 
of interpretation, we summarize the findings by cancer and no cancer differences, sex differences, and cancer type 
differences in adherence. 
 
2.4.2.1 Cancer versus No Cancer and Medication Adherence 
CCW were less likely to be adherent to both statins and ACEIs/ARBs/beta-blockers compared to NCW [OR = 
0.72; 95% CI = 0.61; 0.83, P < 0.001]. However, BCW were more likely to be adherent to both medication classes 
compared to NCW [OR = 1.09; 95% CI = 1.01, 1.17; P < 0.05]. Similarly, CCM were less likely to be adherent to 
both medication classes compared to NCM [OR = 0.66; 95% CI = 0.55, 0.78; P < 0.001]. PCM were less likely to be 
adherent to both medication classes compared to NCM [OR = 0.92; 95% CI = 0.85; 0.99, P = 0.026]. Among those 
with single medication use, similar patterns were observed. 
 
2.4.2.2 Sex and Medication Adherence 
We compared NCW to NCM and CCW to CCM to infer sex differences in adherence categories. There were no 
significant differences in adherence to both medication classes by sex in the unadjusted. However, NCW [AOR = 
1.10; 95% CI = 1.06, 1.14] and CCW [AOR = 1.21; 95% CI = 1.08, 1.34] were more likely to be either adherent to 
one (out of two) medication class or adherent to one medication class among those with one medication class 
compared to NCM and CCM respectively. 
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Table 2.3. Weighted Percent and Unadjusted GEE Models with IPTW on Medication Adherence Categories 
Characteristics 
ADH 2 Rx  
(Weighted %) 
N = 80,957 
No ADH 2 Rx 
(Weighted %)  
N = 41,016 
ADH 1 of 2 Rx 
(Weighted %) 
N = 60,167 
ADH  1 Rx  
(Weighted %) 
N = 55,536 
No ADH 1 Rx 
(Weighted %) 
N = 40,500 
All 29.1% 14.7% 21.6% 20.0% 14.6% 
Cancer and No Cancer Categories  
BCW 28.7 13.3 22.2 21.2 14.6 
CCW 24.5 16.9 23.5 18.7 16.4 
NCW 27.3 13.9 21 22.7 15.2 
CCM 27.3 19.6 23 13.9 16.2 
PCM 31.5 16.5 23.2 15.6 13.2 
NCM 32.1 15.3 21.6 17.4 13.6 
      
 OR [95% CI] Reference group OR [95% CI] OR [95% CI] OR [95% CI] 
Cancer vs no cancer differences in adherence (Reference: NCW) 
BCW 1.10 [1.02,1.18]*  1.10 [1.03,1.17]** 0.97 [0.88,1.07] 1.00 [0.90,1.10] 
CCW 0.73 [0.61,0.84]***  0.91 [0.81,1.01] 0.67 [0.53,0.81]*** 0.88 [0.74,1.03] 
CCM 0.69 [0.58,0.81]***  0.77 [0.67,0.87]*** 0.42 [0.26,0.58]*** 0.75 [0.59,0.90]*** 
PCM 0.96 [0.90,1.03]  0.93 [0.86,0.99]* 0.57 [0.48,0.66]*** 0.73 [0.63,0.82]*** 
NCM 1.06 [0.99,1.11]  0.93 [0.89,0.98]** 0.69 [0.63,0.76]*** 0.81 [0.75,0.88]*** 
Cancer vs no cancer differences in adherence (Reference: NCM) 
BCW 1.03 [0.95,1.11]  1.18 [1.11,1.26]*** 1.40 [1.30,1.50]*** 1.23 [1.12,1.34]*** 
CCW 0.68 [0.57,0.80]***  0.98 [0.88,1.08] 0.96 [0.82,1.11] 1.09 [0.94,1.23] 
CCM 0.65 [0.53,0.77]***  0.82 [0.72,0.92]*** 0.61 [0.45,0.77]*** 0.92 [0.76,1.08]*** 
PCM 0.91 [0.84,0.98]**  0.99 [0.93,1.06] 0.83 [0.73,0.92]*** 0.90 [0.80,1.00] 
NCW 0.94 [0.89,1.00]  1.07 [1.03,1.12]** 1.44 [1.38,1.50]*** 1.23 [1.17,1.30]* 
Sex Differences in adherence (other categories not displayed)† 
NCW 0.94 [0.89,1.00]  1.07 [1.03,1.12]** 1.44 [1.38,1.50]*** 1.23 [1.17,1.30]* 
NCM Reference         
CCW 1.05 [0.89,1.20]  1.19 [1.05,1.32]* 1.58 [1.37,1.78]*** 1.18 [0.98,1.39] 
CCM Reference     
Cancer Type Differences in adherence (other categories not displayed)‡ 
BCW 1.51 [1.38,1.64]***  1.21 [1.10,1.32]** 1.46 [1.30,1.62]*** 1.13 [0.97,1.30] 
CCW Reference     
PCM 1.40 [1.27,1.52]***  1.21 [1.10,1.32]*** 1.35 [1.18,1.53]*** 0.97 [0.80,1.15] 
CCM Reference     
The analysis was based on 6 repeated measures. 
†Other categories not displayed are: BCW and PCM. ‡Other categories not displayed are: NCW and NCM. 
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Description of medication use and adherence 
ADH 2 Rx: Adherent to both medication classes (statins and ACEIs/ARBs/beta-blockers) 
No ADH 2 Rx: Not adherent to both medication classes (reference) 
ADH 1 of 2 Rx: Adherent to either statins or ACEIs/ARBs/beta-blockers 
ADH 1 Rx: Use of one medication class (either statins or ACEIs/ARBs/beta-blockers) and adherent to that class 
No ADH 1 Rx: Use of one medication class and not adherent to that medication class 
 
Asterisks represent significant differences in cancer diagnosis categories, derived from GEE, which accounts for repeated observations  
***p < 0.001; **0.001 ≤ p < 0.01; *0.01 ≤ p < 0.05. 
Abbreviations 
BCW: Women with breast cancer women; CCM: Men with colorectal cancer; CCW: Women with colorectal cancer; GEE: Generalized estimating equations; 
IPTW: Inverse probability of treatment weighting; NCM: Men with no cancer; NCW: Women with no cancer; PCM: Men with prostate cancer
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2.4.2.3 Cancer Type and Medication Adherence 
BCW were more likely to be adherent to both [OR = 1.51; 95% CI = 1.38, 1.64; P < 0.001] medication classes 
compared to CCW. PCM were more likely to be adherent to both medication classes compared to CCM [OR = 1.39; 
95% CI = 1.27, 1.52; P < 0.001]. Among those with single medication use, similar patterns were observed. 
Table 2.4 displays the adjusted odds ratios (AORs) and 95% CI from the adjusted GEE regressions on 
adherence categories. The findings were similar to unadjusted models. For example, CCW were less likely to be 
adherent to both classes of medications compared to NCW [AOR = 0.70; 95% CI = 0.58, 0.81; P < 0.0001]. 
Similarly, CCM [AOR = 0.63; 95% CI = 0.51, 0.75; P < 0.0001] and PCM [AOR = 0.92; 95% CI = 0.85, 0.99; P = 
0.022] were less likely to be adherent to both classes of medications compared to NCM. 
However, there was no significant differences observed in any of the adherence categories between BCW 
compared to NCW, after controlling for other factors. This is in contrast to unadjusted model, in which, there was 
significant different between BCW as compared to NCW. 
Table 2.5 displays the AORs and 95% CI from the adjusted GEE models on adherence for other independent 
variables. Medicare beneficiaries who were < 80 years, Whites, had no concordant physical health conditions, had 
discordant physical health conditions, had mental health conditions, had tobacco and alcohol use, and had no 
cardiologist visit were less likely to be adherent to both medication classes 
 
2.4.3 Secondary Analyses 
As CCW and CCM were generally non-adherent to medications, we further examined the relationship between 
cancer-related factors (stage of diagnosis and cancer treatment (surgery, chemo, radiation therapies) among men and 
women with CAD and incident colorectal cancer (CC) (Table 2.6). These analyses indicated that those with 
advanced cancer stage were less likely to be adherent to both medication classes (AOR = 0.55; 95% CI = 0.31, 0.78) 
compared to early-stage cancer. Similarly, those who had surgery were less likely to be adherent to both medication 
classes (AOR = 0.64; 95% CI = 0.45, 0.82). 
.
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Table 2.4. Adjusted GEE Models with IPTW on Adherence to Medication Adherence Categories 
Sex and cancer categories ADH 2 Rx ADH 1 Rx of 2 ADH 1 Rx No ADH 1 Rx AOR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig 
Cancer vs no cancer differences in adherence (Reference = NCW) 
BCW 1.08 [1.00,1.17]   1.08 [1.00,1.15]   1.03 [0.93,1.13]   1.06 [0.96,1.17]   
CCW 0.70 [0.58,0.81] *** 0.87 [0.77,0.97] ** 0.65 [0.51,0.80] *** 0.91 [0.76,1.05]  
CCM 0.63 [0.51,0.75] *** 0.71 [0.61,0.82] *** 0.46 [0.30,0.63] *** 0.85 [0.70,1.01]  
PCM 0.92 [0.85,0.99] * 0.89 [0.82,0.95] *** 0.68 [0.59,0.78] *** 0.86 [0.76,0.96] ** 
NCM 1.02 [0.97,1.07]   0.91 [0.86,0.96] *** 0.78 [0.71,0.84] *** 0.89 [0.82,0.96] ** 
NCW Reference                     
Cancer vs no cancer differences in adherence (Reference = NCM) 
BCW 1.06 [0.98,1.15]   1.18 [1.11,1.26] *** 1.32 [1.22,1.43] *** 1.19 [1.08,1.30] ** 
CCW 0.68 [0.56,0.80] *** 0.96 [0.86,1.07]   0.84 [0.69,0.99] * 1.02 [0.87,1.17]  
CCM 0.62 [0.49,0.74] *** 0.78 [0.68,0.89] *** 0.59 [0.42,0.76] *** 0.96 [0.80,1.12]  
PCM 0.90 [0.83,0.98] ** 0.98 [0.91,1.04]   0.88 [0.78,0.98] * 0.96 [0.86,1.07]  
NCW 0.98 [0.93,1.03]   1.10 [1.05,1.15] *** 1.29 [1.22,1.36] *** 1.12 [1.05,1.19] ** 
NCM Reference              
Sex Differences in adherence (other categories not displayed)† 
NCW 0.98 [0.93,1.03]   1.10 [1.05,1.15] *** 1.29 [1.22,1.36] *** 1.12 [1.05,1.19] ** 
NCM Reference                     
CCW 1.11 [0.95,1.27]   1.23 [1.09,1.36] ** 1.41 [1.20,1.63] ** 1.06 [0.85,1.27]  
CCM Reference                     
Cancer Type Differences in adherence (other categories not displayed)‡ 
BCW 1.55 [1.42,1.69] *** 1.23 [1.11,1.35] *** 1.57 [1.40,1.74] *** 1.17 [1.00,1.34]  
CCW Reference                     
PCM 1.46 [1.33,1.60] *** 1.24 [1.13,1.36] *** 1.48 [1.30,1.66] *** 1.01 [0.83,1.18]  
CCM Reference                     
†Other categories not displayed include BCW and PCM. ‡Other categories not displayed include NCW and NCM. 
Description of medication use and adherence 
ADH 2 Rx: Adherent to both medication classes (statins and ACEIs/ARBs/beta-blockers) 
No ADH 2 Rx: Not adherent to both medication classes (reference) 
ADH 1 of 2 Rx: Adherent to either statins or ACEIs/ARBs/beta-blockers 
ADH 1 Rx: Use of one medication class (either statins or ACEIs/ARBs/beta-blockers) and adherent to that class 
No ADH 1 Rx: Use of one medication class and not adherent to that medication class 
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Asterisks represent significant differences in cancer diagnosis categories, derived from GEE, which accounts for repeated observations. Adjusted GEE model 
controlled for patient, physician, health-system, and environmental factors. 
***p < 0.001; **0.001 ≤ p < 0.01; *0.01 ≤ p < 0.05. 
 
Abbreviations 
AOR: Adjusted odds ratio; BCW: Women with breast cancer; CAD: Coronary artery disease; CCM: Men with colorectal cancer; CCW: Women with colorectal 
cancer; CI: Confidence interval; GEE: Generalized estimating equations; IPTW: Inverse probability of treatment weighting; NCM: Men with no cancer; Women 
with no cancer; PCM: Men with prostate cancer; Sig: Significance 
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Table 2.5. Adjusted GEE Models with IPTW on Medication Adherence Categories–Other factors included based on conceptual framework 
Characteristics ADH 2 Rx ADH 1 of 2 Rx ADH 1 Rx No ADH 1 Rx AOR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig 
Patient-level factors - Demographics 
Age groups (in years)               
68-70 0.94 [0.88,1.00]   0.98 [0.92,1.03]   0.55 [0.47,0.63] *** 0.67 [0.59,0.76] *** 
71-74 0.90 [0.84,0.96] *** 0.98 [0.92,1.03]   0.58 [0.50,0.65] *** 0.66 [0.58,0.74] *** 
75-79 0.95 [0.90,1.01]   1.01 [0.96,1.06]   0.68 [0.61,0.75] *** 0.76 [0.69,0.84] *** 
≥80 Reference - - - 
Race/Ethnicity                
African Americans 0.63 [0.55,0.72] *** 0.78 [0.71,0.85] *** 0.75 [0.65,0.85] *** 1.04 [0.95,1.14]  
Hispanics 0.59 [0.47,0.71] *** 0.74 [0.63,0.84] *** 0.61 [0.46,0.76] *** 0.85 [0.71,1.00] * 
Others 0.90 [0.83,0.98] * 0.87 [0.80,0.94] *** 0.83 [0.73,0.93] *** 0.89 [0.79,1.00] * 
Whites Reference                
Patient-level factors - Census-tract socioeconomic status 
Education level                
<12% (national avg) 1.01 [0.96,1.07]   0.99 [0.95,1.04]   1.00 [0.94,1.07]   1.05 [0.98,1.11]  
≥12% (national avg) Reference - - - 
Poverty level                
<14.3% (national avg) 1.03 [0.98,1.08]   1.06 [1.02,1.11] ** 1.11 [1.04,1.17] ** 1.10 [1.04,1.16] ** 
≥ 14.3% (national avg) Reference - - - 
Patient-level factors - Chronic physical and mental health conditions 
Concordant PHCs                
Yes 1.40 [1.29,1.50] *** 1.40 [1.31,1.50] *** 0.70 [0.59,0.81] *** 0.48 [0.37,0.60] *** 
No Reference - - - 
Discordant PHCs                
Yes 0.78 [0.73,0.83] *** 0.88 [0.84,0.92] *** 1.12 [1.06,1.17] *** 1.27 [1.22,1.33] *** 
No Reference - - - 
Mental health conditions               
Yes 0.66 [0.60,0.71] *** 0.77 [0.72,0.82] *** 0.88 [0.82,0.95] *** 1.08 [1.02,1.15] * 
No Reference - - - 
CAD severity 1.02 [0.91,1.13]   1.05 [0.95,1.15]   0.57 [0.42,0.71] *** 0.63 [0.49,0.78] *** 
Patient-level factors - Personal health behavior 
Tobacco use                
Yes 1.32 [1.21,1.43] *** 1.22 [1.13,1.31] *** 1.44 [1.30,1.58] *** 1.14 [1.01,1.28]  
No Reference - - - 
Alcohol use                
Yes 1.48 [1.27,1.69] *** 1.28 [1.10,1.46] ** 1.00 [0.74,1.26]   0.63 [0.39,0.87] *** 
No Reference - - - 
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Characteristics ADH 2 Rx ADH 1 of 2 Rx ADH 1 Rx No ADH 1 Rx AOR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig 
Health System Factors 
Donut hole                
Exceeded 0.96 [0.87,1.05]   0.99 [0.89,1.09]   1.00 [0.91,1.10]   0.99 [0.88,1.10]  
Not reached 0.35 [0.26,0.43] *** 0.59 [0.51,0.68] *** 0.66 [0.56,0.77] *** 1.32 [1.20,1.44] *** 
Reached Reference - - - 
Provider Related Factors 
Primary care visit                
Yes 1.01 [0.97,1.05]   1.08 [1.04,1.11] *** 0.95 [0.91,1.00]   0.96 [0.91,1.01]  
No Reference - - - 
Cardiologist visit                
Yes 1.04 [1.01,1.07] * 1.12 [1.09,1.15] *** 0.69 [0.65,0.73] *** 0.70 [0.66,0.74] *** 
No Reference - - - 
External Environment and County-level Factors 
SEER Region                
Northeast 1.07 [1.00,1.15]   1.05 [0.99,1.12]   1.07 [0.97,1.16]   0.94 [0.84,1.03]  
South 0.96 [0.89,1.04]   1.05 [0.99,1.12]   0.98 [0.88,1.07]   1.02 [0.92,1.12]  
North-central 1.17 [1.09,1.25] *** 1.08 [1.01,1.15] * 1.14 [1.04,1.24] ** 0.94 [0.84,1.05]  
West Reference - - - 
Metropolitan status                
Metro 0.92 [0.84,0.99] * 0.94 [0.87,1.00] * 0.89 [0.80,0.98] * 1.00 [0.91,1.10]  
Non-metro Reference - - - 
HPSA                
No shortage 1.07 [0.98,1.15]   1.04 [0.96,1.12]   1.03 [0.92,1.13]   0.95 [0.83,1.06]  
Part county 1.07 [1.01,1.12] * 1.03 [0.99,1.08]   1.02 [0.96,1.09]   1.04 [0.97,1.11]  
Whole county Reference - - - 
FQHC                
None 1.15 [1.05,1.26] ** 1.04 [0.95,1.13]   1.14 [1.01,1.26]   1.03 [0.90,1.16]  
1 to 10 1.05 [0.98,1.11]   0.99 [0.94,1.05]   1.10 [1.02,1.18] * 1.05 [0.97,1.14]  
≥11 Reference - - - 
Rural health centers                
Yes 1.02 [0.97,1.08]   0.99 [0.94,1.05]   1.02 [0.95,1.09]   1.03 [0.96,1.10]  
No Reference - - - 
% cardiologists in county 0.84 [0.75,0.93] *** 0.92 [0.84,1.00] * 1.08 [0.96,1.19]   1.14 [1.02,1.25] * 
% oncologists in county 2.23 [1.79,2.68] *** 1.37 [0.99,1.76]   0.68 [0.13,1.24]   0.55 [0.02,1.12] * 
Time 1.41 [1.40,1.41] *** 1.26 [1.25,1.26] *** 1.35 [1.35,1.36] *** 1.12 [1.12,1.13] *** 
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Time-invariant characteristics include cancer diagnosis categories, age, race/ethnicity, poverty status, high school education, concordant and discordant physical 
health conditions, SMI, SEER region, and county-level characteristics. Time-variant characteristics include, tobacco use, alcohol use, depression, anxiety, and 
routine follow-up with primary care physician and/or cardiologist, and donut hole. 
 
Concordant physical health conditions consisted of diabetes, hyperlipidemia, hypertension, stroke, cardiac arrhythmia, and congestive heart failure. Discordant 
physical health conditions consisted of arthritis, asthma, chronic obstructive pulmonary disease, osteoporosis, dementia, human immunodeficiency virus, and 
hepatitis. Mental health conditions include anxiety, depression, SMI (schizophrenia, bipolar disorder, and psychoses) 
 
Description of medication use and adherence 
ADH 2 Rx: Adherent to both medication classes (statins and ACEIs/ARBs/beta-blockers) 
No ADH 2 Rx: Not adherent to both medication classes (reference) 
ADH 1 of 2 Rx: Adherent to either statins or ACEIs/ARBs/beta-blockers 
ADH 1 Rx: Use of one medication class (either statins or ACEIs/ARBs/beta-blockers) and adherent to that class 
No ADH 1 Rx: Use of one medication class and not adherent to that medication class 
Asterisks represent significant differences in cancer diagnosis categories, derived from GEE, which accounts for repeated observations.  
***p < 0.001; **0.001 ≤ p < 0.01; *0.01 ≤ p < 0.05. 
 
Abbreviations 
AOR: Adjusted odds ratio; CI: Confidence interval; FQHC: Federally qualified health centers; GEE: Generalized estimating equations; HPSA: Health 
professional shortage area; IPTW: inverse probability treatment weights; PHC: Physical health condition; Sig: Significance; SMI: Severe mental illness 
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Table 2.6. Adjusted GEE models on Medication Adherence Categories among Patients with Colorectal Cancer (N = 3,104) 
Characteristics ADH 2 Rx ADH 1 of 2 Rx ADH 1 Rx No ADH 1 Rx AOR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig 
Cancer stage                
Stage II 0.77 [0.54,0.99] * 0.82 [0.61,1.02]   1.09 [0.82,1.35]   1.21 [0.94,1.48]  
Stage III/IV 0.55 [0.31,0.78] *** 0.63 [0.41,0.84] *** 0.72 [0.43,1.00] * 0.84 [0.56,1.13]  
Stage 0/I Reference       
Surgery                
Yes 0.64 [0.45,0.82] *** 0.72 [0.53,0.91] *** 0.66 [0.47,0.85] *** 0.96 [0.76,1.16]  
No Reference       
Chemotherapy                
Yes 1.03 [0.77,1.28]   1.25 [1.02,1.49]   0.97 [0.66,1.27]   1.32 [1.03,1.62]  
No Reference       
Radiation therapy                
Yes 0.91 [0.54,1.29]   0.89 [0.52,1.26]   0.74 [0.28,1.19]   0.82 [0.38,1.26]  
No Reference       
Hormone therapy                
Yes 0.87 [0.28,1.42]  0.52 [0.32,1.55]   1.24 [0.80,1.55]   0.42 [0.23,1.57]  
No Reference       
Description of medication use and adherence 
ADH 2 Rx: Adherent to both medication classes (statins and ACEIs/ARBs/beta-blockers) 
No ADH 2 Rx: Not adherent to both medication classes (reference) 
ADH 1 of 2 Rx: Adherent to either statins or ACEIs/ARBs/beta-blockers 
ADH 1 Rx: Use of one medication class (either statins or ACEIs/ARBs/beta-blockers) and adherent to that class 
No ADH 1 Rx: Use of one medication class and not adherent to that medication class 
 
Asterisks represent significant differences in cancer diagnosis categories, derived from GEE models, which controlled for patient, physician, health-system, and 
environmental factors. 
***p < 0.001; **0.001 ≤ p < 0.01; *0.01 ≤ p < 0.05. 
 
Abbreviations 
AOR: Adjusted odds ratio; CI: Confidence interval; GEE: Generalized estimating equations; Sig: Significance
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2.5 Discussion 
The current study analyzed the relationship between incident cancer diagnosis and adherence to statins and/or 
ACEIs/ARBs/beta-blockers among elderly FFS Medicare beneficiaries with pre-existing CAD. To the best of our 
knowledge, this is the first study to compare medication adherence to statins and/or ACEIs/ARBs/beta-blockers 
between cancer and non-cancer cohorts with CAD. In general, only 28.9% of the study population were adherent to 
both statins and ACEIs/ARBs/beta blockers. Although there are no published studies comparing cancer and non-
cancer patients, our figures are similar to existing studies on medication adherence to multiple medication classes in 
those with cardiovascular conditions. Given that there is dearth of studies in the area of multiple medication 
adherence among those with CAD, specifically among those with elderly, it is important to learn from published 
studies in cardiovascular conditions. One study showed that 21.4% adults with cardiovascular conditions were 
adherent to both statins and calcium channel blockers [159]. Similarly, another study reported that 21% had 
combined adherence on beta-blockers, lipid lowering therapy, and aspirin [160]. 
These findings emphasize the need for multimodal interventions for improving medication adherence. Ho et al 
reviewed studies on medication adherence among individuals with cardiovascular health conditions and suggested 
that multimodal interventions including the pharmacist-led interventions may be successful in realizing the benefits 
of medication adherence and reducing the costs of non-adherence [141]. Future studies need to examine whether the 
proven strategies of medication adherence can also be applied to improve medication adherence of multiple drug 
regimens. 
We observed that both men and women diagnosed with incident colorectal cancer were less likely to adhere to 
both statins and ACEIs/ARBs/beta-blockers compared to non-cancer women and men, even after controlling for a 
comprehensive list of factors. Similarly, men with incident prostate cancer were less likely to adhere to both 
medication classes, but the magnitude of difference was much less compared to men with no cancer diagnosis. There 
were no differences in adherence to both medication classes by presence of breast cancer. Taken together, these 
finding suggest that cancer type rather than cancer itself may affect medication adherence. Furthermore, we also 
found that among Medicare beneficiaries with CAD and colorectal cancer, those with late-stage cancer compared to 
early stage cancer and those who had surgical treatment for cancer compared to no surgical treatment were less 
likely to be adherent to both statins and ACEIs/ARBs/beta blockers. These findings suggest that cancer stage and 
cancer treatment may affect medication adherence among colorectal cancer patients. It is also plausible that the life-
threatening nature of CC may lead to prioritization of cancer care. For example, colorectal cancer has lower 5-year 
survival rates compared to breast and prostate cancer (66% vs. 91% and 99%, respectively) [106]. 
Despite the complexity of care among those with multiple chronic conditions (in our case those with CAD and 
CC), it is important to focus on medication adherence for CAD. However, under the fee-for-service programs, there 
are no incentives to coordinate care across multiple systems, providers, and payers [141]. In this context, the new 
fiscal incentives by the CMS in paying physicians who provide care for patients with multiple chronic conditions 
and who invest time and resources to provide more coordinated and patient-centered care [161] may also promote 
adherence. It has to be noted that a systematic review of medication adherence among those with multiple chronic 
conditions reported that medication adherence interventions were “almost exclusively” conducted by the 
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pharmacists [162]. In recognition of the critical role of pharmacists, Medicare now covers Medication Management 
Services (MTM) of pharmacists. There is some evidence that such policies (i.e. MTM services offered by 
pharmacists) can improve adherence and lead to better cardiovascular outcomes [163]. 
 
2.5.1 Clinical Implications 
Our study findings have implications for clinical practice. As mentioned in the introduction, statins and 
ACEIs/ARBs/beta-blockers are central to improving CAD-related health outcomes and statins have been shown to 
reduce cancer-specific mortality in those with breast, colorectal, and prostate cancer [144-146, 164]. Furthermore, 
medications for CAD may also reduce cancer treatment-related cardiotoxicity [71]. We do recognize that medication 
adherence is a multidimensional issue in which providers, patients, payers, and policy makers are inextricably linked 
and all of them need to be involved in improving medication adherence [165]. It may be very challenging for 
clinicians to implement interventions in routine practice because successful to date have included multiple, 
heterogeneous components [141]. In this context, the recent healthcare delivery models such as the medical home 
may help in overcoming the challenges to coordination across different providers. It has been shown that patient-
centered medical homes can improve adherence to medications among those with cardiovascular conditions [166]. 
 
2.5.2 Strengths and Limitations  
Our study findings need to be interpreted in the context of its limitations. The study findings cannot be 
generalized to all Medicare beneficiaries because the study population is restricted to those residing in SEER regions 
and to those with FFS Medicare plans. Although we used a proxy measure for CAD severity, this measure may not 
accurately capture severity of the disease. We were not able to control for patient-level lifestyle health behaviors, 
knowledge, attitude, and preferences as well as number of cancer-related complications, treatment side-effects, and 
cost-related factors that may affect adherence. We used prescription claims for measuring adherence. As part D file 
contains only filled prescriptions, it is not known whether the patient actually used the medications or whether the 
patients they adhered to their providers’ instructions or not. The focus of the study was only on statins and 
ACEIs/ARBs/beta-blockers, as they are recommended by guidelines for CAD long-term therapy. Substitution with 
any other drugs other than those included in the study are considered non-users of the respective medication. This 
does not affect adherence as those drugs are not recommended by guidelines for long-term CAD pharmacotherapy. 
Our study has many advantages. The study used a rigorous study design comparing cancer and non-cancer 
cohort over time and statistical adjustment for selection bias in observed characteristics. Medicare FFS claims data 
enabled us to measure adherence over time and followed a large cohort of patients for a long period of time across a 
variety of providers. The study adjusted a comprehensive list of factors that can influence medication adherence. 
The study included individuals with significant medical comorbidities, typically excluded from randomized clinical 
trials and examined real-world practice patterns. 
 
2.5.3 Conclusions 
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The findings from our study contribute to existing literature on adherence and adds to the nascent field of 
cardio-oncology. We observed that medication adherence was associated with cancer type rather than just the 
presence of cancer itself. Elderly Medicare beneficiaries with colorectal cancer and to a lesser extent men with 
prostate cancer were less likely to be adherent to evidence-based medications for CAD. These findings highlight the 
vulnerability of these individuals and the difficulty in sustaining ongoing therapy for CAD. The recent healthcare 
delivery models such as the medical home may help in overcoming the challenges to coordination across different 
providers and can improve adherence to medications among those with cardiovascular conditions.
 40 
 
3 CHAPTER 3 
Non-adherence to Statins and Antihypertensive Medications and 
Hospitalizations among Elderly Fee-for-Service Medicare Beneficiaries with 
Pre-existing Coronary Artery Disease and Incident Cancer  
 
3.1 Abstract 
Objectives: To examine the relationship between adherence to both statins and ACEIs/ARBs/beta-blockers and 
coronary artery disease (CAD)-related hospitalizations. 
Methods: A retrospective observational longitudinal study was conducted using SEER-Medicare data. Elderly 
Medicare fee-for-service beneficiaries with pre-existing CAD and incident breast, colorectal, or prostate cancer (N = 
12,096) were observed for a period of 12 months before and 12 months after cancer diagnosis. Hospitalizations 
measured every 120-days were categorized into three groups: (1) any CAD-related hospitalization; (2) other 
hospitalizations; or (3) no hospitalization. Medication adherence was categorized into five mutually exclusive 
groups: (1) adherent to both statins and ACEIs/ARBs/beta-blockers (reference group); (2) not adherent to both 
statins and ACEIs/ARBs/beta-blockers; (3) adherent to either statins or ACEIs/ARBs/beta-blockers; (4) use of one 
medication class and adherent to that class; or (5) use of one medication class and not adherent to that medication 
class. The unadjusted and adjusted relationship between medication adherence and hospitalization was analyzed 
using repeated measures multinomial logistic regressions. Inverse probability treatment weights were used to control 
for observed group differences among medication adherence categories. 
Results: Adherence to both statins and ACEIs/ARBs/beta-blockers was estimated at 31.2% during the 120-day 
period immediately after cancer diagnosis; 13.7% were not adherent to both medication classes during the same 
period; 27.4% had CAD-related hospitalizations immediately after cancer diagnosis and this percentage declined to 
10.6% during the last four months of the post-cancer period. In the adjusted analyses, those not adherent to both 
statins and ACEIs/ARBs/beta-blockers were more likely to have CAD-related hospitalization compared to those 
who were adherent to both medication classes [AOR = 1.82; 95% CI = 1.72, 1.92; P < 0.0001]. 
Conclusions: Given the complexity of interaction between CAD and cancer, it is important to routinely monitor 
medication adherence in general clinical practice and provide linkages to support services that can increase 
medication adherence.  
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3.2 Introduction 
Coronary artery disease (CAD) remains the leading cause of hospitalization in the United States (US), although 
the rate of hospitalization for CAD has declined from 77% in 2000 to 44% in 2010 [167]. According to the 
Healthcare Cost and Utilization Project (HCUP), in 2010, CAD accounted for nearly 512,000 hospital admissions 
with an estimated inpatient expenditures of nearly $9.5 billion [168]. Among individuals with CAD, per-capita 
hospital expenditures were estimated at $22,700 in 2014 accounting for about 62% of total direct medical care 
expenditures [4, 169], suggesting that hospitalizations are the primary drivers of total direct medical care 
expenditures. 
Existing evidence also suggests that adults, especially older individuals (age > 65 years) with incident cancer 
may be at risk for non-cancer related hospitalizations. Although not specific to CAD-related hospitalizations, men 
with incident prostate cancer and cardio-metabolic conditions were more likely to experience hospitalization during 
the immediate period after cancer diagnosis [170]. It has been reported that the risk of first hospitalization for CAD 
increases during the six months after cancer diagnosis [171], perhaps due to cardiotoxicity associated with cancer 
treatments such as radiotherapy, chemotherapy, and hormone therapy [60-62]. Some studies have reported increased 
risk of cardiovascular events, complications, and mortality in women who were treated with radiotherapy [172-174] 
or were exposed to cardiotoxic drugs (trastazumab and anthracycline) [108, 175, 176]. Similarly, endocrine 
treatment-related cardiotoxicity has also been reported in prostate cancer patients [177-179]. 
Adherence to angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), beta-
blockers, and statins have been shown to not only improve survival [95, 131] but also reduce the risk of CAD-
related hospitalizations [94, 95]. Specifically, statins have been reported to reduce cancer-specific mortality in those 
with breast, colorectal, and prostate cancer [144-146, 164], suggesting that adherence to statins may be even more 
important for individuals with cancer. 
However, to date, no study has examined the relationship between adherence to statins and ACEIs/ARBs/beta-
blockers, and CAD-related hospitalization in older individuals (age > 65 years) with pre-existing CAD and incident 
cancer. As old age is a risk factor for CAD-related hospitalization [168] and CAD is the most common pre-existing 
condition among older adults diagnosed with cancer [85, 86, 90], it is important to analyze the relationship between 
adherence to both statins and ACEIs/ARBs/beta-blockers and CAD-related hospitalizations among cancer patients. 
Therefore, the present study evaluated the relationship between adherence to both statins and ACEIs/ARBs/beta-
blockers and CAD-related hospitalizations among elderly fee-for-service Medicare beneficiaries with pre-existing 
CAD and incident breast, colorectal or prostate cancer, after controlling for cancer treatment that are cardiotoxic and 
other risk factors that may affect CAD-related hospitalizations. 
 
3.3 Methods 
3.3.1 Conceptual Framework 
This study adapted Andersen’s Behavioral Model of health service utilization to select independent variables 
that may influence CAD-related hospitalizations (Figure 1.2) [124, 125]. This model categorizes variables that may 
influence CAD-related hospitalization into predisposing (age, sex, race), enabling (census tract education level and 
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poverty status, marital status, Medicare prescription drug coverage), need factors (chronic physical and mental 
health conditions, cancer type, cancer stage, cancer treatment), personal health practices (tobacco and alcohol use), 
healthcare use (visits to primary care/cardiologist and adherence to statins and/or ACEIs/ARBs/beta-blockers) and 
external environment (Surveillance, Epidemiology and End Results [SEER] region and county metro status). 
 
3.3.2 Study Design 
The study utilized a retrospective observational longitudinal cohort design with baseline (24-36 months before 
cancer diagnosis), pre-cancer (12 months before cancer diagnosis) and post-cancer (12 months after cancer 
diagnosis) periods (Figure 3.1). 
Figure 3.1. Schematic presentation of study design 
 
3.3.3 Data Sources 
We linked data from four sources: the SEER registries, Medicare claims, the American Community Survey 
(ACS), and the Area Health Resource Files (AHRF). SEER program is an epidemiologic surveillance system 
consisting of population-based tumor registries that collects data on all incident cases of cancer that occur in persons 
residing in 18 SEER areas. SEER data also consists of information about demographic characteristics of the patient, 
diagnosis date, cancer site, stage, and grade [126]. The ACS census tract files provided information on the census 
tract poverty status [128]. The AHRF was used to derive percent cardiologists and oncologists in the county [129]. 
 
3.3.4 Study Population 
Individuals with CAD were identified using a validated algorithm developed by the Centers for Medicare and 
Medicaid Services (CMS) [150]. The algorithm used the International Classifications of Diseases – 9th edition, 
Clinical Modification (ICD-9-CM) codes. Individuals with at least one inpatient or two outpatient claims 
(institutional outpatient, physician office, and home health agency claims) with a primary or secondary diagnosis of 
CAD during the baseline were classified as having pre-existing CAD. Individuals with incident cancer, were 
identified from the SEER registry for the period between January 2008 and December 2011. 
Other inclusion criteria were: (1) age 68 years or older at cancer diagnosis; (2) no missing data for type and 
stage of cancer; (3) alive with continuous FFS Medicare Part A, B enrollment during the entire study period; (4) 
continuous part D enrollment during the pre- and post-index period; (5) no missing information on county, and (6) 
having two or more prescriptions for either statins or two or more prescriptions for any one of the following 
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medication types: ACEIs, ARBs, or beta-blockers. Those who were diagnosed with cancer through autopsy or death 
certificate were also excluded. The selection criteria are presented in Figure 3.2 
 
3.3.5 Measures 
3.3.5.1 Dependent Variable: Any Hospitalization for CAD Events  
The dependent variable was categorized into three mutually exclusive groups based on a hierarchy: (1) any 
CAD-related hospitalization; (2) other hospitalization (hospitalizations other than CAD); and (3) no hospitalization. 
CAD-related hospitalizations were defined as inpatient admissions for any cardiovascular event (heart attack, heart 
failure, angina, or stroke) and were identified from primary and secondary diagnoses using ICD-9-CM codes [180]. 
This measure was calculated during 120-days before cancer-diagnosis and every 120-days during the post-cancer 
period. A 120-day interval before cancer diagnosis was a baseline measurement to ensure that the change in 
hospitalization was associated with adherence and not due to any other factors. 
 
3.3.5.2 Key Independent Variable: Adherence to Statins, ACEIs/ARB/Beta-blockers 
This measure was also calculated for 120-days before cancer-diagnosis and every 120-days during the post-
cancer period. A 120-day interval before cancer diagnosis was a baseline measurement to account for change in 
adherence due to cancer diagnosis. Based on the type of drug regimen and individuals were classified into five 
mutually exclusive groups: (1) adherent to both statins and ACEIs/ARBs/beta-blockers; (2) not adherent to both 
statins and ACEIs/ARBs/beta blockers; (3) adherent to either statins or ACEIs/ARBs/beta-blockers; (4) use of one 
medication class and adherent to that class; and (5) use of one medication class and not adherent to that medication 
class. 
Statins, ACEIs, ARBs, and beta-blockers were identified using the generic names in the Part D event files. 
Proportion of days covered (PDC) was used to measure adherence to statins, ACEIs, ARBs, or beta-blockers and 
was calculated for those who filled at least two prescriptions for either statins or two prescriptions for ACEIs, ARBs, 
or beta-blockers. The PDC was calculated as: 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 𝑜𝑜𝑜𝑜 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝐷𝐷𝑚𝑚𝑚𝑚𝑜𝑜𝑚𝑚 𝐷𝐷𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑚𝑚𝑚𝑚𝑚𝑚 𝑚𝑚𝑠𝑠𝑑𝑑𝑚𝑚𝑚𝑚𝑑𝑑 𝑚𝑚𝐷𝐷𝑚𝑚ℎ 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑠𝑠𝑚𝑚𝑑𝑑𝑚𝑚𝑜𝑜𝑚𝑚 (𝑚𝑚0,𝑚𝑚1,𝑚𝑚2,𝑚𝑚3)
𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 𝑚𝑚𝑚𝑚 𝑚𝑚𝐷𝐷𝑚𝑚ℎ 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑠𝑠𝑚𝑚𝑑𝑑𝑚𝑚𝑜𝑜𝑚𝑚 (120 𝑚𝑚𝐷𝐷𝐷𝐷𝐷𝐷) . For those 
with a drug regimen (i.e. statins and ACEIs, ARBs or beta-blockers), PDC includes days within a specific period 
when an individual is covered for both statins and beta-blockers, ACEIs, or ARBs. PDC was dichotomized, where 
individuals with PDC ≥80% were considered as adherent and those with PDC <80% as non-adherent [153]. 
.
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Figure 3.2. Schematic presentation of selection criteria for study cohort. 
 
Abbreviations – ACEIs: Angiotensin-converting enzyme inhibitors; ARBs: Angiotensin II receptor blockers; BB: Beta-blockers; CAD: Coronary artery disease; 
HMO: Health Maintenance Organization; Rx: Prescription
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3.3.5.3 Other Independent Variables 
Predisposing Factors 
These were time-invariant and comprised age in years measured at index month of incident cancer diagnosis, 
sex, and race/ethnicity. 
 
Enabling Factors 
These factors included marital status (measured at index month of incident cancer diagnosis), census tract-level 
education level and poverty status (measured at baseline), and Medicare Part D coverage gap (measured every 120 
days). Medicare Part D coverage gap or “donut hole” is the phase between the annual coverage limit and 
catastrophic coverage. The Part D plans typically starts with an annual deductible, after which Medicare pays for the 
prescription drugs up to an initial coverage limit with certain coinsurance associated with those payments. The 
coverage is terminated once an individual reaches the annual coverage limit until the cost of prescription drugs 
reaches to catastrophic limit [156]. 
 
Need-based Factors 
The cancer-related factors comprised cancer diagnosis categories, stage of cancer, and cancer treatment, 
measured at incident cancer diagnosis. Cancer diagnosis was categorized based on cancer type and sex because the 
study included sex-specific cancers (breast and prostate cancer). This variable was categorized into four groups to 
distinguish cancer type in relation to sex, women with breast cancer, women with colorectal cancer, men with 
prostate cancer, and men with colorectal cancer. Stage of cancer was defined using American Joint Committee on 
Cancer (AJCC) classification, categorized from stage 0 to IV [181]. Cancer treatment was categorized into three 
groups based on cancer site, receipt of and type of initial cancer treatment (during first four months of cancer 
diagnosis), and cardiotoxic nature of treatment [63-67] – (a) cardiotoxic cancer treatment includes chemotherapy, 
hormone therapy, and/or radiotherapy for breast cancer, chemotherapy and/or hormone therapy for prostate cancer, 
and chemotherapy for colorectal cancer, (b) non-cardiotoxic cancer treatment includes radiation therapy for 
colorectal and prostate cancer and cancer surgery (all three cancers), and (c) no cancer treatment. 
For CAD severity, a proxy measure was used, constructed based on the CMS hierarchical condition category 
(HCC) classification system. Based on the CMS risk adjustment model, each of the HCC codes for CAD was 
assigned specific score based on the risk and severity [154], ranging from 0.231 to 0.349, where higher scores 
represented severe manifestations of CAD. 
Other physical and mental health conditions were selected using the Multiple Chronic Conditions working 
group chronic conditions grouping [155]. Physical chronic conditions, measured at baseline, were categorized into 
concordant (cardiac arrhythmias, congestive heart failure, diabetes, hyperlipidemia, hypertension, and stroke) and 
discordant (dementia, asthma, chronic obstructive pulmonary disease, arthritis, hepatitis, human immunodeficiency 
virus, and osteoporosis) conditions. Mental health conditions comprised severe mental illness (measured at baseline) 
and anxiety and depression (measured every 120 days). 
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Healthcare utilization 
Healthcare-seeking behavior was defined as primary care and cardiologist visits, measured every 120 days. 
 
Personal Health Care Practices 
This included tobacco and alcohol use as these practices negatively impact cardiovascular health. These 
variables were measured every 120 days. 
 
External Environment Factors 
This domain included SEER region – Northeast (Connecticut, New Jersey), South (Kentucky, Louisiana, 
Atlanta, rural Georgia, and Greater Georgia), North-central (Detroit, Iowa), and West (San Francisco, Hawaii, New 
Mexico, Seattle, Utah, San Jose, Los Angeles, Greater California), county metro status (based on urban/rural 
continuum codes from the AHRF), and percentage of cardiologists and oncologists in the county). These were time-
invariant and measured at baseline. 
 
3.3.6 Statistical Analyses 
Unadjusted subgroup differences in time-invariant characteristics between medication adherence categories 
were tested with chi-square statistics. As medication adherence was measured every 120 days during pre- and post-
index period, each individual had four observations. These four observations were not independent, therefore, we 
analyzed the relationship between adherence categories and CAD-related hospitalizations using multinomial logistic 
regression for repeated measures. As we are interested in describing changes in CAD-related hospitalization, given 
changes in adherence categories, while accounting for non-independence of observations within individuals, we 
selected the marginal models (i.e. population-averaged models) [182]. 
 
3.3.6.1 Inverse Probability Treatment Weight (IPTW) 
As can be seen from Table 3.1, there were significant associations between medication adherence categories 
and for age, race/ethnicity, cancer type and sex, cancer stage, cancer treatment, concordant and discordant physical 
health conditions, mental health conditions, CAD severity, tobacco use, alcohol use, primary care visit, cardiologist 
visit, Part D Medicare coverage, and SEER region. Therefore, we derived IPTWs to balance the independent 
variables using a multinomial logistic regression on medication adherence categories during the period immediately 
after cancer diagnosis to take advantage of the availability of cancer-related variables (i.e. stage, cancer type, and 
cancer treatment). These IPTWs derived for each individual were then used as weights in CAD-related 
hospitalization analyses. 
 
3.3.6.2 Instrument Variable (IV) Regression 
It is plausible that there are some unobserved variables that can affect medication adherence and affect the 
relationship between medication adherence categories and CAD hospitalizations. IV regression is one approach to 
control for such unobserved selection bias. We selected the percentage of oncologists at the county-level as an 
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instrument variable under the assumption that the effect of oncologists on CAD-related hospitalization occurs only 
through medication adherence categories. For this analysis, we dichotomized adherence categories into adherent to 
both medication and other; CAD hospitalization was dichotomized into CAD-related hospitalization and no CAD 
hospitalization that included no CAD hospitalization and other hospitalizations.
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Table 3.1. Multinomial Logistic Regression Models used to derive IPTW 
Characteristics No ADH 2 Rx ADH 1 of 2 Rx ADH 1 Rx  No ADH 1 Rx  AOR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig 
Age groups                
68-70 years 0.65 0.54, 0.79 *** 0.99 0.85, 1.16   0.71 0.60, 0.84 *** 0.75 0.63, 0.90 ** 
71-74 years 0.79 0.67, 0.93 ** 1.01 0.88, 1.15   0.74 0.64, 0.86 *** 0.70 0.59, 0.82 *** 
75-79 years 0.77 0.66, 0.90 ** 1.01 0.89, 1.16   0.81 0.70, 0.93 ** 0.72 0.61, 0.84 *** 
80 years and older Ref               
Race/Ethnicity                
African Americans 1.88 1.52, 2.32 *** 1.17 0.96, 1.43   1.42 1.16, 1.74 *** 1.90 1.54, 2.35 *** 
Others 1.47 1.20, 1.80 *** 1.17 0.98, 1.39   1.07 0.88, 1.30   1.12 0.90, 1.38  
Whites Ref               
Part D Medicare coverage                
Exceeded 2.93 1.96, 4.38 *** 1.51 1.14, 1.99 ** 2.14 1.52, 3.01 *** 3.61 2.33, 5.60 *** 
Not reached 1.10 0.66, 1.83   0.92 0.65, 1.32   1.09 0.71, 1.68   1.13 0.65, 1.96  
Reached                
Cancer diagnosis categories                
Women with breast cancer 0.86 0.71, 1.04   1.08 0.92, 1.25   1.54 1.31, 1.81 *** 1.33 1.11, 1.60 ** 
Women with colorectal cancer 2.28 1.84, 2.82 *** 1.71 1.42, 2.07 *** 1.55 1.26, 1.92 *** 2.76 2.22, 3.43 *** 
Men with colorectal cancer 2.31 1.88, 2.84 *** 1.29 1.07, 1.56 ** 1.11 0.89, 1.39   2.37 1.90, 2.95 *** 
Men with prostate cancer Ref               
Cancer stage                
Stage 0/I 0.61 0.50, 0.74 *** 0.89 0.75, 1.05   0.80 0.67, 0.97 * 0.67 0.55, 0.82 *** 
Stage II 0.76 0.64, 0.90 ** 0.91 0.78, 1.07   0.87 0.74, 1.04   0.91 0.76, 1.09  
Stage III/IV Ref               
Cancer treatment                
Cardiotoxic cancer treatment 1.00 0.83, 1.21   0.97 0.83, 1.13   0.89 0.75, 1.05   0.98 0.82, 1.19  
No cancer treatment 1.17 0.98, 1.39   0.92 0.80, 1.07   0.98 0.84, 1.14   1.01 0.84, 1.20  
Non-cardiotoxic cancer treatment Ref    0.91 0.83, 1.00 * 0.89 0.81, 0.97 * 0.99 0.88, 1.10  
Discordant PHC                
Yes 1.29 1.14, 1.47 *** 1.15 1.04, 1.28 ** 1.34 1.20, 1.50 *** 1.57 1.39, 1.79 *** 
No Ref               
Concordant PHC                
Yes 0.66 0.49, 0.90 ** 0.84 0.65, 1.10   0.49 0.38, 0.63 *** 0.32 0.25, 0.41 *** 
No Ref               
MHC                
Yes 1.60 1.36, 1.89 *** 1.16 0.99, 1.34   1.20 1.02, 1.41 * 1.77 1.50, 2.09 *** 
No Ref               
Tobacco use                
Yes 1.39 1.04, 1.85 * 1.16 0.90, 1.51   0.98 0.73, 1.31   1.12 0.83, 1.52  
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Characteristics No ADH 2 Rx ADH 1 of 2 Rx ADH 1 Rx  No ADH 1 Rx  AOR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig 
No Ref               
Alcohol use                
Yes 1.22 0.67, 2.20   0.99 0.58, 1.71   1.35 0.78, 2.34   2.53 1.53, 4.19 *** 
No Ref               
Primary care visit             
Yes 1.34 1.11, 1.61 ** 1.14 0.99, 1.32   1.00 0.87, 1.17   1.05 0.88, 1.24  
No Ref               
Cardiologist visit                
Yes 1.03 0.90, 1.18   1.08 0.97, 1.21   0.65 0.58, 0.73 *** 0.73 0.64, 0.83 *** 
No Ref               
CAD severity 1.15 0.85, 1.56   0.98 0.75, 1.27   0.61 0.46, 0.83 ** 0.69 0.50, 0.96 * 
SEER Region                
Northeast 1.04 0.88, 1.22   1.07 0.94, 1.22   1.15 1.00, 1.33 * 0.92 0.78, 1.08  
South 1.24 1.06, 1.46 ** 1.17 1.02, 1.33 * 1.05 0.91, 1.22   1.10 0.94, 1.29  
North-central 0.92 0.76, 1.11   1.01 0.87, 1.18   0.96 0.82, 1.14   0.76 0.62, 0.92 ** 
West Ref                       
Based on 12,096 elderly fee-for-service Medicare beneficiaries with pre-existing CAD and incident breast, colorectal, and prostate cancer. Weights were derived 
using the Inverse Probability Treatment Weighting approach. 
 
Description of medication use and adherence 
No ADH 2 Rx: Not adherent to both statins and ACEIs/ARBs/beta-blockers; 
ADH 1 of 2 Rx: Adherent to either statins or ACEIs/ARBs/beta-blockers; 
ADH 1 Rx: Use of one medication class and adherent to that class; 
No ADH 1 Rx: Use of one medication class and not adherent to that medication class 
 
Asterisks represent significant differences in study population characteristics (time-invariant). Reference category is Adherent to both statins and 
ACEIs/ARBs/beta-blockers 
   
***p < 0.001; **0.001 ≤ p < 0.01; *0.01 ≤ p < 0.05. 
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Time-invariant characteristics include cancer diagnosis categories, age, race/ethnicity, concordant and discordant physical health conditions, CAD severity, SMI, 
SEER region. Time-variant characteristics include tobacco use, alcohol use, depression, anxiety, and routine follow-up with primary care physician and/or 
cardiologist, and Part D Medicare coverage. 
Concordant physical health conditions consisted of diabetes, hyperlipidemia, hypertension, stroke, cardiac arrhythmia, and congestive heart failure. Discordant 
physical health conditions consisted of arthritis, asthma, chronic obstructive pulmonary disease, osteoporosis, dementia, human immunodeficiency virus, and 
hepatitis. Mental health conditions include anxiety, depression, SMI (schizophrenia, bipolar disorder, and psychoses) 
 
Abbreviations 
ACEIs: Angiotensin-converting enzyme inhibitors; ARBs: Angiotensin II receptor blockers; CAD: Coronary artery disease; FFS: Fee-for-service; IPTW: inverse 
probability treatment weighting; MHC: Mental health conditions; PHC: Physical health conditions; Ref: Reference; Rx: Prescription; SEER: Surveillance, 
Epidemiology and End Results 
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3.4 Results 
3.4.1 Characteristics of the Study Population 
The study population comprised 12,096 elderly FFS Medicare beneficiaries with pre-existing CAD and incident 
cancer diagnosis. There were 33.1% women with breast cancer, 14.1% women with colorectal cancer; 11.6% men 
with colorectal cancer, and 41.2% men with prostate cancer (Table 3.2). Nearly one-third (29.5%) were diagnosed 
with stage 0 or I. Only 16.8% received no cancer treatment. 
 
3.4.1.1 Characteristics of the Study Population by Medication Adherence Categories - Before and After IPTW 
Adjustment 
Table 3.3 summarizes the characteristics of the cohort by adherence to statins and/or ACEIs/ARBs/beta-
blockers before and after IPTW adjustment. Prior to IPTW adjustment, there were statistically significant 
differences in age, race/ethnicity, cancer type and sex, cancer stage, cancer treatment, concordant physical 
conditions, discordant physical conditions, mental health conditions, tobacco use, alcohol use, any primary care 
visit, cardiologist visit, Part D Medicare coverage, and SEER region between the medication adherence groups. 
After IPTW adjustment, there were no significant differences in these variables between the medication adherence 
groups. 
Adherence to both statins and ACEIs/ARBs/beta-blockers was estimated at 31.2% during the 120-day period 
immediately after cancer diagnosis; 13.7% were not adherent to both medication classes during the same period. 
Table 3.4 summarizes the CAD-related hospitalizations over time. The prevalence of CAD-related hospitalizations 
was 27.4% during the 120-day period immediately after cancer diagnosis and this percentage declined to 10.6% 
during the last four months of post-cancer period.
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Table 3.2. Selected Characteristics of Study Population 
Characteristics Total population N % 
Age groups   
68-70 years 1,983 16.4 
71-74 years 2,887 23.9 
75-79 years 3,158 26.1 
80 years and older 4,068 33.6 
Race/Ethnicity   
Whites 9,928 82.1 
African Americans 1,013 8.4 
Others 1,155 9.5 
Cancer diagnosis   
Women with breast cancer 4,007 33.1 
Women with colorectal cancer 1,705 14.1 
Men with colorectal cancer 1,399 11.6 
Men with prostate cancer 4,985 41.2 
Cancer stage   
Stage 0/I 3,565 29.5 
Stage II 6,572 54.3 
Stage III/IV 1,959 16.2 
Cancer treatment   
Cardiotoxic cancer treatment 4,821 34.9 
Non-cardiotoxic cancer treatment 6,668 48.3 
No cancer treatment 2,322 16.8 
SEER Region   
Northeast 2,749 22.7 
South 2,977 24.6 
North-central 1,691 14.0 
West 4,679 38.7 
Index year   
2008 2,966 24.5 
2009 2,975 24.6 
2010 2,992 24.7 
2011 3,163 26.1 
Note: Based on 12,096 elderly fee-for-service Medicare beneficiaries with pre-existing CAD and incident breast, 
colorectal, and prostate cancer between 2008 and 2011. Table includes time-invariant characteristics.  
 
Abbreviation: SEER: Surveillance, Epidemiology and End Results
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Table 3.3. Unweighted and Weighted Percent of Selected Characteristics by Adherence to Statins and/or ACEIs/ARBs/Beta-blockers 
Characteristics 
Before IPTW (%) After IPTW (Wt. %) 
ADH 2 
Rx  
No 
ADH 2 
Rx  
ADH 1 
of 2 Rx  
ADH 1 
Rx  
No 
ADH 1 
Rx 
Sig ADH 2 Rx  
No 
ADH 2 
Rx  
ADH 1 
of 2 Rx  
ADH 1 
Rx  
No 
ADH 1 
Rx 
Sig 
Age groups      ***      NS 
68-70 years 18.0 13.7 17.1 14.9 16.3   16.5 16.8 16.3 16.5 16.6  
71-74 years 25.7 23.3 24.9 22.0 21.1   24.0 23.8 23.9 24.0 24.0  
75-79 years 27.3 24.6 27.2 25.9 23.4   26.4 26.0 25.9 25.8 26.3  
80 years and older 29.0 38.4 30.8 37.2 39.2   33.1 33.4 33.8 33.8 33.0  
Race/Ethnicity      ***      NS 
Whites 84.5 77.6 82.7 82.4 79.6   82.2 81.6 82.2 81.7 82.3  
African Americans 6.4 10.8 7.6 8.8 11.2   8.4 8.4 8.2 8.5 8.5  
Others 9.1 11.6 9.8 8.8 9.3   9.4 10.0 9.5 9.7 9.2  
Part D Medicare coverage      ***      NS 
Exceeded 5.6 2.7 3.9 3.4 2.4   4.1 4.3 4.0 4.1 3.8  
Not reached 90.5 95.4 93.1 94.5 96.1   93.2 93.1 93.3 93.1 93.4  
Reached 3.8 1.9 3.0 2.1 1.5   2.8 2.6 2.7 2.8 2.7  
Cancer diagnosis categories      ***      NS 
Women with breast cancer 33.8 23.3 32.5 41.6 31.2   34.0 33.5 33.2 33.5 33.5  
Women with colorectal cancer  9.3 21.2 14.8 12.1 19.4   13.7 13.9 14.1 13.8 13.7  
Men with colorectal cancer  9.5 19.0 11.0 7.9 14.6   11.3 11.4 11.4 11.7 11.4  
Men with prostate cancer 47.4 36.5 41.7 38.4 34.8   41.0 41.3 41.3 41.0 41.3  
Cancer stage      ***      NS 
Stage 0/I 29.2 25.9 30.3 32.6 27.9   29.8 29.4 29.4 29.4 29.8  
Stage II 57.4 51.9 53.8 52.5 53.0   54.0 55.0 54.4 54.3 54.1  
Stage III/IV 13.4 22.1 15.8 14.9 19.1   16.2 15.6 16.2 16.3 16.1  
Cancer treatment      ***      NS 
Cardiotoxic cancer treatment 37.3 30.3 36.5 35.4 33.2   35.7 36.1 35.4 35.3 35.5  
Non-cardiotoxic cancer treatment 16.8 14.7 16.7 16.7 16.0   16.5 16.8 16.3 16.5 16.2  
No cancer treatment 45.9 55.0 46.8 47.8 50.9   47.9 47.1 48.3 48.2 48.3  
Discordant PHC      ***      NS 
Yes 35.7 43.4 39.6 43.2 47.1   40.7 41.0 40.9 40.9 40.8  
No 64.3 56.6 60.4 56.8 52.9   59.3 59.0 59.1 59.1 59.2  
Concordant PHC      ***      NS 
Yes 96.6 95.8 96.3 93.8 91.5   95.2 95.4 95.2 95.3 95.1  
No 3.4 4.2 3.7 6.2 8.5   4.8 4.6 4.8 4.7 4.9  
MHC      *      NS 
Yes 11.9 18.8 14.1 14.6 20.5   15.0 14.3 14.9 15.0 14.8  
No 88.1 81.2 85.9 85.4 79.5   85.0 85.7 85.1 85.0 85.2  
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Characteristics 
Before IPTW (%) After IPTW (Wt. %) 
ADH 2 
Rx  
No 
ADH 2 
Rx  
ADH 1 
of 2 Rx  
ADH 1 
Rx  
No 
ADH 1 
Rx 
Sig ADH 2 Rx  
No 
ADH 2 
Rx  
ADH 1 
of 2 Rx  
ADH 1 
Rx  
No 
ADH 1 
Rx 
Sig 
Tobacco use      **      NS 
Yes 3.4 5.3 4.3 3.5 4.7   3.9 4.4 4.0 4.0 3.7  
No 96.6 94.7 95.7 96.5 95.3   96.1 95.6 96.0 96.0 96.3  
Alcohol use      ***      NS 
Yes 0.8 1.1 0.9 1.0 2.2   0.9 1.0 1.1 1.0 0.9  
No 99.2 98.9 99.1 99.0 97.8   99.1 99.0 98.9 99.0 99.1  
Primary care visit     ***      NS 
Yes 83.0 89.4 85.9 84.7 86.8   85.2 84.7 85.3 85.4 85.3  
No 17.0 10.6 14.1 15.3 13.2   14.8 15.3 14.7 14.6 14.7  
Cardiologist visit      ***      NS 
Yes 68.1 73.2 71.1 59.6 64.5   66.8 67.6 67.2 67.4 66.7  
No 31.9 26.8 28.9 40.4 35.5   33.2 32.4 32.8 32.6 33.3  
SEER Region      *      NS 
Northeast 22.9 21.4 22.8 24.6 20.5   22.5 21.9 22.7 22.4 22.7  
South 23.4 25.8 25.5 23.4 26.6   25.0 25.6 24.7 24.9 24.7  
North-central 14.8 13.1 13.8 14.4 12.3   13.9 13.6 13.9 13.8 14.3  
West 38.8 39.7 37.9 37.6 40.5   38.6 38.9 38.7 39.0 38.4   
 
Note: Based on 12,096 elderly fee-for-service Medicare beneficiaries with pre-existing CAD and incident breast, colorectal, and prostate cancer diagnosis. 
Weights were derived using the Inverse Probability Treatment Weighting approach.  
 
Description of medication use and adherence 
ADH 2 Rx: Adherent to both statins and ACEIs/ARBs/beta-blockers; 
No ADH 2 Rx: Not adherent to both statins and ACEIs/ARBs/beta-blockers; 
ADH 1 of 2 Rx: Adherent to either statins or ACEIs/ARBs/beta-blockers; 
ADH 1 Rx: Use of one medication class and adherent to that class; 
No ADH 1 Rx: Use of one medication class and not adherent to that medication class 
 
Asterisks represent significant differences in time-invariant patient-level characteristics based on chi-square tests   
***p < 0.001; **0.001 ≤ p < 0.01; *0.01 ≤ p < 0.05. Column percentages are reported. 
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Time-invariant characteristics include cancer diagnosis categories, age, race/ethnicity, concordant and discordant physical health conditions, SMI, SEER region. 
Time-variant characteristics include tobacco use, alcohol use, depression, anxiety, and routine follow-up with primary care physician and/or cardiologist, and 
Part D Medicare coverage. 
Concordant physical health conditions consisted of diabetes, hyperlipidemia, hypertension, stroke, cardiac arrhythmia, and congestive heart failure. Discordant 
physical health conditions consisted of arthritis, asthma, chronic obstructive pulmonary disease, osteoporosis, dementia, human immunodeficiency virus, and 
hepatitis. Mental health conditions include anxiety, depression, SMI (schizophrenia, bipolar disorder, and psychoses) 
 
Abbreviations 
ACEIs: Angiotensin-converting enzyme inhibitors; ARBs: Angiotensin II receptor blockers; CAD: Coronary artery disease; FFS: Fee-for-service; IPTW: inverse 
probability treatment weighting; MHC: Mental health conditions; PHC: Physical health conditions; Rx: Prescription; SEER: Surveillance, Epidemiology and End 
Results; Wt.: Weighted
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Table 3.4. Weighted percentage with CAD-related hospitalizations over different time periods 
Use and adherence to CAD-related 
pharmacotherapy 
Pre-cancer dx 
period 
Initial cancer 
tx period Post-tx period 
t0 t1 t2 t3 
Wt. % Wt.  % Wt.  % Wt. % 
CAD-related hospitalization 
ADH 2 Rx 7.5 28.6 8.9 7.6 
No ADH 2 Rx 10.4 31.4 18.0 14.7 
ADH 1 of 2 Rx 8.5 28.1 12.6 11.2 
ADH 1 Rx 5.7 19.9 7.3 7.1 
No ADH 1 Rx 7.6 22.7 9.7 10.2 
Other hospitalization 
ADH 2 Rx 2.1 14.2 3.5 2.6 
No ADH 2 Rx 3.6 18.3 7.0 6.2 
ADH 1 of 2 Rx 2.8 17.4 3.9 4.4 
ADH 1 Rx 3.2 22.7 5.7 4.0 
No ADH 1 Rx 4.3 23.8 8.0 6.3 
 
Note: Based on 12,096 elderly fee-for-service Medicare beneficiaries with pre-existing CAD and incident breast, 
colorectal, and prostate cancer diagnosis. Weights were derived using the Inverse Probability Treatment Weighting 
approach. 
 
Description of medication use and adherence 
ADH 2 Rx: Adherent to both statins and ACEIs/ARBs/beta-blockers; 
No ADH 2 Rx: Not adherent to both statins and ACEIs/ARBs/beta-blockers; 
ADH 1 of 2 Rx: Adherent to either statins or ACEIs/ARBs/beta-blockers; 
ADH 1 Rx: Use of one medication class and adherent to that class; 
No ADH 1 Rx: Use of one medication class and not adherent to that medication class 
 
Abbreviations 
CAD: Coronary artery disease
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3.4.1.2 Unadjusted and Adjusted Associations between Adherence to Statins and/or ACEIs/ARBs/Beta-
blockers and CAD-related Hospitalization 
Table 3.5 displays the results from the unadjusted and adjusted multinomial logistic regression models with 
IPTW for repeated measures on CAD-related hospitalization. The adjusted model controlled for time, age, 
race/ethnicity, census tract education level and poverty status, marital status, Part D Medicare coverage, concordant 
and discordant physical health conditions, and mental health conditions, cancer type and sex, cancer stage, cancer 
treatment, tobacco use, alcohol use, visits to primary care/cardiologist, SEER region, and county metro status. 
Reference category for the dependent variable was no CAD hospitalization. 
In unadjusted analyses, those not adherent to both medication classes [OR = 1.67; 95% CI = 1.58, 1.76; P < 
0.0001] and those who were adherent to one (out of two) medication class [OR = 1.22; 95% CI = 1.15, 1.30; P < 
0.0001] were more likely to have CAD-related hospitalization, compared to those who were adherent to both 
medication classes. However, those with the use of one medication class and adherent to that medication class were 
significantly less likely to have CAD-related hospitalization compared to those who were adherent to both 
medication classes [OR = 0.76; 95% CI = 0.66, 0.86; P < 0.0001]. 
Consistent with the findings from unadjusted model, compared to those who were adherent to both medication 
classes, those not adherent to both medication classes [AOR = 1.82; 95% CI = 1.72, 1.92; P < 0.0001] and those 
who were adherent to one (out of two) medication class [AOR = 1.26; 95% CI = 1.17, 1.34; P < 0.0001] were more 
likely to have CAD-related hospitalization in the adjusted model. Further, those with the use of one medication class 
and adherent to that medication class were significantly less likely to have CAD-related hospitalization compared to 
those who were adherent to both medication classes [AOR = 0.80; 95% CI = 0.70, 0.90; P < 0.0001]. However, 
those with use of one medication class and not adherent to that medication class [AOR = 1.20; 95% CI = 1.09, 1.31; 
P = 0.005] were more likely to have CAD-related hospitalization.
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Table 3.5. Odds Ratios, Adjusted Odds Ratios, and 95% Confidence Intervals of Medication Adherence 
Categories from Multinomial Logistic Regression Models with Repeated Measures on Hospitalization 
Categories – IPTW (Reference Group = No Hospitalizations) 
Variables CAD-related hospitalization Other hospitalization OR 95% CI Sig OR 95% CI Sig 
Unadjusted analysis 
Medication adherence categories 
No ADH 2 Rx 1.67 [1.58,1.76] *** 1.88 [1.75,2.00] *** 
ADH 1 of 2 Rx 1.22 [1.15,1.30] *** 1.36 [1.25,1.46] *** 
ADH 1 Rx 0.76 [0.66,0.86] *** 1.59 [1.48,1.70] *** 
No ADH 1 Rx 1.05 [0.94,1.15] 
 
2.10 [1.99,2.22] *** 
ADH 2 Rx  Reference   Reference  
Cancer diagnosis categories       
Women with breast cancer 1.15 [1.07,1.23] *** 1.61 [1.52,1.70] *** 
Women with colorectal cancer 3.39 [3.31,3.47] *** 4.23 [4.14,4.32] *** 
Men with colorectal cancer 3.60 [3.52,3.68] *** 2.91 [2.80,3.02] *** 
Men with prostate cancer  Reference   Reference  
Cancer stage       
Stage 0/I 0.93 [0.87,0.99] * 0.82 [0.77,0.88] *** 
Stage III/IV 2.04 [1.97,2.12] *** 2.31 [2.22,2.40] *** 
Stage II  Reference   Reference  
Cancer treatment       
Cardiotoxic cancer treatment 1.30 [1.16,1.44] *** 2.36 [2.16,2.56] *** 
No cancer treatment 0.88 [0.76,1.00] * 1.11 [0.93,1.29]  
Non-cardiotoxic cancer 
treatment  Reference   Reference  
Adjusted analysis 
Variables AOR 95% CI Sig AOR 95% CI Sig 
Medication adherence categories 
No ADH 2 Rx 1.82 [1.72,1.92] *** 2.00 [1.87,2.13] *** 
ADH 1 of 2 Rx 1.26 [1.17,1.34] *** 1.39 [1.28,1.49] *** 
ADH 1 Rx 0.80 [0.70,0.90] *** 1.65 [1.54,1.76] *** 
No ADH 1 Rx 1.20 [1.09,1.31] ** 2.34 [2.22,2.46] *** 
ADH 2 Rx Reference Reference 
Cancer diagnosis categories      
Women with breast cancer 1.18 [1.08,1.29] ** 1.59 [1.47,1.71] *** 
Women with colorectal cancer 3.31 [3.20,3.42] *** 4.20 [4.07,4.33] *** 
Men with colorectal cancer 3.78 [3.67,3.88] *** 2.80 [2.67,2.93] *** 
Men with prostate cancer Reference  Reference  
Cancer stage       
Stage 0/I 0.65 [0.55,0.74] *** 0.71 [0.60,0.81] *** 
Stage III/IV 1.25 [1.15,1.34] *** 1.37 [1.26,1.47] *** 
Stage II  Reference    Reference  
Cancer treatment       
Cardiotoxic cancer treatment 1.31 [1.14,1.49] ** 2.14 [1.91,2.37] *** 
No cancer treatment 0.84 [0.69,0.98] * 1.07 [0.86,1.28]  
Non-cardiotoxic cancer 
treatment  Reference    Reference  
Note: Based on 12,096 elderly fee-for-service Medicare beneficiaries with pre-existing CAD and incident breast, 
colorectal, and prostate cancer diagnosis. Weights were derived using the Inverse Probability Treatment Weighting 
approach. 
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Description of medication use and adherence 
ADH 2 Rx: Adherent to both statins and ACEIs/ARBs/beta-blockers; 
No ADH 2 Rx: Not adherent to both statins and ACEIs/ARBs/beta-blockers; 
ADH 1 of 2 Rx: Adherent to either statins or ACEIs/ARBs/beta-blockers; 
ADH 1 Rx: Use of one medication class and adherent to that class; 
No ADH 1 Rx: Use of one medication class and not adherent to that medication class 
 
Asterisks represent significant differences in medication adherence groups, derived from multinomial logistic 
regression models with repeated measures. Reference category for dependent variable is no hospitalization. 
***p < 0.001; **0.001 ≤ p < 0.01; *0.01 ≤ p < 0.05. 
 
ORs are reported for unadjusted GEE model and AORs are reported for adjusted GEE model.  
Adjusted model controlled for independent variables. Time-invariant characteristics include cancer diagnosis 
categories, age, race/ethnicity, poverty status, high school education, concordant and discordant physical health 
conditions, SMI, SEER region, and county-level characteristics. Time-variant characteristics include, tobacco use, 
alcohol use, depression, anxiety, and routine follow-up with primary care physician and/or cardiologist, and Part D 
Medicare coverage. 
 
Abbreviations 
AOR: Adjusted odds ratio; CAD: Coronary artery disease; CI: Confidence interval; FFS: Fee-for-service; GEE: 
Generalized estimating equations; OR: Odds ratio; IPTW: Inverse Probability treatment weighting; Sig: 
Significance; SEER: Surveillance, Epidemiology, and End Result.
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3.4.2 Sensitivity Analyses  
We found that the percent of oncologists at the county-level was a strong and valid instrument variable. The 
variable oncologists at the county-level were significantly associated with medication adherence [OR = 4.27; 95% 
CI = 2.15,8.47; P < 0.0001] and medication adherence was an endogenous variable [Wald test, P < 0.0001]. Results 
from IV regression revealed that Medicare beneficiaries in other medication adherence category (not adherent to one 
or both medication classes) were more likely to have CAD-related hospitalization compared to those who were 
adherent to both medication classes [Beta = 1.20; SE = 0.10; P < 0.0001]. The results did not change when 
medication adherence was categorized into three categories, those not adherent to one or both medication classes 
were more likely to have CAD-related hospitalization [Beta = 1.22; SE = 0.12; P < 0.0001], whereas those with 
single medication use and adherent to that medication [Beta = -0.98; SE = 0.13; P < 0.0001] were less likely to have 
CAD-related hospitalization when compared to those adherent to both medications. 
Table 3.6 displays the AORs and 95% CI for from the adjusted multinomial logistic regressions on CAD-
related hospitalization that accounted for IPTW and repeated measures, where CAD-related hospitalizations were 
identified from primary diagnosis. There were some similarities and differences in comparison to GEE model with 
hospitalization identified from both primary and secondary diagnosis (primary analyses). 
Consistent with the primary analyses (adjusted model), those who were not adherent to both medication classes 
[AOR = 2.57; 95% CI = 2.41, 2.74; P < 0.0001], adherent to one (out of two) medication class [AOR = 1.42; 95% 
CI = 1.27, 1.57; P < 0.0001], or were using single medication class and not adherent to that medication class [AOR 
= 1.42; 95% CI = 1.27, 1.57; P = 0.0002] were more likely to have CAD-related hospitalization compared to those 
who were adherent to both medication classes. However, in contrast to the primary analyses, there was no 
significant difference in those using one medication class and adherent to that medication class compared to those 
who were adherent to both medication classes. 
 
3.4.3 Adjusted Associations between Other Independent Variables and CAD Hospitalization 
Appendix 4 displays the AORs and 95% CI from the adjusted GEE models with IPTW on adherence for other 
independent variables. Other variables, such as cancer diagnosis categories, cancer stage, and cancer treatment were 
significantly associated with CAD-related hospitalization categories. Compared to men with prostate cancer, women 
with breast cancer [AOR = 1.18; 95% CI = 1.08, 1.29], women with colorectal cancer [AOR = 3.31; 95% CI = 3.20, 
3.42], and men with colorectal cancer [AOR = 3.78; 95% CI = 3.67, 3.88] were more likely to have CAD-related 
hospitalizations. Those with cancer stage III/IV versus stage II [AOR = 1.25; 95% CI = 1.15, 1.34] and those 
receiving cardiotoxic cancer treatment versus no cardiotoxic cancer treatment [AOR = 1.31; 95% CI = 1.14, 1.49] 
were more likely to have CAD-related hospitalization.
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Table 3.6. Sensitivity analysis: CAD Hospitalization Identified from Primary Diagnosis Odds Ratios, 
Adjusted Odds Ratios, and 95% Confidence Intervals of Medication Adherence Categories GEE Models with 
IPTW on CAD Hospitalization 
Medication adherence 
categories 
CAD-related hospitalization Other hospitalization 
OR/AOR 95% CI Sig OR/AOR 95% CI Sig 
Unadjusted GEE analysis 
No ADH 2 Rx 2.36 [2.20,2.52] *** 1.61 [1.53,1.70] *** 
ADH 1 of 2 Rx 1.38 [1.24,1.52] *** 1.24 [1.17,1.31] *** 
ADH 1 Rx 0.76 [0.56,0.95] ** 1.06 [0.98,1.13]  
No ADH 1 Rx 1.23 [1.03,1.43] * 1.39 [1.31,1.47] *** 
ADH 2 Rx Reference Reference 
Adjusted GEE analysis 
No ADH 2 Rx 2.57 [2.41,2.74] *** 1.75 [1.66,1.84] *** 
ADH 1 of 2 Rx 1.42 [1.27,1.57] *** 1.27 [1.20,1.35] *** 
ADH 1 Rx 0.83 [0.63,1.02]  1.11 [1.03,1.19] ** 
No ADH 1 Rx 1.46 [1.26,1.66] *** 1.58 [1.49,1.67] *** 
ADH 2 Rx Reference Reference 
Note: Based on 12,096 elderly fee-for-service Medicare beneficiaries with pre-existing CAD and incident breast, 
colorectal, and prostate cancer diagnosis. Weights were derived using the Inverse Probability Treatment Weighting 
approach. 
 
Description of medication use and adherence 
ADH 2 Rx: Adherent to both statins and ACEIs/ARBs/beta-blockers; 
No ADH 2 Rx: Not adherent to both statins and ACEIs/ARBs/beta-blockers; 
ADH 1 of 2 Rx: Adherent to either statins or ACEIs/ARBs/beta-blockers; 
ADH 1 Rx: Use of one medication class and adherent to that class; 
No ADH 1 Rx: Use of one medication class and not adherent to that medication class 
 
Asterisks represent significant differences in medication adherence groups, derived from GEE. Reference category 
for dependent variable is no hospitalization. 
***p < 0.001; **0.001 ≤ p < 0.01; *0.01 ≤ p < 0.05. 
 
ORs are reported for unadjusted GEE model and AORs are reported for adjusted GEE model.  
Adjusted model controlled for independent variables. Time-invariant characteristics include cancer diagnosis 
categories, age, race/ethnicity, poverty status, high school education, concordant and discordant physical health 
conditions, SMI, SEER region, and county-level characteristics. Time-variant characteristics include, tobacco use, 
alcohol use, depression, anxiety, and routine follow-up with primary care physician and/or cardiologist, and donut 
hole. 
 
Abbreviations 
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AOR: Adjusted odds ratio; CAD: Coronary artery disease; CI: Confidence interval; FFS: Fee-for-service; GEE: 
Generalized estimating equations; OR: Odds ratio; IPTW: Inverse Probability treatment weighting; Sig: 
Significance; SEER: Surveillance, Epidemiology, and End Results
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3.5 Discussion 
To the best of our knowledge, this is the first study to examine the impact of adherence to statins and 
ACEIs/ARBs/beta-blockers on CAD hospitalizations in elderly FFS Medicare beneficiaries with pre-existing CAD 
and incident cancer diagnosis. Compared to Medicare beneficiaries with CAD and cancer who were adherent to both 
statins and ACEIs/ARBs/beta-blockers, those who were non-adherent to either both or single medication classes 
were more likely to have CAD-related hospitalization. Findings from the current study are consistent with published 
literature that is not specific to cancer. In these studies, non-adherence to statins and ACEIs/ARBs/beta-blockers has 
been reported to have negative cardiovascular health consequences, including cardiovascular events and 
hospitalization [94-96]. 
Counterintuitively, our study findings indicated that those using single medication class and adherent to that 
single medication class were less likely to have CAD-related hospitalization compared to those who were adherent 
to both medication classes. This is an unanticipated finding and plausible reasons could be that this specific 
population may have lower CAD severity or may be different in unobserved characteristics such as healthy eating, 
exercise, and maintaining normal weight. Further research is needed to understand the role of these factors in 
reducing CAD-related hospitalizations in the elderly Medicare beneficiaries with CAD. Interestingly, in a sensitivity 
analysis where CAD hospitalization was the primary diagnosis, no significant difference was observed between 
single medication users (adherent) and those adherent to both medication classes. 
Consistent with a previous study on patients with prostate cancer diagnosis [170], we observed that CAD-
related hospitalizations increased in the period immediately after cancer diagnosis for all medication adherence 
categories. As stated in the introduction, cardiotoxic cancer treatments can increase the risk of CAD-related 
hospitalizations [60-62]. This is also evident from our study findings, where those receiving cardiotoxic cancer 
treatment were more likely to have CAD-related hospitalizations compared to those not receiving non-cardiotoxic 
cancer treatment.  
A meta-analysis of clinical trials showed that the prophylactic use of beta-blockers, ACEI, ARBs, or statins 
reduced the risk of newly developed heart failure in patients administered anthracycline [71]. We assessed the 
interaction between medication adherence categories and cancer treatment on CAD-related hospitalization. Our 
study findings revealed that the interaction effect between adherence to both medication classes and cardio-toxic 
cancer treatment was not statistically significant. It is possible that the established CAD diminishes the cardio-
protective effect of these medications. In addition, the meta-analysis did not specifically focus on elderly population 
and specific cancers included in our study. Future studies that include characteristics that were not measured in the 
current study (example: physical activity, alternative and complementary medicine, polypharmacy) are needed to 
provide conclusive evidence on the lack of interaction between adherence and cardio-toxic cancer treatment. 
 
3.5.1 Clinical and Policy Implications 
Both CAD and cancer are life-threatening conditions and co-management of both conditions can be 
challenging. However, lack of effective management of CAD may not only increase CAD complications, but can 
also have negative consequences for cancer prognosis. Current clinical practices recommend stabilizing pre-existing 
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CAD prior to initiating cancer treatment. For example, appropriate pharmacologic management (statins and beta-
blockers) of the patient with pre-existing CAD is recommended for those undergoing cancer surgery [72]. Given the 
complexity of interaction between CAD and cancer, it is important to routinely monitor medication adherence in 
general clinical practice and provide linkages to support services that can increase medication adherence. This may 
warrant integration of cardiovascular care in the elderly diagnosed with incident cancer. An example of integrated 
care is the cardio-oncology clinics that provide interdisciplinary and integrative management approach to cancer 
patients with cardiovascular risks or conditions [183]. 
It is possible that certain CAD-related hospitalizations in our study may be readmission or preventable 
hospitalizations, which have policy implications. The Affordable Care Act, under Hospital Readmissions Reduction 
Program, provided CMS the authority to reduce payments to certain hospital readmissions that it deemed avoidable 
[184]. The emphasis was on Medicare readmissions related to heart failure, myocardial infarction, and pneumonia. 
Reducing avoidable readmissions can enhance patient quality of care and lower health care spending. In addition, 
based on Agency for Healthcare Research and Quality’s (AHRQ) prevention quality indicators, hospitalizations 
related to conditions, such as angina without procedure and congestive heart failure, are considered preventable 
hospitalizations with good outpatient care. Therefore, it is important to implement interventions for improving 
medication adherence and to have integrated care for patients with pre-existing CAD and incident cancer diagnosis 
for reducing avoidable hospitalizations. 
 
3.5.2 Strengths and Limitations  
Our study findings need to be interpreted in the context of its limitations. First, the study findings cannot be 
generalized to all Medicare beneficiaries because the study population is restricted to those residing in SEER regions 
and to those with FFS Medicare plans. Further, the study population was restricted to elderly population with breast, 
colorectal, or prostate cancer and pre-existing CAD. The findings cannot be generalized to younger population or 
those with other cancer types. Second, we were not able to control for many other variables such as lifestyle health 
behaviors, knowledge, attitude, preferences and other factors that may affect adherence as well as hospitalizations 
[185]. Further, we did not look at specific cardiotoxic agents, which to some extent have overestimated 
cardiotoxicity measure in the study. However, we controlled for a comprehensive list of variables to examine 
multivariable associations. We used a proxy measure for CAD severity, which may not reflect the precise CAD 
severity in the population. Gold standards for measuring CAD severity, such as stress tests, are not available in 
Medicare database. Lastly, we used prescription claims for measuring adherence. As part D file contains only filled 
prescriptions, it is not known whether the patient actually used the medications or whether the patients adhered to 
their providers’ instructions or not. 
Despite these limitations, our study adds to the nascent literature on cardio-oncology and has several strengths. 
First, the current study included a large cohort of patients over a long period of time across a variety of providers 
and focused on real-world practice patterns. Second, the study used a robust repeated measure design. Third, the 
study used a variety of statistical methods to control for both observed and unobserved selection bias to ensure 
robustness of findings. 
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3.5.3 Conclusions 
Non-adherence to both statins, ACEIs/ARBs/beta blockers can increase the risk other CAD-related 
hospitalizations in pre-existing CAD and incident breast, colorectal, or prostate cancer. Future studies need to 
examine the role of patient-related factors that were not measured in this study on adherence so that strategies to 
improve adherence in this population can be developed.
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4 CHAPTER 4 
Impact of Incident Cancer on Short-term CAD-related Medicare 
Expenditures among Medicare Beneficiaries with Pre-existing Coronary 
Artery Disease 
 
4.1 Abstract 
Objectives: To examine the association between incident cancer and short-term coronary artery disease (CAD)-
related Medicare expenditures among elderly with incident breast, colorectal and prostate cancer.  
Methods: A retrospective observational longitudinal study was conducted among elderly Medicare fee-for-service 
beneficiaries with pre-existing CAD and those with incident breast (BC), colorectal (CC), or prostate (PC) cancer (N 
= 12,095) and those with no cancer (NC) (N = 34,237). CAD-related healthcare expenditures were measured every 
120 days during the one-year pre- and one-year post-index period. Due to the overlap between cancer type and sex, 
cancer diagnosis was grouped into: (1) women with BC; (2) women with CC; (3) women with NC; (4) men with PC; 
(5) men with CC; and (6) men with NC. CAD-related healthcare expenditures consisted of the actual Medicare 
payments for inpatient, home healthcare (HHA), and outpatient services corresponding to the ICD-9-CM primary 
and secondary diagnosis code for CAD. The adjusted relationship between incident cancer and CAD-related 
expenditures was analyzed using the generalized linear mixed models (GLMM). Inverse probability treatment 
weights were used to account for observed group differences between cancer and non-cancer groups. 
Results: Overall, CAD-related mean healthcare expenditures at pre-index period accounted for about 32.6% - 39.5% 
of total expenditures among women and 41.5% - 46.8% among men. In the adjusted GLMM, all cancer groups had 
significantly higher CAD-related healthcare expenditures compared to the non-cancer groups. Women with CC 
153% higher expenditures compared to women with no cancer [β = 0.93, P < 0.0001].  Men with CC had 166% 
higher expenditures compared to men with NC [β = 0.98, P < 0.0001]. Further, men and women with CC had 57% 
and 55% higher expenditures compared to men with PC and women with BC, respectively. 
Conclusions: CAD-related Medicare expenditures were higher for those with cancer as compared to Medicare 
beneficiaries without cancer. Elderly with CC were particularly vulnerable for high CAD-related expenditures. 
These study findings make a compelling case for of designing effective programs and policies to reduce CAD-
related expenditures. Close monitoring and surveillance of CC patients with CAD may be needed to prevent CAD-
related events and expenditures.  
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4.2 Introduction 
In 2013, cardiovascular disease, which included coronary artery disease (CAD) and cerebrovascular disease, 
ranked first in healthcare expenditures with an estimated $231.1 billion among a mutually exclusive list of 155 
conditions [186].  It has also been documented that healthcare spending for services directly resulting from CAD 
(i.e. CAD-related expenditures such as) were higher than for other chronic conditions [187, 188]. For these 
individuals, CAD-related expenditures can be higher than those with only CAD [189]. Furthermore, CAD-related 
healthcare expenditures in the United States (US) are projected to increase by 198% in 2030 with increase in aging 
population [187]. 
 Evidence also suggests that individuals with CAD have many pre-existing conditions or due to the shared risk 
factor, may develop new conditions such as cancer [190]. For these individuals, CAD-related expenditures can be 
higher than those with only CAD [56, 189]. Specifically, CAD-related expenditures may be higher among 
individuals with incident cancer (and CAD) during the period immediately after cancer diagnosis because of several 
reasons: 1) cardiotoxicity from specific cancer treatments can exacerbate pre-existing CAD [60, 61, 72]; and 2) 
diagnosis of incident cancer may impede with the management of CAD, thereby increasing the risk of CAD-related 
complications, given that cancer is considered a dominant condition [69]. 
 However, there is a dearth of studies on the impact of cancer on CAD-related expenditures. It is important to 
analyze CAD-related expenditures among Medicare beneficiaries because there are large differences in healthcare 
expenditures directly attributed to CAD and total expenditures of a person with CAD [187]. More specifically, 
published studies suggest that inpatient accounts for nearly 43% of total expenditures for cardiovascular diseases 
[191]. Furthermore, CAD-related expenditures may be higher among elderly due to aging.  For example, Dieleman 
et al. reported that 65.2% of expenditures for CAD and related diseases were for individuals 65 years and older, 
suggesting that elderly individuals account for most of the expenditures for CAD care [186]. As nearly 84% of the 
elderly are covered by Medicare [99], payments made by Medicare for CAD are substantial, suggesting that it is 
important to estimate Medicare payments for CAD care. In 2012, the Medicare program paid $273 billion for heart 
disease, with per-person cost of $10,345 [192]. 
 Estimating the extent to which incident cancer affects CAD-related expenditures can help the payers with the 
emerging healthcare delivery reform initiatives, which are focused on financial incentives to improve healthcare 
quality with lower healthcare expenditures.  For example, new payment models from the Centers for Medicare and 
Medicaid Services (CMS) support bundled payments for episodes of care. One of the experimental initiatives will 
support bundled payments for clinicians providing care to patients with CAD [193]. Such models have the potential 
to be extended to those who develop cancer after CAD. In addition, estimating payments for CAD-related care may 
also help providers by reducing costs and increasing coordination across providers. For example, Medicare Access 
and Children’s Health Insurance Program Reauthorization Act (MACRA) of 2015, a payment reform by Medicare 
has created alternative payment models [193], provides financial incentives for providing value-based care and 
penalties for poor quality of care.  These models require risk adjustment of patients [194-196], and therefore, 
identifying who are at risk for high-cost is important.  
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The present study examined the impact of cancer on CAD-related expenditures using data from a cohort of 
elderly fee-for-service (FFS) Medicare beneficiaries with and without cancer. We also analyzed CAD-related 
inpatient expenditures and outpatient expenditures.  The cancer cohort consisted of elderly with incident breast, 
colorectal or prostate cancer. These cancers were selected as they have a higher prevalence among elderly 
population with [107] and pre-existing CAD is highly prevalent among the elderly diagnosed with these cancers 
[109-112, 114, 197]. 
 
4.3 Methods 
4.3.1 Conceptual Framework 
The conceptual framework was adapted based on the Andersen’s Behavioral Model of Health Service Use for 
understanding CAD-related healthcare expenditures and a priori selection of independent variables (Figure 1.3) 
[124, 125]. This model posits that individual’s predisposing (age, sex, race/ethnicity), enabling (marital status, 
prescription drug coverage, census tract, and poverty status), need factors (chronic physical and mental health 
conditions), personal health practices (tobacco and alcohol use), healthcare use (visits to primary care/cardiologist 
and adherence to CAD medications) and external environment (Surveillance, Epidemiology and End Results 
[SEER] region and county metro status) may influence healthcare expenditures [126]. 
 
4.3.2 Study Design 
A retrospective observational longitudinal cohort design with a 12-month pre- and 12-month post-index period 
was used (Figure 2.1). For the cancer cohort, pre- and post-index periods were based on cancer diagnosis dates. For 
the non-cancer cohort, pre- and post-index periods were derived using pseudo-diagnosis dates, which were randomly 
selected from the dates of service. Each individual was observed for 48 months with 24-month baseline (for 
identification of CAD and baseline characteristics) period, 12-month pre-index, and 12-month post-index periods 
CAD-related healthcare expenditures and selected independent variables were measured repeatedly every 120 days 
during the pre- (t1, t2, and t3) and post-index (t4, t5, and t6) period, yielding a total of six repeated measures for every 
single individual.  
 
4.3.3 Data Sources 
The data were linked from different sources, including the SEER registries; Medicare claims linked with the 
SEER registries; 5% non-cancer random sample of Medicare beneficiaries in SEER region; the American 
Community Survey (ACS), and the Area Health Resource Files (AHRF). SEER program is an epidemiologic 
surveillance system comprising population-based tumor registries. It collects data on all incident cases of cancer in 
persons residing in 18 SEER areas. SEER data also encompass information on demographic characteristics, 
diagnosis date, cancer site, stage, and grade, and type of surgical treatment, and radiation therapy provided (if 
provided) within four months of diagnosis [126]. Medicare beneficiaries without cancer were identified from the 5% 
non-cancer sample of these beneficiaries living in same catchment areas as those in SEER program, randomly 
selected based on the last two digits of their social security number [126]. The individuals who have been reported 
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to SEER with an incident cancer are removed from this 5% random sample. The information on census-tract level 
poverty status and education was derived from the ACS [128]. County-level healthcare environment factors 
(community health clinics, Healthcare Professional Shortage Area (HPSA), and percent of cardiologists and 
oncologists in the county) were derived from the AHRF [129]. 
 
4.3.4 Study Population 
The study population comprised beneficiaries with pre-existing CAD and those with incident breast, colorectal, 
or prostate cancer and those without cancer. CAD was identified using a validated algorithm developed by the 
Centers for Medicare and Medicaid Services (CMS) [150]. The algorithm used the International Classifications of 
Diseases – 9th edition, Clinical Modification (ICD-9-CM) codes. Individuals with at least two inpatient, outpatient 
and carrier claims (clinician encounters only), or home health agency service Medicare claims with a primary or 
secondary diagnosis of CAD during the baseline were classified as having pre-existing CAD. Incident cancer, 
January 2008 through December 2011, was identified using the International Classification of Diseases for 
Oncology, 3rd Edition (ICD-O-3) codes from the SEER registries. Individuals without cancer were identified from 
the 5% non-cancer Medicare claims from the SEER regions. 
Other inclusion criteria were age 68 years or older, alive with continuous FFS Medicare Part A, B enrollment 
during the entire study period, continuous part D enrollment during the pre- and post-index period, no missing 
information on county, who had two or more prescriptions for either statins or two prescriptions for any or 
combinations of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), or 
beta-blockers, and total expenditures greater than zero over the two-year period (pre- and post-index period). In the 
non-cancer cohort, individuals with end-stage renal disease were excluded prior to diagnosis date assignments. In 
the cancer cohort, individuals with missing data for type and stage of cancer and those who were diagnosed with 
cancer through autopsy or death certificate were excluded. The selection criteria are presented in  
Figure 4.1..
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Figure 4.1. Schematic presentation of selection criteria for study cohort. 
 
Abbreviations – CAD: Coronary artery disease; HMO: Health Maintenance Organization 
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4.3.5 Measures 
4.3.5.1 Dependent variable: CAD-related Expenditures 
CAD-related healthcare expenditures consisted of Medicare payments for inpatient, home healthcare agency 
(HHA), and outpatient services for CAD-related care and were measured for every 120 days (t1, t2, t3, t4, t5, and t6). 
CAD-related services were identified using ICD-9-CM primary and secondary diagnosis codes for CAD [198, 199]. 
Prescription medication and durable medical equipment (DME) expenditures were not included because of the 
challenges in identifying CAD-related expenditures in DME and prescription drug claims. We also calculated total 
expenditures for inpatient, home healthcare (HHA), and outpatient services (obtained from outpatient and carrier 
claims) so that we can calculate the proportion of CAD-related expenditures to total expenditures. The outpatient 
claims included institutional outpatient  services emergency services, laboratory tests, X-rays/other radiology, 
medical supplies, and preventive/screening services [200]. Carrier claims included physician services and services 
from other non-institutional providers, such as physician assistants and nurse practitioners [201]. The healthcare 
expenditures were adjusted by the Consumer Price Index for medical services [202] and expressed in 2012 constant 
dollars.  
 
4.3.5.2 Key independent Variable – Cancer Type and Sex 
As the study included women with breast cancer and men with prostate cancer, our key time-invariant 
independent variable accounted for both sex and cancer type and was categorized into six mutually exclusive 
groups: women with breast cancer (BCW), women with colorectal cancer (CCW), women with no cancer (NCW), 
men with prostate cancer (PCM), men with colorectal cancer (CCM), and men with no cancer (NCM).  
 
4.3.5.3 Other Independent Variables 
Predisposing Factors 
These were time-invariant and consisted of age in years measured at index month of incident cancer diagnosis 
and race/ethnicity. 
 
Enabling Factors 
These factors Medicare Part D coverage gap (measured every 120 days) and included census tract-level 
education level and poverty status (measured at baseline). Medicare Part D coverage gap, also referred to as “donut 
hole” is the phase between the annual coverage limit and catastrophic coverage. Thus, Part D plans start with an 
annual deductible, after which Medicare pays for the prescription drugs up to an initial coverage limit with certain 
coinsurance associated with those payments.  Prescription drugs are not covered during the period when an 
individual reaches the annual coverage limit and until the cost of prescription drugs reaches to catastrophic limit 
[156]. This creates the donut hole. 
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Need-based Factors 
Physical health conditions were measured at baseline and categorized into concordant (cardiac arrhythmias, 
congestive heart failure, diabetes, hyperlipidemia, hypertension, and stroke) and discordant (dementia, asthma, 
chronic obstructive pulmonary disease, arthritis, hepatitis, human immunodeficiency virus, and osteoporosis) 
conditions. Mental health conditions included severe mental illness (schizophrenia, bipolar disorder, and psychoses) 
(measured at baseline) and anxiety, and depression (measured every 120 days). For CAD severity, a proxy measure, 
measured at baseline, was constructed based on the CMS hierarchical condition category (HCC) classification 
system. Based on the CMS risk adjustment model, each of the HCC codes for CAD was assigned specific score 
based on the risk and severity [154], ranging from 0.231 to 0.349. Thus, higher scores represented severe 
manifestations of CAD. 
 
Personal Health Care Practices 
This included tobacco use and alcohol abuse as these practices have been reported to negatively affect 
cardiovascular health [203, 204]. These variables were measured every 120 days. 
 
Healthcare use 
This included primary care visits, cardiologist visits, and adherence to statins and/or ACEIs, ARBs, or beta-
blockers measured every 120 days. Adherence to these medication classes were defined as proportion of days 
covered (PDC). It was calculated among only those who filled at least two prescriptions for either statins or any two 
prescriptions of, ACEIs, ARBs, or beta-blockers. The denominator for PDC was 120 days. For those who were on 
both statins and ACEIs, ARBs or beta-blockers), PDC was derived by considering the number of days with both 
classes of medications. Individuals with PDC ≥80% were considered as adherent and those with PDC <80% were 
considered as non-adherent [153]. Adherence was classified into five mutually exclusive groups: adherent to both 
statins and ACEIs/ARBs/beta-blockers, not adherent to both statins and ACEIs/ARBs/beta blockers, adherent to 
either statins or ACEIs/ARBs/beta-blockers, use of one medication class and adherent to that class, and use of one 
medication class and not adherent to that medication class.  
 
External Environment Factors 
These were time-invariant and measured at baseline. This domain included SEER region – Northeast 
(Connecticut, New Jersey), South (Kentucky, Louisiana, Atlanta, rural Georgia, and Greater Georgia), North-central 
(Detroit, Iowa), and West (San Francisco, Hawaii, New Mexico, Seattle, Utah, San Jose, Los Angeles, Greater 
California), county metro status (based on urban/rural continuum codes from the AHRF), and percentage of 
cardiologists and oncologists in the county. 
In addition to the above-mentioned factors, we also controlled for time (t1 through t6) to better reflect for 
changes with time in treatment practices.  
 
4.3.6 Statistical Analyses 
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Unadjusted subgroup differences in time-invariant characteristics between cancer and no cancer categories by 
sex (six groups) were tested with chi-square statistics. Our preliminary analyses indicated that there were significant 
group differences in age, race/ethnicity, concordant and discordant physical health conditions, mental health 
conditions, SEER region, and index year between the categories. Therefore, inverse probability treatment weights 
(IPTW) were derived using the multinomial logistic regression on cancer and no cancer categories. These IPTWs 
were used when modeling expenditures to adjust for the observed differences between the categories. As seen in 
Table 4.1, such weighting enabled us to balance the difference among the six groups. Table 4.2 summarizes the 
findings from the multinomial logistic regression used to calculate IPTW. 
Healthcare expenditures have unique features such as: 1) non-negative values; 2) a large number of individuals 
having zero expenditures; and 3) a small number of individuals having very high expenditures. Therefore, ordinary 
least squares regression on expenditures is not suitable. An alternative is to transform the expenditures with natural 
logarithms. With log-transformed expenditures, the impact of cancer on healthcare expenditures reflect percent 
change in expenditures. Retransformation of the regression coefficients to original dollars involves using smearing-
estimators and can become very challenging [205]. Estimating expenditures with generalized linear models (GLM) 
with appropriate family of distribution and link function can overcome some of these problems [205].  
As we measured CAD-related healthcare expenditures every 120 days during pre- and post-index period, each 
individual had six observations. These six observations were not independent, therefore, we used generalized linear 
mixed models (GLMM) with gamma distribution and log-link to analyze adjusted relationships between cancer and 
non-cancer groups and CAD-related healthcare expenditures. This is the most commonly used approach in previous 
cost analyses [206, 207].  In these GLMMs, predisposing, enabling and need factors as well as external 
environmental characteristics affecting healthcare expenditures were included.  These models also included time as a 
continuous variable which varied from t1 through t6, and index years with 2008 as the reference group.  
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Table 4.1. Unweighted and Weighted Percent of Selected Characteristics by Cancer Diagnosis 
Characteristics BCW (%) 
CCW 
(%) 
CCM 
(%) 
PCM 
(%) 
NCW 
(%) 
NCM 
(%) Sig 
BCW 
(wt. %) 
CCW 
(wt. %) 
CCM 
(wt. 
%) 
PCM 
(wt. 
%) 
NCW 
(wt. %) 
NCM 
(wt. 
%) 
Sig 
Age groups       ***       NS 
68-70 years 13.8 9.2 14.7 21.4 13.7 22.4   17.0 16.6 16.7 16.5 16.8 16.9  
71-74 years 19.8 14.5 23.4 30.5 17.2 23.8   20.7 20.8 20.7 20.6 20.6 20.6  
75-79 years 26.0 22.2 25.0 27.8 21.2 23.4   22.8 23.5 23.4 23.0 23.1 22.9  
80 years and older 40.4 54.1 36.9 20.3 47.9 30.4   39.5 39.2 39.2 39.9 39.5 39.6  
Race/Ethnicity       ***       NS 
Whites 82.5 78.7 82.8 82.7 75.0 77.6   77.5 77.0 77.1 76.0 77.2 77.1  
African Americans 9.4 11.2 4.9 7.6 10.4 5.7   8.7 8.8 8.7 9.0 8.7 8.7  
Hispanics 2.9 2.3 2.1 2.6 4.3 4.0   3.7 3.6 4.1 4.2 3.9 4.0  
Others 5.2 7.8 10.2 7.1 10.3 12.7   10.0 10.6 10.0 10.8 10.2 10.2  
Concordant PHCa       ***       NS 
Yes 95.5 96.4 95.4 94.6 94.0 92.4   93.8 93.4 94.0 94.3 93.9 93.9  
No 4.5 3.6 4.6 5.4 6.0 7.6   6.2 6.6 6.0 5.7 6.1 6.1  
Discordant PHCa       ***        
Yes 48.1 51.4 37.5 31.7 50.1 33.9   43.2 43.9 43.4 43.9 43.5 43.8  
No 51.9 48.6 62.5 68.3 49.9 66.1   56.8 56.1 56.6 56.1 56.5 56.2  
MHCa       ***        
Yes 13.0 13.1 8.9 5.7 15.2 9.3   12.1 12.6 12.4 12.6 12.2 12.6  
No 87.0 86.9 91.1 94.3 84.8 90.7   87.9 87.4 87.6 87.4 87.8 87.4  
SEER Region       ***       NS 
Northeast 24.1 26.3 24.0 20.0 22.7 18.9   21.9 21.6 21.7 20.1 21.6 21.7  
South 25.1 25.4 22.2 24.6 25.6 23.8   24.9 24.5 24.7 25.2 24.7 24.5  
North-central 13.9 14.5 12.8 14.2 11.8 10.5   12.1 11.5 12.1 12.8 12.0 11.9  
West 36.9 33.8 41.0 41.1 39.9 46.8   41.1 42.3 41.5 41.9 41.6 41.9  
Index year       **       NS 
2008 24.0 25.1 24.9 24.6 23.9 23.4   24.1 25.9 23.7 22.8 23.9 24.7  
2009 24.5 23.9 23.8 25.1 23.8 24.7   23.8 23.7 24.9 23.6 24.2 24.2  
2010 25.4 25.6 25.3 23.8 26.1 24.8   26.0 25.7 25.6 25.5 25.4 25.2  
2011 26.1 25.3 25.9 26.5 26.3 27.1   26.2 24.7 25.7 28.1 26.6 25.9   
Note: Based on 46,332 elderly fee-for-service Medicare beneficiaries with pre-existing CAD between 2008 and 2011 (12,095 cancer cohort and 34,237 non-
cancer cohort). 
  
Individuals with incident breast, colorectal, and prostate cancer were derived from the SEER registries and individuals with no cancer were derived from the 5% 
non-cancer sample from the SEER region. Weights were derived using the Inverse Probability Treatment Weights approach. 
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Asterisks represent significant differences in time-invariant patient-level characteristics based on chi-square tests.   
***p < 0.001; **0.001 ≤ p < 0.01; *0.01 ≤ p < 0.05. Column percentages are reported. 
 
Time-invariant characteristics include cancer diagnosis categories, age, race/ethnicity, poverty status, high school education, concordant and discordant physical 
health conditions, SMI, SEER region, and county-level characteristics. Time-variant characteristics include, tobacco use, alcohol use, depression, anxiety, and 
routine follow-up with primary care physician and/or cardiologist, and donut hole. 
 
a Concordant physical health conditions consisted of diabetes, hyperlipidemia, hypertension, stroke, cardiac arrhythmia, and congestive heart failure. Discordant 
physical health conditions consisted of arthritis, asthma, chronic obstructive pulmonary disease, osteoporosis, dementia, human immunodeficiency virus, and 
hepatitis. Mental health conditions include anxiety, depression, SMI (schizophrenia, bipolar disorder, and psychoses) 
 
Abbreviations  
BCW: Women with breast cancer; CAD: Coronary artery disease; CCM: Men with colorectal cancer; CCW: Women with colorectal cancer; FFS: Fee-for-
service; MHC: Mental health conditions; NCM: Men with no cancer; NCW: Women with no cancer; PCM: Men with prostate cancer; PHC: Physical health 
conditions; SEER: Surveillance, Epidemiology and End Results; SMI: Severe mental illness; Wt.: Weighted
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Table 4.2. Multinomial Logistic Regression Models used to derive IPTW 
Characteristics BCW CCW CCM PCM NCW 
  OR 95% CI Sig OR 95% CI Sig OR 95% CI Sig OR 95% CI Sig OR 95% CI Sig 
Age groups                    
68-70 years 0.48 [0.43, 0.54] *** 0.24 [0.20, 0.28] *** 0.56 [0.47, 0.67] *** 1.45 [1.31, 1.60] *** 0.39 [0.37, 0.42] *** 
71-74 years 0.66 [0.60, 0.73] *** 0.36 [0.31, 0.42] *** 0.84 [0.73, 0.98] * 1.94 [1.77, 2.13] *** 0.47 [0.45, 0.51] *** 
75-79 years 0.87 [0.80, 0.96] ** 0.55 [0.49, 0.63] *** 0.91 [0.78, 1.05]  1.81 [1.64, 1.99] *** 0.59 [0.56, 0.63] *** 
80 years and older Ref               
Race/Ethnicity                
African Americans 1.51 [1.32, 1.72] *** 1.93 [1.62, 2.29] *** 0.80 [0.62, 1.04]  1.21 [1.06, 1.38] ** 1.87 [1.71, 2.05] *** 
Hispanics 0.7 [0.57, 0.86] *** 0.59 [0.42, 0.83] ** 0.51 [0.35, 0.74] *** 0.65 [0.54, 0.80] *** 1.13 [1.01, 1.27] * 
Others 0.41 [0.35, 0.48] *** 0.72 [0.59, 0.88] ** 0.78 [0.64, 0.95] * 0.52 [0.46, 0.59] *** 0.93 [0.86, 1.00]  
Whites Ref               
Concordant PHC                
Yes 1.46 [1.24, 1.73] *** 1.69 [1.29, 2.20] *** 1.61 [1.25, 2.09] *** 1.54 [1.34, 1.78] *** 1.00 [0.92, 1.09]  
No Ref               
Discordant PHC                
Yes 1.68 [1.56, 1.81] *** 1.82 [1.64, 2.02] *** 1.13 [1.01, 1.27] * 0.96 [0.89, 1.03]  1.75 [1.67, 1.84] *** 
No Ref               
MHC                
Yes 1.20 [1.07, 1.34] ** 1.19 [1.02, 1.39] * 0.89 [0.73, 1.09]  0.58 [0.50, 0.66] *** 1.48 [1.37, 1.59] *** 
No Ref               
SEER Region                
Northeast 1.31 [1.19, 1.45] *** 1.58 [1.38, 1.81] *** 1.32 [1.14, 1.54] *** 1.09 [0.99, 1.20]  1.27 [1.20, 1.36] *** 
South 1.12 [1.02, 1.24] * 1.34 [1.16, 1.54] *** 1.02 [0.87, 1.18]  0.99 [0.91, 1.08]  1.24 [1.16, 1.31] *** 
North-central 1.41 [1.25, 1.58] *** 1.68 [1.42, 1.98] *** 1.30 [1.08, 1.56] ** 1.35 [1.22, 1.51] *** 1.26 [1.17, 1.36] *** 
West Ref               
Index year                
2008 0.93 [0.84, 1.04]  0.91 [0.78, 1.05]  1.02 [0.87, 1.20]  1.12 [1.02, 1.23] * 0.89 [0.83, 0.95] *** 
2009 0.95 [0.86, 1.05]  0.89 [0.77, 1.03]  0.94 [0.80, 1.10]  1.06 [0.96, 1.16]  0.90 [0.84, 0.96] *** 
2010 0.97 [0.87, 1.07]  0.94 [0.82, 1.09]  0.98 [0.84, 1.14]  0.97 [0.89, 1.07]  0.98 [0.92, 1.05]  
2011 Ref                             
Note: Based on 46,332 elderly fee-for-service Medicare beneficiaries with pre-existing CAD between 2008 and 2011 (12,095 cancer cohort and 34,237 non-
cancer cohort). 
  
Individuals with incident breast, colorectal, and prostate cancer were derived from the SEER registries and individuals with no cancer were derived from the 5% 
non-cancer sample from the SEER region. Weights were derived using the Inverse Probability Treatment Weights approach. 
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Asterisks represent significant differences in patient-level characteristics. NCM is the reference category for dependent variable. 
***p < 0.001; **0.001 ≤ p < 0.01; *0.01 ≤ p < 0.05. 
 
Abbreviations 
BCW: Women with breast cancer; CAD: Coronary artery disease; CCM: Men with colorectal cancer; CCW: Women with colorectal cancer; FFS: Fee-for-
service; NCM: Men with no cancer; NCW: Women with no cancer; PCM: Men with prostate cancer; SEER: Surveillance, Epidemiology and End Results; Wt.: 
Weighted
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4.4 Results 
4.4.1 Characteristics of the Study Population before and after IPTW Adjustment 
The study cohort comprised 46,332 elderly FFS Medicare beneficiaries with pre-existing CAD (12,095 with 
cancer and 34,237 without cancer). Table 4.1 summarizes the characteristics of cancer diagnosis categories before 
and after IPTW adjustment. Prior to adjustment, there were statistically significant differences in age, race/ethnicity, 
concordant physical conditions, discordant physical conditions, mental health conditions, SEER region, and index 
year. After adjusting with IPTW, there were no significant differences in these variables between the cancer 
diagnosis categories. 
Table 4.3 summarizes the mean CAD-related and total expenditures during pre- and post-index period. For 
purposes of this table, expenditures for t1, t2, and t3 were aggregated and represented pre-index period expenditures 
and expenditures for t4, t5, and t6 were aggregated to represent post-index period.  The average CAD-related 
expenditures ranged from $3,423 (BCW) to 7,022 (PCM). For all groups, the post-index period expenditures were 
higher than the pre-index periods. CAD-related expenditures in the post-index period were approximately 3 times 
higher for CCW and CCM, 2 times for BCW, and 1.5 times for PCM. The post-index CAD-related expenditures for 
NCM and NCW, in comparison, were similar to those in the pre-index period. 
The proportion of CAD-related expenditures ranged from 32.6% (BCW) to 45.8% (NCM) during the pre-index 
period and 20.8% (BCW) to 46.1% (NCM) during post-index period.  Among CCM, the proportion of CAD-related 
expenditures was the highest during the pre-index period (46.8%) and second highest during post-index period 
(40.5%). 
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Table 4.3. Mean and Standard Deviation of Coronary Artery Disease-related Expenditures by Cancer and Non-Cancer Adjusted with IPTW 
 Pre-index Post-index 
 
Total 
Wt. Mean 
(SD)† 
CAD-related 
Wt. Mean  
(SD)† 
% CAD-related‡ 
Total 
Wt. Mean 
(SD)† 
CAD-related 
Wt. Mean (SD)† % CAD-related‡ 
BCW 10,493  (18,644) 
3,423 
 (10,504) 32.6% 
29,596 
 (27,749) 
6,154 
 (14,419) 20.8% 
CCW 14,504  (27,138) 
5,722 
 (15,071) 39.5% 
55,895 
 (45,829) 
18,916 
 (27,102) 33.8% 
NCW 12,099  (22,579) 
4,662 
 (13,670) 38.5% 
10,656 
 (22,379) 
4,164  
(13,370) 39.1% 
CCM 17,548  (31,452) 
8,220  
(19,298) 46.8% 
56,849  
(48,323) 
23,021  
(28,781) 40.5% 
PCM 11,089  (18,689) 
4,603 
 (12,063) 41.5% 
28,040 
 (27,099) 
7,022  
(16,316) 25.0% 
NCM 13,943  (26,758) 
6,380 
 (16,668) 45.8% 
11,659  
(26,681) 
5,377  
(15,594) 46.1% 
Note: Based on 46,332 elderly fee-for-service Medicare beneficiaries with pre-existing CAD between 2008 and 2011 (12,095 cancer cohort and 34,237 non-
cancer cohort). 
  
Individuals with incident breast, colorectal, and prostate cancer were derived from the SEER registries and individuals with no cancer were derived from the 5% 
non-cancer sample from the SEER region. Weights were derived using the Inverse Probability Treatment Weights approach. 
†All expenditures reported in 2012 USD, ‡Percentage CAD-related = 𝐶𝐶𝐶𝐶𝐷𝐷−𝑑𝑑𝑚𝑚𝑠𝑠𝐷𝐷𝑚𝑚𝑚𝑚𝑚𝑚 𝑚𝑚𝑒𝑒𝑠𝑠𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑠𝑠𝑑𝑑𝑚𝑚𝐷𝐷
𝑇𝑇𝑜𝑜𝑚𝑚𝐷𝐷𝑠𝑠 𝑚𝑚𝑒𝑒𝑠𝑠𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑠𝑠𝑑𝑑𝑚𝑚𝐷𝐷  𝑋𝑋 100 
 
Abbreviations 
BCW: Women with breast cancer; CAD: Coronary artery disease; CCM: Men with colorectal cancer; CCW: Women with colorectal cancer; FFS: Fee-for-
service; IPTW: Inverse Probability Treatment Weights; NCM: Men with no cancer; NCW: Women with no cancer; PCM: Men with prostate cancer; SEER: 
Surveillance, Epidemiology and End Results, Wt.: Weighted
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4.4.2 CAD-related Expenditures over time by Cancer and Non-Cancer Status 
Figure 4.2 displays CAD-related expenditures over time for cancer and non-cancer groups. When time was included as an adjustor, the time coefficient was 
positive across all cancer group, suggesting that CAD-related expenditures increased over time for all cancer groups.  However, no such differences were 
observed for non-cancer groups. 
 
4.4.3 Adjusted Relationships between Cancer and CAD-related Healthcare Expenditures 
Beta coefficient, standard error (SE), percent change, from the adjusted GLMM with gamma distribution and log link are presented in Table 4.4 (total CAD-
related expenditures) and Table 4.5 (inpatient and outpatient CAD-related expenditures).  Because the cancer and non-cancer groups were grouped by sex, we 
present CAD-related expenditures with the following contrasts: cancer versus no cancer, women versus men and cancer type (breast cancer versus women with 
colorectal cancer and prostate cancer versus men with colorectal cancer). 
 
4.4.3.1 Cancer versus No cancer and CAD-related Healthcare Expenditures 
After controlling for all the independent variables and time, mentioned in the methods section, and with NCW as the reference group, both BCW and CCW 
groups had 14% and 151% higher expenditures, respectively. With NCM as the reference group, both CCM and PCM had 164% and 12% higher expenditures, 
respectively. 
With NCW as the reference group, CCW had 239% higher inpatient CAD-related expenditures. There was no significant difference between BCW and 
NCW for inpatient CAD-related expenditures. However, compared to NCW, both BCW and CCW had 54% and 48% significantly higher outpatient CAD-related 
expenditures, respectively. 
Similarly, with NCM as the reference group, CCM had 249% significantly higher inpatient CAD-related expenditures compared to NCM. There was no 
significant difference between PCM and NCM for inpatient CAD-related expenditures. However, compared to NCM, both CCM and PCM had 51% and 31% 
significantly higher outpatient CAD-related expenditures, respectively 
 
4.4.3.2 Sex and CAD-related Healthcare Expenditures 
When examined by sex, healthcare expenditures were 21% lower among NCW compared to NCM; CCW had 25% lower expenditures compared to CCM. 
Similarly, NCW and CCW had lower inpatient and outpatient expenditures compared to NCM and CCM, respectively. 
 
4.4.3.3 Cancer Type and CAD-related Healthcare Expenditures 
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Healthcare expenditures were 55% higher among CCW compared to BCW. Similarly, healthcare expenditures were 57% higher among CCM compared to 
PCM. Further, CCW and CCM had 67% and 68% higher inpatient CAD-related expenditures compared to BCW and PCM, respectively. However, there was no 
significant difference between CCW and BCW as well as CCM and PCM for outpatient healthcare expenditures. 
 
Figure 4.2. Weighted Average CAD-related Expenditures among Cancer and Non-cancer Cohorts across 120-day intervals 
Note: Based on 46,332 elderly fee-for-service Medicare beneficiaries with pre-existing CAD between 2008 and 2011 (12,095 cancer cohort and 34,237 non-
cancer cohort). 
 
Individuals with incident breast, colorectal, and prostate cancer were derived from the SEER registries and individuals with no cancer were derived from the 5% 
non-cancer sample from the SEER region. Weights were derived using the Inverse Probability Treatment Weights approach. 
 
Asterisks represent significant differences in cancer and non-cancer groups. 
***p < 0.001; **0.001 ≤ p < 0.01; *0.01 ≤ p < 0.05 
 
Abbreviations 
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BCW: Women with breast cancer; CAD: Coronary artery disease; CCM: Men with colorectal cancer; CCW: Women with colorectal cancer; FFS: Fee-for-
service; NCM: Men with no cancer; NCW: Women with no cancer; PCM: Men with prostate cancer; SEER: Surveillance, Epidemiology and End Results; Wt.: 
Weighted
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Table 4.4. Parameter Estimates from Generalized Linear Mixed Models on CAD-related Expenditures with 
IPTW 
Cancer dx 
categories Coefficient Std error P value % change 
Cancer versus non-cancer differences in expenditures (Reference: NCW)a 
BCW 0.13 0.04 0.002 14% 
CCW 0.92 0.05 0.000 151% 
Intercept 4.01 0.14   
 
Cancer versus non-cancer differences in expenditures (Reference: NCM)b 
CCM 0.97 0.05 0.000 164% 
PCM 0.11 0.04 0.008 12% 
Intercept 4.25 0.14   
Sex differences in expenditures (Reference: NCM)c 
NCW -0.24 0.03 0.000 -21% 
Intercept 4.25 0.14    
Sex differences in expenditures (References: CCM)d 
CCW -0.29 0.07 0.000 -25% 
Intercept 5.22 0.15   
Cancer type differences in expenditures (Reference: BCW)e 
CCW 0.79 0.06 0.000 55% 
Intercept 4.93 0.15    
Cancer type differences in expenditures (Reference: PCM)f 
CCM 0.85 0.06 0.000 57% 
Intercept 5.22 0.15     
Note: Based on 46,332 elderly fee-for-service Medicare beneficiaries with pre-existing CAD between 2008 and 
2011 (12,095 cancer cohort and 34,237 non-cancer cohort). 
 
Individuals with incident breast, colorectal, and prostate cancer were derived from the SEER registries and 
individuals with no cancer were derived from the 5% non-cancer sample from the SEER region. Weights were 
derived using the Inverse Probability Treatment Weights approach. Adjusted models controlled for time, 
predisposing, enabling, need, healthcare behavior, healthcare use, and environmental factors. 
 
Significance was derived from adjusted generalized linear model with Gamma distribution and log-link. The 
analysis used 6 repeated measures. 
% Change for GLMM was calculated as (e(intercept + β) – eintercept)/eintercept.  
 
a Other categories not displayed are: CCM, PCM, and NCM. 
b Other categories not displayed are: BCW, CCW, and NCW. 
c Other categories not displayed are: BCW, CCW, CCM, and PCM. 
d Other categories not displayed are: BCW, PCM, NCW, and NCM. 
e Other categories not displayed are: CCM, PCM, NCW, and NCM. 
f Other categories not displayed are: BCW, CCW, NCW, and NCM. 
 
 
 84 
 
Abbreviations 
BCW: Women with breast cancer; CAD: Coronary artery disease; CCM: Men with colorectal cancer; CCW: 
Women with colorectal cancer; FFS: Fee-for-service; GLMM: Generalized linear mixed models; IPTW: Inverse 
Probability Treatment Weights; NCM: Men with no cancer; NCW: Women with no cancer; PCM: Men with 
prostate cancer; SE: Standard error; SEER: Surveillance, Epidemiology and End Results; Wt.: Weighted
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Table 4.5. Parameter Estimates from Generalized Linear Mixed Models on CAD-related Expenditures with IPTW 
Cancer dx categories Inpatient CAD-related expenditures Outpatient CAD-related expenditures Coefficient Std error P value Change Coefficient Std error P value Change 
Cancer versus non-cancer differences in expenditures (Reference: NCW)a 
BCW 0.11 0.08 0.15 12% 0.43 0.04 0.000 54% 
CCW 1.22 0.08 0.000 239% 0.39 0.05 0.000 48% 
Intercept 2.36 0.20    3.13 0.12   
Cancer versus non-cancer differences in expenditures (Reference: NCM)b 
CCM 1.25 0.08 0.000 249% 0.41 0.06 0.000 51% 
PCM 0.10 0.07 0.152 11% 0.27 0.04 0.000 31% 
Intercept 2.71 0.20    3.47 0.11   
Sex differences in expenditures (Reference: NCM)c 
NCW -0.35 0.06 0.000 -30% -0.35 0.03 0.000 -30% 
Intercept 2.71 0.20    3.47 0.11   
Sex differences in expenditures (Reference: CCM)d 
CCW -0.38 0.10 0.000 -32% -0.37 0.07 0.000 -31% 
Intercept 3.96 0.21    3.89 0.13   
Cancer type differences in expenditures (Reference: BCW)e 
CCW 1.11 0.1 0.000 67% -0.04 0.06 0.522 -4% 
Intercept 3.58 0.21    3.52 0.13   
Cancer type differences in expenditures (Reference: PCM)f 
CCM 1.14 0.09 0.000 68% 0.14 0.09 0.056 13% 
Intercept 3.96 0.21     3.89 0.13     
Note: Based on 46,332 elderly fee-for-service Medicare beneficiaries with pre-existing CAD between 2008 and 2011 (12,095 cancer cohort and 34,237 non-
cancer cohort). 
Individuals with incident breast, colorectal, and prostate cancer were derived from the SEER registries and individuals with no cancer were derived from the 5% 
non-cancer sample from the SEER region. Weights were derived using the Inverse Probability Treatment Weights approach. Adjusted models controlled for 
time, predisposing, enabling, need, healthcare behavior, healthcare use, and environmental factors. 
 
aOther categories not displayed are: CCM, PCM, and NCM. 
bOther categories not displayed are: BCW, CCW, and NCW. 
cOther categories not displayed are: BCW, CCW, CCM, and PCM. 
dOther categories not displayed are: BCW, PCM, NCW, and NCM. 
eOther categories not displayed are: CCM, PCM, NCW, and NCM. 
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fOther categories not displayed are: BCW, CCW, NCW, and NCM. 
 
Significance was derived from adjusted generalized linear model with Gamma distribution and log-link. The analysis used 6 repeated measures. 
% Change for GLMM was calculated as (e(intercept + β) – eintercept)/eintercept. 
 
Abbreviations 
BCW: Women with breast cancer; CAD: Coronary artery disease; CCM: Men with colorectal cancer; CCW: Women with colorectal cancer; FFS: Fee-for-
service; IPTW: Inverse Probability Treatment Weights; NCM: Men with no cancer; NCW: Women with no cancer; PCM: Men with prostate cancer; SEER: 
Surveillance, Epidemiology and End Results; Wt.: Weighted
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4.4.4 Relationship between Other Independent Variables and Expenditures 
Table 4.6 displays regression coefficient, standard errors, and P values of other independent variables from the 
adjusted GLMM models. Factors associated with significantly increased expenditures included age ≥80 years, 
concordant and discordant physical health conditions, mental health conditions, higher CAD severity, tobacco use, 
alcohol use, those with primary care physician or cardiologist visit, and those not adherent to one or both medication 
classes (for those using both medication classes).
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Table 4.6. Adjusted Relationship between Other Characteristics and CAD-related Expenditures, Repeated 
Measures Regressions with IPTW 
Characteristics β SE P value 
Predisposing factors 
Age groups (in years)    
68-70 -0.50 0.04 0.000 
71-74 -0.48 0.04 0.000 
75-79 -0.35 0.03 0.000 
≥80 Ref   
Race/Ethnicity    
Whites 0.33 0.05 0.000 
African Americans 0.79 0.07 0.000 
Hispanics 0.31 0.08 0.000 
Others Ref   
Enabling factors 
Education level    
Less than national avg 12% 0.06 0.03 0.031 
GE national avg 12% Ref   
Poverty level    
Less than national avg 14.3% -0.03 0.03 0.262 
GE national avg 14.3% Ref   
Donut hole    
Not reached -0.35 0.05 0.000 
Reached 0.06 0.06 0.337 
Exceeded Ref   
Need factors 
Concordant PHCsa    
Yes 0.64 0.08 0.000 
No Ref   
Discordant PHCsa    
Yes 0.39 0.03 0.000 
No Ref   
Mental health conditionsa    
Yes 0.74 0.03 0.000 
No Ref   
CAD severity 0.80 0.06 0.000 
Health behavior 
Tobacco use    
Yes 0.36 0.05 0.000 
No Ref   
Alcohol use    
Yes 0.43 0.11 0.000 
No Ref   
Healthcare use 
Primary care visit    
Yes 1.23 0.03 0.000 
No Ref   
Cardiologist visit    
Yes 1.96 0.02 0.000 
No Ref   
Adherence to medication    
No ADH 2 Rx 0.55 0.04 0.000 
ADH 1 of 2 Rx 0.22 0.03 0.000 
ADH 1 Rx -0.18 0.04 0.000 
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No ADH 1 Rx 0.25 0.04 0.000 
ADH 2 Rx Ref   
External Environment and County-level Factors 
SEER Region    
Northeast -0.25 0.05 0.000 
South -0.02 0.05 0.710 
North-central -0.12 0.05 0.010 
West Ref   
Metropolitan status    
Metro -0.25 0.04 0.000 
Non-metro Ref   
HPSA    
No shortage -0.05 0.05 0.276 
Part county 0.13 0.03 0.000 
Whole county Ref   
FQHC    
None 0.04 0.06 0.510 
1 to 10 0.06 0.04 0.119 
GE 11 Ref   
Rural health centers    
Yes 0.02 0.03 0.534 
No Ref   
Time 0.02 0.01 0.000 
Note: Based on 46,332 elderly fee-for-service Medicare beneficiaries with pre-existing CAD between 2008 and 
2011 (12,095 cancer cohort and 34,237 non-cancer cohort). 
 
Individuals with incident breast, colorectal, and prostate cancer were derived from the SEER registries and 
individuals with no cancer were derived from the 5% non-cancer sample from the SEER region. Weights were 
derived using the Inverse Probability Treatment Weights approach. 
 
Time-invariant characteristics include cancer diagnosis categories, age, race/ethnicity, poverty status, high school 
education, concordant and discordant physical health conditions, SMI, SEER region, and county-level 
characteristics. Time-variant characteristics include, tobacco use, alcohol use, depression, anxiety, and routine 
follow-up with primary care physician and/or cardiologist, and donut hole. 
 
aConcordant physical health conditions consisted of diabetes, hyperlipidemia, hypertension, stroke, cardiac 
arrhythmia, and congestive heart failure. Discordant physical health conditions consisted of arthritis, asthma, chronic 
obstructive pulmonary disease, osteoporosis, dementia, human immunodeficiency virus, and hepatitis. Mental health 
conditions include anxiety, depression, SMI (schizophrenia, bipolar disorder, and psychoses) 
 
Significance was derived from adjusted generalized linear model with Gamma distribution and log-link. The 
analysis used 6 repeated measures. 
 
Abbreviations 
ADH 2 Rx: Adherent to both statins and ACEIs/ARBs/beta-blockers; 
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No ADH 2 Rx: Not adherent to both medication classes 
ADH 1 of 2 Rx: Adherent to either statins or ACEIs/ARBs/beta-blockers; 
ADH 1 Rx: Use of one medication class and adherent to that class; 
No ADH 1 Rx: Use of one medication class and not adherent to that medication class; 
 
Abbreviations: 
ACEIs: Angiotensin-converting enzyme inhibitors; ARBs: Angiotensin II receptor blockers; CAD: Coronary artery 
disease; FFS: Fee-for-service; IPTW: Inverse Probability Treatment Weights; PHC: physical health conditions; SE: 
Standard error; SEER: Surveillance, Epidemiology and End Results; Wt.: Weighted
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4.5 Discussion 
To date, this is amongst the first study to estimate CAD-related expenditures among cancer and non-cancer FFS 
Medicare beneficiaries with pre-existing CAD and analyze the relationship between incident cancer diagnosis and 
short-term CAD-related (inpatient and outpatient) expenditures. In general, CAD accounted for 32.6% to 46.8% of 
total expenditures during pre-index period and 20.8% to 46.1% during the post-index period among cancer patients. 
These findings suggest that a substantial portion of total expenditures accounted for care that is directly related to 
CAD.   
Our study findings suggest that CAD-related expenditures were higher among those with cancer than those 
without cancer. We speculate that part of the CAD-related expenditures among patients with cancer may have 
resulted from cancer treatments [60, 61, 72]. Moreover, it is plausible that cancer may take precedence over CAD 
management and impede the recommended care for CAD, thereby increasing CAD-related complications [69] 
leading to higher CAD-related expenditures. For patients undergoing cancer surgery, CAD may need to be stabilized 
using medical management [72], further adding to the overall CAD-related expenditures among cancer patients. 
A noteworthy finding is that CAD-related expenditures were highest among elderly with colorectal cancer 
compared to breast cancer or prostate cancer or no cancer. We observed that CAD-related expenditures were highest 
during 120 days immediately after colorectal cancer diagnosis. We also found that a majority of patients had 
advanced stage (63.0%) colorectal cancer. Colorectal cancer treatments primarily consist of surgery and adjuvant 
chemotherapy (e.g., 5-fluorouracil and capecitabine) for those with Stages II- IV [67]. Taken together, these findings 
suggest that CAD-related expenditures may be higher among those with colorectal cancer due to chemotherapy-
related cardiotoxicity. Our preliminary study findings demonstrated that non-adherence to statins and 
ACEIs/ARBs/beta-blockers was significantly higher in colorectal cancer patients who had surgery (81% in this 
study). Non-adherence to these medications has been previously shown to increase the risk of CAD-related 
complications and hospitalizations, thereby increasing inpatient expenditures [94].  
CAD-related expenditures increased over time for all cancer groups. A closer examination of the study findings 
indicated that CAD-related expenditures were highest during the 120-day interval immediately after cancer 
diagnosis, suggesting that the period after cancer diagnosis may be the crucial in terms of monitoring and 
management of CAD. 
Our study findings have significant implications for the policy makers and insurance providers. The Centers for 
Medicare and Medicaid Services’ has rolled out demonstration projects for new bundled payment models that 
support payments for episodes of care [193].  Similarly, the Medicare’s shared savings program provides 
Accountable Care Organizations financial incentives to reduce spending and improve quality [208].  These programs 
use risk adjustment and also calculate expenditure benchmarks needed to provide care and get shared savings from 
the CMS.  Collectively, our findings can help the payers to calculate these benchmark expenditures by adjusting for 
case-mix of Medicare beneficiaries, specifically those with pre-existing CAD and incident cancer [194-196].  In 
addition, our findings can help capture the episode-specific contribution of individual risk factors (age, gender, 
comorbidities, episode severity, etc.) to resource use similar to those implemented by the PROMETHEUS payment 
models [196, 209]. Currently, there are no specific payment models that account for cancer and CAD, but available 
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models, such as PROMETHEUS can be tailored to the specific patterns of resource use within CAD. Therefore, it is 
crucial to understand the extent to which a specific cancer contributes to CAD-related expenditures to implement 
these models. Based on our study findings, it is apparent that resource allocation for CAD-related expenditures 
should be higher for those with colorectal cancer, followed by prostate and breast cancer. 
We also found that CAD-related inpatient expenditures accounted for two-thirds of the overall CAD-related 
health care expenditures.  Although CMS has imposed penalties for potential hospital readmissions and preventable 
hospitalizations, such as inpatient admissions for angina without procedures [210], these initiatives may not be 
effective in patients with complex conditions such as CAD and cancer.  In this context, future research needs to 
focus on collaborative care models such as the patient-centered medical home (PCMH) because such models have 
been shown to reduce inpatient use. For example, a review focusing on patient-centered medical home (PCMH) 
indicated that PCMH was associated with reduction in inpatient hospital expenditures [211]; Geisinger Health 
System’s patient-centered medical home clinics reported 18.6% cost savings for inpatient care, the largest 
contributor to the total cost savings [212]. 
Another noteworthy finding was that women had lower CAD-related expenditures compared to men. Chiha et 
al. assessed the differences in CAD severity among men and women and noted that women were more likely to have 
normal coronary arteries or less severe disease than age-matched men [213]. Although we controlled for severity of 
CAD with HCC, future research needs to explore whether the lower expenditures among women are due to sex 
differences in severity of CAD. 
 
4.5.1 Strengths and limitations 
This study adopted a longitudinal design and compared expenditures over time between cancer and non-cancer 
groups.  We also used statistical adjustment for selection bias in observed and unobservable characteristics. The use 
of Medicare FFS claims data enabled us to track individuals across various providers and settings and calculate 
expenditures and measure variables for specific time periods. The study also adjusted a comprehensive list of factors 
that can influence CAD-related expenditures. The study included individuals with significant medical comorbidities. 
Our study findings need to be interpreted in the context of its limitations. The study findings cannot be 
generalized to all Medicare beneficiaries because the study population is restricted to those residing in SEER regions 
and to those with FFS Medicare plans. Further, the SEER-Medicare data are not developed for research purposes 
and therefore have limitations associated with its use for estimating healthcare expenditures. It is possible that CAD 
diagnosis may be under-coded or misclassified in claims data, as these data are dependent on professional ICD 
coding. Therefore, there might be underestimation of CAD-related diagnosis, which in turn, may undermine CAD-
related expenditures. Finally, we were not able to control for patient-level lifestyle health behaviors, knowledge, 
attitude, and preferences as well as number of cancer-related complications, treatment side-effects, and cost-related 
factors that may affect CAD-related expenditures.  
 
4.5.2 Conclusions 
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Our study provided unique information and contributed to the nascent literature on cardio-oncology by 
comparing CAD-related expenditures among elderly FFS Medicare beneficiaries with and without cancer. We found 
that incident cancer diagnosis was associated with higher short-term CAD-related expenditures as compared to those 
with no cancer diagnosis. Specifically, inpatient expenditures for colorectal cancer patients were considerably higher 
than outpatient expenditures. This suggests that more emphasis is warranted on preventing cardiac events in the 
outpatient setting in order to reduce the more expensive inpatient encounters. Future studies need to explore whether 
the emerging payment reforms and collaborative care models can lower costs while maintaining high quality CAD 
care for patients with and without cancer. 
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5 Chapter 5 
Discussion of Findings and Research Implications 
 
5.1 Summary of Findings and Discussion 
Coronary artery disease (CAD) is one of the most burdensome chronic conditions in the elderly [4, 12, 24, 25, 
27]. The two key goals of long-term management of CAD are (i) to reduce symptoms and ischemia and (ii) prevent 
myocardial infarction and death, by lowering lipids and blood pressure [29]. Of all the risk reduction strategies, use 
and adherence to concomitant pharmacotherapy with statins and beta-blockers, angiotensin-converting enzyme 
inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) have been shown to be highly effective and has 
become the cornerstone of CAD management. However, adherence to concomitant pharmacotherapy can be 
influenced by many factors including the development of other life-threatening conditions such as cancer. The 
presence of CAD and incident cancer is a prototype example of AHRQ definition of a complex chronic illness “two 
or more chronic conditions in which each condition might influence the care of the other condition, either through a 
limitation on life expectancy imposed by one of the conditions or because these two conditions generally entail 
therapies which are likely to have interactions with each other, or thirdly wherein one of these conditions might be 
requiring therapies that are contraindicated by the presence of the other conditions” [73]. To date, no real-world 
study has assessed how incident cancer can affect adherence to concomitant pharmacotherapy and whether 
concomitant pharmacotherapy can minimize the negative effects of some cancer treatments on CAD-related 
morbidity and expenditures among individuals with CAD and incident cancer. 
The subsequent presence of incident cancer among individuals with CAD is especially important for many 
reasons: (i) CAD and cancer have shared risk factors and unique pathophysiology; (ii) adults with CAD are more 
likely to develop cancer; (iii) there can be negative effects of some cancer treatments on cardiovascular health; (iv) 
as both CAD and cancer are life-threatening conditions, the co-management of these conditions is especially 
challenging; and (v) both conditions are very costly to treat and manage and such heavy financial burden has 
implications for payers, healthcare providers and patients. 
Cardio-oncology or onco-cardiology is an emerging field and most of the existing evidence on management of 
heart diseases in individuals with cancer is based on the clinical expert opinion. However, there is paucity of studies 
on the influence of cancer diagnosis on management of CAD. The current study contributes to the nascent literature 
on management of CAD in patients with cancer. This study focused on 1) association between incident breast, 
colorectal, and prostate cancer diagnosis and adherence to statins and/or ACEIs/ARBs/beta-blockers among elderly 
fee-for-service (FFS) Medicare beneficiaries with pre-existing CAD; 2) the impact of non-adherence to these 
medication classes on short-term CAD-related hospitalizations in patients with incident cancer diagnosis; and 3) the 
impact of incident cancer diagnosis on short-term CAD-related inpatient and outpatient healthcare expenditures. 
We observed that both men and women diagnosed with incident colorectal cancer were less likely to adhere to 
both statins and ACEIs/ARBs/beta-blockers compared to non-cancer women and men, even after controlling for a 
comprehensive list of factors. In addition, men with incident prostate cancer were less likely to adhere to both 
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medication classes, but the magnitude of difference was much less compared to men with no cancer. There were no 
differences in adherence to both medication classes by presence of breast cancer. Taken together, these finding 
suggest that cancer type rather than cancer itself may affect medication adherence. Furthermore, we also found that 
among Medicare beneficiaries with CAD and colorectal cancer, those with late-stage cancer compared to early stage 
cancer and those who had surgical treatment for cancer compared to no surgical treatment were less likely to be 
adherent to both statins and ACEIs/ARBs/beta-blockers. These findings suggest that cancer stage and cancer 
treatment may affect medication adherence among colorectal cancer patients. 
These findings from our study highlight the difficulty in sustaining ongoing therapy for CAD among these 
individuals and their vulnerability to CAD-related complications. Extant literature shows that non-adherence to 
statins and ACEIs/ARBs/beta-blockers has negative cardiovascular health consequences, including cardiovascular 
events and hospitalization [94-96]. Further evidence suggests an increase in the risk of first hospitalization for CAD 
during the six months after cancer diagnosis [171], perhaps due to cardiotoxicity associated with cancer treatments 
such as radiotherapy, chemotherapy, and hormone therapy [60-62]. We analyzed the relationship between adherence 
to both statins and ACEIs/ARBs/beta-blockers and CAD-related hospitalizations among the elderly Medicare 
beneficiaries with pre-existing CAD and incident breast, colorectal, or prostate cancer. 
Compared to Medicare beneficiaries with CAD and cancer who were adherent to both statins and 
ACEIs/ARBs/beta-blockers, those who were non-adherent to either both or single medication classes were more 
likely to have CAD-related hospitalization. We also observed that CAD-related hospitalizations increased in the 
period immediately following cancer diagnosis for all medication adherence categories. Our findings are consistent 
with the published literature (not specific to cancer) that non-adherence to statins and ACEIs/ARBs/beta-blockers 
have negative cardiovascular health consequences [94-96]. 
Coronary artery disease is ranked first in healthcare expenditures, with an estimated $231.1 billion (2013) [186]. 
A large proportion of these expenditures can be attributed to CAD-related hospitalizations and outpatient care [188]. 
For the individuals with incident cancer diagnosis, CAD-related expenditures can be higher than those with only 
CAD [189] as specific cancer treatments may worsen pre-existing CAD and cancer treatment may, dominantly, 
impede the continual management of CAD. We analyzed the impact of incident cancer on CAD-related expenditures 
within our study population. 
Our findings suggest that CAD accounted for substantial proportion of total expenditures, i.e., ranging from 
32.6% to 46.8% at pre-index period. These are similar to the findings from existing studies [186], which suggest that 
CAD is one of the most expensive chronic conditions. In addition, CAD-related expenditures were higher among 
those with cancer than those without cancer. We can speculate that higher CAD-related expenditures among patients 
with cancer can be due to pre-existing cardiac health, resulting from cancer treatments [60, 61, 72]. 
Surprisingly, CAD-related expenditures were highest among elderly with colorectal cancer and significantly 
higher for colorectal cancer compared to breast cancer or prostate cancer. We observed that CAD-related 
expenditures were highest during 120 days immediately following colorectal cancer diagnosis. We also found that a 
majority of patients had advanced stage (63.0%) colorectal cancer. The treatment for colorectal cancer primarily 
consists of surgery and adjuvant chemotherapy (e.g., 5-fluorouracil and capecitabine) for those with Stages II- IV 
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[67]. It has been reported that patients receiving 5-fluorouracil have 45% risk of angina and 22% risk of MI [67]. 
Taken together, these findings suggest that CAD-related expenditures may be higher among those with colorectal 
cancer due to chemotherapy-related cardiotoxicity, interference from cancer treatment, and/or non-adherence to 
CAD medications. Noticeably higher inpatient expenditures in our study for those with colorectal cancer compared 
to non-cancer or other cancer (breast and prostate) groups can be attributed to increase in CAD-related 
complications in these patients. Our study findings also demonstrated that the time coefficient was positive across all 
cancer groups and no such difference was observed for non-cancer groups. This suggests that CAD-related 
expenditures increased over time for all cancer groups. A closer examination of the study findings indicated that 
CAD-related expenditures were highest during the 120-day interval immediately after cancer diagnosis. This 
suggests that the period after cancer diagnosis is the crucial period for co-management of CAD and cancer. 
Together, our study findings suggest that cancer diagnosis negatively impacts adherence to CAD 
pharmacotherapy. Reduction in adherence was associated with increase in CAD-related hospitalizations and 
subsequent increase in CAD-related expenditures. Our study findings warrant the integration of cardiovascular care 
in the elderly diagnosed with cancer. 
 
5.2 Clinical Implications of the Findings 
5.2.1 Clinical Implications 
Both CAD and cancer are life-threatening conditions and co-management of both conditions can be 
challenging. Lack of effective management of CAD may not only increase CAD complications, but can also have 
negative consequences for cancer prognosis. Current clinical practices recommend stabilizing pre-existing CAD 
prior to initiating cancer treatment. For example, appropriate pharmacologic management (statins and beta-blockers) 
of the patient with pre-existing CAD is recommended for those undergoing cancer surgery [72]. In addition, statins 
and ACEIs/ARBs/beta-blockers are central to improving CAD-related health outcomes. Statins have been shown to 
reduce cancer-specific mortality in those with breast, colorectal, and prostate cancer [144-146, 164]. Further, 
medications for CAD may also reduce cancer treatment-related cardiotoxicity [71]. Given the complexity of 
interaction between CAD and cancer, it is important to routinely monitor medication adherence in general clinical 
practice and provide linkages to support services that can increase medication adherence. 
Medication adherence is a multidimensional issue in which providers, patients, payers, and policy makers are 
inextricably linked and all of them need to be involved in improving medication adherence [165]. It may be very 
challenging for clinicians to implement interventions in routine practice because those successful-to-date have 
included multiple, heterogeneous components [141]. In this context, the recent healthcare delivery models such as 
the medical home may help in overcoming the challenges to coordination across different providers. It has been 
shown that patient-centered medical homes can improve adherence to medications among those with cardiovascular 
conditions [166]. Therefore, an interdisciplinary and integrated approach to cardiovascular management in the 
elderly diagnosed with incident cancer, such as the burgeoning cardio-oncology clinics, would improve 
cardiovascular outcomes [183]. 
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5.2.2 Policy Implications 
Recognition and management of CAD alongside cancer care are pivotal priorities. Our study findings have 
several policy implications. First, examination of adherence to statins and ACEIs/ARBs/beta-blockers among the 
elderly is important for policy purposes because Medicare provides coverage for almost all of the elderly in the US 
[99] and Medicare payments for CAD [100] and cancer care [101] are substantial. Our study findings highlight the 
need for practice and policy measures to increase CAD management, especially adherence to CAD pharmacotherapy 
among elderly diagnosed with incident colorectal cancer. However, under the FFS programs, there are no incentives 
to coordinate care across multiple systems, providers, and payers [141]. In this context, the new fiscal incentives by 
the CMS in paying physicians who provide care for patients with multiple chronic conditions and who invest time 
and resources to provide more coordinated and patient-centered care [161] may also promote adherence. It has to be 
noted that a systematic review of medication adherence among those with multiple chronic conditions reported that 
medication adherence interventions were “almost exclusively” conducted by the pharmacists [162]. In recognition of 
the critical role of pharmacists, Medicare now covers Medication Management Services (MTM) of pharmacists. 
Therefore, implementation of such policies among CAD patients can improve adherence [163]. 
Second, policy measures have also focused on reducing CAD-related hospitalizations, specifically readmission 
and preventable hospitalizations. The Affordable Care Act, under Hospital Readmissions Reduction Program, 
provided CMS the authority to reduce payments to hospital readmissions for certain conditions (heart failure, 
myocardial infarction, and pneumonia) that it deemed avoidable [184]. CMS has imposed penalties for potential 
hospital readmissions and preventable hospitalizations, such as inpatient admissions for angina without procedures 
[210], these initiatives may not work in patients with complex conditions such as CAD and cancer and alternative 
models may be needed to reduce inpatient expenditures. In addition, based on AHRQ’s prevention quality 
indicators, hospitalizations related to conditions, such as angina without procedure and congestive heart failure, are 
considered preventable hospitalizations with good outpatient care. Therefore, it is important to implement policies 
focusing on integrated care for patients with pre-existing CAD and incident cancer diagnosis in order to reduce 
avoidable hospitalizations. Future research needs to focus on collaborative care models such as the patient-centered 
medical home because such models have been shown to reduce inpatient use. A review focusing on patient-centered 
medical home (PCMH) indicated that PMCH was associated with reduction in inpatient hospital expenditures [211]. 
For example, Geisinger Health System’s patient-centered medical home clinics showed 18.6% cost savings for 
inpatient care, the largest contributor to the total cost savings [212]. 
Third, estimating the extent to which incident cancer affects CAD-related expenditures can help the payers with 
the emerging healthcare delivery reform initiatives, which are focused on financial incentives to improve healthcare 
quality with lower healthcare expenditures.  New payment models from the CMS support bundled payments to 
clinicians for providing care to patients with CAD [193]. Such models have the potential to be extended to those 
who develop cancer after CAD. In addition, estimating payments for CAD-related care may also help providers 
because the Medicare Access and Children’s Health Insurance Program Reauthorization Act of 2015 (MACRA; 
payment reform by Medicare) has created alternative payment models [193]. Similarly, the Medicare’s shared 
savings program provides Accountable Care Organizations financial incentives to reduce spending and improve 
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quality [208]. These programs use risk adjustment while also setting the expected expenditure benchmark for 
individuals with pre-existing CAD and incident cancer diagnosis [194-196]. For example, bundled payment model, 
PROMETHEUS, creates different risk adjustment models for each episode of care, where each model captures the 
episode-specific contribution of individual risk factors (age, gender, comorbidities, episode severity, etc.) to 
resource use [196, 209]. Understanding the extent to which a specific cancer contributes to CAD-related 
expenditures can tailor such models to the specific patterns of resource use within CAD.  
 
5.3 Unique Contributions of the Study 
There are several facets of our study that makes it unique. First, it fills a critical knowledge gap on the 
management of chronic conditions among patients with incident cancer diagnosis. It is important to recognize ways 
in which cancer could affect the management of pre-existing CAD in cancer patients so that patient-centered care 
and individualized treatment can be achieved. Second, the study findings can illuminate the complex relationship 
between CAD management and incident cancer. Prior studies have suggested that cardiovascular disease 
management is compromised in cancer patients. Third, this study is a population-based study utilizing “real-world” 
data. It has been pointed out by the investigators of the CLARIFY study that real-world studies on CAD are 
warranted because “clinical trials or registries which often have stringent exclusion criteria, and do not adequately 
represent populations with stable CAD (in terms of age, comorbidity, and concomitant therapy)”. This study is the 
next best alternative to clinical trials for understanding this relationship. Fourth, this dissertation focuses on elderly 
population and it is estimated that by 2050, there will be 83.7 million over the age of 65. More importantly, both 
CAD and cancer are highly prevalent in aging population. An understanding of the influence of life events such as 
cancer diagnosis on management of pre-existing CAD is important to the growing elderly population with these 
chronic conditions. Lastly, this study focuses on elderly FFS Medicare beneficiaries. Medicare is the primary payer 
of healthcare for elderly in the US and bears the largest share of the clinical, humanistic, and economic burden in 
this population. The findings from this study will have implications for the various healthcare delivery and financing 
reforms such as the establishment of accountable care organizations, patient-centered medical home and others 
undertaken by the Centers for Medicare and Medicaid Services, which is responsible for setting policy priorities and 
healthcare payments. 
 
5.4 Strengths and Limitations of the Study 
5.4.1 Study Strengths 
The study has several strengths. First, a robust repeated measures study design was used comparing a large 
cohort of cancer and non-cancer cohort over a long period of time across a variety of providers. Further, the study 
used a variety of statistical methods to control for both observed and unobserved selection bias to ensure robustness 
of findings Second, Medicare FFS claims data aided in the measurement of adherence over time and followed a 
large cohort of patients for a long period of time across a variety of providers. Third, the study adjusted a 
comprehensive list of factors that can influence medication adherence. Fourth, the study included individuals with 
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significant medical comorbidities, typically excluded from randomized clinical trials and examined real-world 
practice patterns. 
 
5.4.2 Study Limitations 
The study findings need to be interpreted in the context of its limitations. First, the study findings cannot be 
generalized to all Medicare beneficiaries because the study population is restricted to those residing in SEER regions 
and to those with FFS Medicare plans. It is anticipated that those with health maintenance organization plans may 
receive improved quality of care, hence, the study might have underestimated adherence and may have 
overestimated hospitalizations and expenditures by focusing only on FFS Medicare beneficiaries. Further, the study 
population was restricted to elderly population with breast, colorectal, or prostate cancer and pre-existing CAD. 
Second, a proxy measure was used for CAD severity, which may not reflect the precise CAD severity in the 
population. Gold standards for measuring CAD severity, such as stress tests, are not available in Medicare database. 
Also, with claims database, it is not possible to determine how cancer was confirmed. Third, the study did not 
control for patient-level lifestyle health behaviors, knowledge, attitude, and preferences as well as number of cancer-
related complications, treatment side-effects, and cost-related factors that may affect adherence as well as 
hospitalizations. However, a comprehensive list of variables was controlled to examine multivariable associations. 
Fourth, the SEER-Medicare data are not developed for research purposes and therefore have limitations associated 
with its use for estimating healthcare expenditures. Fifth, the study included patients who were alive during the 
study period, which might have underestimated expenditures as patients receiving end-of-life care are anticipated to 
have higher expenditures and CAD-related hospitalizations. Further, those receiving end-of-life care are anticipated 
to have lower adherence. Lastly, prescription claims were used for measuring adherence. As part D file contains 
only filled prescriptions, it is not known whether the patient actually used the medications or whether the patients 
they adhered to their providers’ instructions or not. 
 
5.5 Suggestions for Future Research 
The current study has implications for further investigation. Studies need to examine whether the proven 
strategies of medication adherence can also be applied to improve medication adherence of multiple drug regimens. 
Our study findings indicated that those using single medication class and adherent to that single medication 
class were less likely to have CAD-related hospitalization compared to those who were adherent to both medication 
classes. In addition, the interaction between medication adherence categories and cardiotoxic cancer treatment on 
CAD-related hospitalization was not statistically significant. Therefore, future studies are needed to provide 
conclusive evidence on the role of CAD severity and unobserved factors (healthy eating, exercise, alternative and 
complementary medicine, and polypharmacy) for the stated findings.  
Our study findings indicated that CAD-related expenditures were highest during the 120-day interval 
immediately following cancer diagnosis. This suggests that the period after cancer diagnosis is the crucial period for 
co-management of CAD and cancer. This is an interesting finding and needs further research to understand the 
cancer-related factors that might contribute to this increase in expenditures with time in those diagnosed with cancer. 
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Our study findings also indicated that those with colorectal cancer may be particularly at risk for high CAD-related 
healthcare expenditures. Future studies need to explore whether the emerging collaborative care models, such as 
medical homes, can reduce inpatient use, and consequently, CAD-related expenditures. 
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Appendix A. Codes related to cancer diagnosis and treatment 
Cancer/treatment 
ICD-9-CM Codes 
Site recode ICD-O-
3/WHO recodes 
ICD-9-CM Procedure Codes HCPCS/CPT Codes Revenue Center Codes 
Cancer type 
Breast Cancer 26000 - - - 
Colorectal Cancer 21041 - 21049,  21051 - 21052 - - - 
Prostate Cancer 28010    
Cancer Treatment - Surgery 
Breast Cancer - 8520-8529, 8533-8536, 8540-8548 19120, 19125, 9126, 19300-19307,   
Colorectal Cancer - 
4530-4534, 4541-4543, 4549, 4550-
4552, 4561-4563, 4570-4576, 4579, 
4580-4583, 4590-4595, 4601, 4603, 
4604, 4610, 4611, 4613, 4614, 
4620-4623, 4835,4840-4843, 4849-
4852, 4859-4865, 4869 
44140, 44141, 4143-44147, 4150, 
44160, 44204-44208, 4150-44153, 
44155, 4158, 44210-44212, 5160, 
45170, 45171, 5110-45114, 45116, 
5119-45121, 45123, 5126, 45395, 
45397 
 
Prostate Cancer - 602-606 
55801, 55810, 5812, 55815, 
5821,55831, 55840, 55842, 5845, 
55866 
 
Cancer Treatment - Chemotherapy 
- V581, V662, V672 9925, 9928 
96401- 96549, Q0083-Q0085, 
J9000-J9999, S9329-S9331, 
J8501-8999, J0640 
0331, 0332, 0335 
Cancer Treatment - Radiation Therapy 
- V580, V661, V671 9220-9239 77261-77799, C1715-C1720, C2634-C2699, C1728 0330, 0333 
Abbreviations: 
CPT-4: Common Procedural Terminology, 4th Edition; HCPCS: Health Care Procedure Classification Code; ICD-9-CM: International Classification of 
Diseases, Ninth Revision, Clinical Modification; ICD-O-3: International Classification of Diseases for Oncology, 3rd Edition; WHO: World Health Organization
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Appendix B. List of statins 
Monotherapy Combination therapy 
Brand Generic Brand Generic 
Lipitor Atorvastatin Advicor Lovastatin-Niacin 
Lescol Fluvastatin Caudet Atorvastatin-Amlodipine  
Altocor, Mevacor Lovastatin Inegy Simvastatin-Ezetimibe  
Livalo Pitavastatin Simcor Simvastatin-Niacin 
Pravachol Pravastatin Juvisync Simvastatin-Sitagliptin 
Crestor Rosuvastatin Liptruzet Ezetimibe/Atorvastatin calcium 
Zocor Simvastatin     
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Appendix C. List of angiotensin-converting enzyme inhibitors 
Monotherapy Combination therapy 
Brand Generic Brand Generic 
Lotensin Benazepril Accuretic Quinapril-Hydrochlorothiazide 
Capoten Captopril Capozide Captopril-Hydrochlorothiazide 
Vasotec Enalapril Lexxel Enalapril-Hydrochlorothiazide 
Monopril Fosinopril Lotensin HCT Benazepril-Hydrochlorothiazide 
Prinivil, Zestril Lisinopril Lotrel Benazepril-Amlodipdine 
Univasc Moexipril Monopril HCT Fosinopril-Hydrochlorothiazide 
Aceon Perindopril Prinizide, Zestoretic Lisinopril-Hydrochlorothiazide 
Accupril Quinapril Tarka Trandolapril-Verapamil 
Altace Ramipril Uniretic Moexipril-Hydrochlorothiazide 
Mavik Trandolapril Vasoteretic Enalapril-Hydrochlorothiazide 
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Appendix D. List of angiotensin II receptor blockers 
Monotherapy Combination therapy 
Brand Generic Brand Generic 
Diovan Valsartan Atacand HCT Candesartan-Hydrochlorothiazide 
Atacand Candesartan Tevetan HCT Eprosartan-Hydrochlorothiazide 
Tevetan Eprosartan Avalide Irbesartan-Hydrochlorothiazide 
Avapro Irbesartan Hyzaar Losartan-Hydrochlorothiazide 
Cozaar Losartan Benicar HCT Olmesartan-Hydrochlorothiazide 
Benicar Olmesartan Micardis HCT Telmisartan-Hydrochlorothiazide 
Micardis Telmisartan Diovan HCT Valsartan-Hydrochlorothiazide 
Edarbi Azilsartan Azor Olmesartan-Amlodipine 
    Exforge Valsartan-Amlodipine 
    Exforge HCT Valsartan-Amlodipine-Hydrochlorothiazide 
    Valturna Valsartan-Aliskerin 
    Edarbyclor Azilsartan-Chlorthalidone 
    Tribenzor Olmesartan-Amlodipine-Hydrochlorothiazide 
    Twynsta Telmisartan-Amlodipine 
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Appendix E. List of beta-blockers 
Monotherapy Combination therapy 
Brand Generic Brand Generic 
Betapace Sotalol  Corzide Nadolol-Bendroflumethiazide 
Blocadren Timolol Inderide Propanolol-Hydrochlorothiazide 
Brevibloc Esmolol Tenoretic Atenolol-Chlorthalidone 
Cartrol Carteolol Ziac Bisoprolol-Hydrochlorothiazide 
Coreg Carvedilol Lopressor-HCT Metoprolol-Hydrochlorothiazide 
Corgard Nadolol     
Inderal Propanolol     
Kerlone Betaxolol     
Levatol Penbutolol     
Lopressor Metoprolol      
Sectral Acebutolol     
Tenormin Atenolol     
Trandate Normodyne Labetalol      
Visken Pindolol     
Zebeta Bisoprolol     
Bystolic Nebivolol     
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Appendix F. Heart disease ICD-9-CM diagnosis and procedure codes 
 
 
 
 
 
 
 
 
 
 
Note: Other heart diseases (stroke and heart failure) and procedure codes were used for CAD-related hospitalization. 
Heart diseases ICD-9-CM diagnosis/procedure code 
Acute Myocardial infarction 410.01, 410.11, 410.21, 410.31, 410.41, 410.51, 410.61, 410.71, 410.81, 410.91 
Ischemic Heart Disease 410.00, 410.01, 410.02, 410.10, 410.11, 410.12, 410.20, 410.21, 410.22, 410.30, 
410.31, 410.32, 410.40, 410.41, 410.42, 410.50, 410.51, 410.52, 410.60, 410.61, 
410.62, 410.70, 410.71, 410.72, 410.80, 410.81, 410.82, 410.90, 410.91, 410.92, 
411.0, 411.1, 411.81, 411.89, 412, 413.0, 413.1, 413.9, 414.00, 414.01, 414.02, 
414.03, 414.04, 414.05, 414.06, 414.07, 414.12, 414.2, 414.3, 414.4, 414.8, 414.9 
Stroke / Transient Ischemic 
Attack 
430, 431, 433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.00, 434.01, 434.10, 
434.11, 434.90, 434.91, 435.0, 435.1, 435.3, 435.8, 435.9, 436, 997.02 
Heart Failure 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 
428.0, 428.1, 428.20, 428.21, 428.22, 428.23, 428.30, 428.31, 428.32, 428.33, 
428.40, 428.41, 428.42, 428.43, 428.9 
CAD-related Procedures 0066, 3601, 3602, 3603, 3604, 3605, 3606, 3607, 3609, 3610, 3611, 3612, 
3613, 3614, 3615, 3616, 3617, 3619, 362, 3631, 3632 
